PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17005319-0	2007	Sanguinarine induces apoptosis of human pancreatic carcinoma AsPC-1 and BxPC-3 cells via modulations in Bcl-2 family proteins.	sanguinarine	0-12	BCL2 apoptosis regulator	Homo sapiens	104-109
17667597-0	2007	Induction of apoptosis by sanguinarine in C6 rat glioblastoma cells is associated with the modulation of the Bcl-2 family and activation of caspases through downregulation of extracellular signal-regulated kinase and Akt.	sanguinarine	26-38	BCL2, apoptosis regulator	Rattus norvegicus	109-114
17667597-0	2007	Induction of apoptosis by sanguinarine in C6 rat glioblastoma cells is associated with the modulation of the Bcl-2 family and activation of caspases through downregulation of extracellular signal-regulated kinase and Akt.	sanguinarine	26-38	AKT serine/threonine kinase 1	Rattus norvegicus	217-220
17667597-4	2007	The sanguinarine treatment induced the proteolytic activation of caspases and ICAD/DFF45, which was associated with the modulation of the Bcl-2 family, concomitant degradation of poly(ADP ribose) polymerase and phospholipase C-gamma1 protein, and DNA fragmentation.	sanguinarine	4-16	BCL2, apoptosis regulator	Rattus norvegicus	138-143
17310078-5	2007	For this purpose, we studied the effect of 300 nM SA on the production of vascular endothelial growth factor (VEGF) by swine granulosa cells from follicles >5 mm and on the activation of Akt, the main effector of the VEGF signalling pathway.	sanguinarine	50-52	vascular endothelial growth factor A	Sus scrofa	74-108
17310078-5	2007	For this purpose, we studied the effect of 300 nM SA on the production of vascular endothelial growth factor (VEGF) by swine granulosa cells from follicles >5 mm and on the activation of Akt, the main effector of the VEGF signalling pathway.	sanguinarine	50-52	vascular endothelial growth factor A	Sus scrofa	110-114
17310078-7	2007	SA inhibited both VEGF production and VEGF-induced Akt activation in swine granulosa cells.	sanguinarine	0-2	vascular endothelial growth factor A	Sus scrofa	18-22
17310078-7	2007	SA inhibited both VEGF production and VEGF-induced Akt activation in swine granulosa cells.	sanguinarine	0-2	vascular endothelial growth factor A	Sus scrofa	38-42
17310078-7	2007	SA inhibited both VEGF production and VEGF-induced Akt activation in swine granulosa cells.	sanguinarine	0-2	AKT serine/threonine kinase 1	Sus scrofa	51-54
17005319-6	2007	Further, sanguinarine-treatment to AsPC-1 and BxPC-3 cells resulted in a dose dependent (i) increase in pro-apoptotic Bax, Bid and Bak proteins; (ii) decrease in anti-apoptotic Bcl-2 and Bcl-X(L) proteins; and (iii) decrease in p53 with an increase in its phosphorylation.	sanguinarine	9-21	BCL2 associated X, apoptosis regulator	Homo sapiens	118-121
17005319-6	2007	Further, sanguinarine-treatment to AsPC-1 and BxPC-3 cells resulted in a dose dependent (i) increase in pro-apoptotic Bax, Bid and Bak proteins; (ii) decrease in anti-apoptotic Bcl-2 and Bcl-X(L) proteins; and (iii) decrease in p53 with an increase in its phosphorylation.	sanguinarine	9-21	BH3 interacting domain death agonist	Homo sapiens	123-126
17005319-6	2007	Further, sanguinarine-treatment to AsPC-1 and BxPC-3 cells resulted in a dose dependent (i) increase in pro-apoptotic Bax, Bid and Bak proteins; (ii) decrease in anti-apoptotic Bcl-2 and Bcl-X(L) proteins; and (iii) decrease in p53 with an increase in its phosphorylation.	sanguinarine	9-21	BCL2 antagonist/killer 1	Homo sapiens	131-134
17005319-6	2007	Further, sanguinarine-treatment to AsPC-1 and BxPC-3 cells resulted in a dose dependent (i) increase in pro-apoptotic Bax, Bid and Bak proteins; (ii) decrease in anti-apoptotic Bcl-2 and Bcl-X(L) proteins; and (iii) decrease in p53 with an increase in its phosphorylation.	sanguinarine	9-21	BCL2 apoptosis regulator	Homo sapiens	177-182
17005319-6	2007	Further, sanguinarine-treatment to AsPC-1 and BxPC-3 cells resulted in a dose dependent (i) increase in pro-apoptotic Bax, Bid and Bak proteins; (ii) decrease in anti-apoptotic Bcl-2 and Bcl-X(L) proteins; and (iii) decrease in p53 with an increase in its phosphorylation.	sanguinarine	9-21	BCL2 like 1	Homo sapiens	187-195
17005319-6	2007	Further, sanguinarine-treatment to AsPC-1 and BxPC-3 cells resulted in a dose dependent (i) increase in pro-apoptotic Bax, Bid and Bak proteins; (ii) decrease in anti-apoptotic Bcl-2 and Bcl-X(L) proteins; and (iii) decrease in p53 with an increase in its phosphorylation.	sanguinarine	9-21	tumor protein p53	Homo sapiens	228-231
17440103-5	2007	Sanguinarine-induced release of cytochrome c results in activation of caspase-9 and caspase-3 and poly(ADP-ribose) polymerase (PARP) cleavage, leading to induction of caspase-dependent apoptosis.	sanguinarine	0-12	cytochrome c, somatic	Homo sapiens	32-44
17440103-5	2007	Sanguinarine-induced release of cytochrome c results in activation of caspase-9 and caspase-3 and poly(ADP-ribose) polymerase (PARP) cleavage, leading to induction of caspase-dependent apoptosis.	sanguinarine	0-12	caspase 9	Homo sapiens	70-79
17440103-3	2007	Our data show that sanguinarine treatment of PEL cells results in up-regulation of death receptor 5 (DR5) expression via generation of reactive oxygen species (ROS) and causes activation of caspase-8 and truncation of Bid (tBid).	sanguinarine	19-31	TNF receptor superfamily member 10b	Homo sapiens	83-99
17440103-3	2007	Our data show that sanguinarine treatment of PEL cells results in up-regulation of death receptor 5 (DR5) expression via generation of reactive oxygen species (ROS) and causes activation of caspase-8 and truncation of Bid (tBid).	sanguinarine	19-31	TNF receptor superfamily member 10b	Homo sapiens	101-104
17440103-5	2007	Sanguinarine-induced release of cytochrome c results in activation of caspase-9 and caspase-3 and poly(ADP-ribose) polymerase (PARP) cleavage, leading to induction of caspase-dependent apoptosis.	sanguinarine	0-12	caspase 3	Homo sapiens	84-93
17440103-3	2007	Our data show that sanguinarine treatment of PEL cells results in up-regulation of death receptor 5 (DR5) expression via generation of reactive oxygen species (ROS) and causes activation of caspase-8 and truncation of Bid (tBid).	sanguinarine	19-31	caspase 8	Homo sapiens	190-199
17440103-5	2007	Sanguinarine-induced release of cytochrome c results in activation of caspase-9 and caspase-3 and poly(ADP-ribose) polymerase (PARP) cleavage, leading to induction of caspase-dependent apoptosis.	sanguinarine	0-12	poly(ADP-ribose) polymerase 1	Homo sapiens	98-125
17440103-3	2007	Our data show that sanguinarine treatment of PEL cells results in up-regulation of death receptor 5 (DR5) expression via generation of reactive oxygen species (ROS) and causes activation of caspase-8 and truncation of Bid (tBid).	sanguinarine	19-31	BH3 interacting domain death agonist	Homo sapiens	218-221
17440103-5	2007	Sanguinarine-induced release of cytochrome c results in activation of caspase-9 and caspase-3 and poly(ADP-ribose) polymerase (PARP) cleavage, leading to induction of caspase-dependent apoptosis.	sanguinarine	0-12	poly(ADP-ribose) polymerase 1	Homo sapiens	127-131
17440103-6	2007	In addition, we show that pretreatment of PEL cells with carbobenzoxy-Val-Ala-Asp-fluoromethylketone, a universal inhibitor of caspases, abrogates caspase and PARP activation and prevents cell death induced by sanguinarine.	sanguinarine	210-222	caspase 8	Homo sapiens	127-135
17440103-8	2007	Finally, N-acetylcysteine, an inhibitor of ROS, inhibits sanguinarine-induced generation of ROS, up-regulation of DR5, Bax conformational changes, activation of caspase-3, and down-regulation of IAPs.	sanguinarine	57-69	TNF receptor superfamily member 10b	Homo sapiens	114-117
17440103-8	2007	Finally, N-acetylcysteine, an inhibitor of ROS, inhibits sanguinarine-induced generation of ROS, up-regulation of DR5, Bax conformational changes, activation of caspase-3, and down-regulation of IAPs.	sanguinarine	57-69	BCL2 associated X, apoptosis regulator	Homo sapiens	119-122
17440103-8	2007	Finally, N-acetylcysteine, an inhibitor of ROS, inhibits sanguinarine-induced generation of ROS, up-regulation of DR5, Bax conformational changes, activation of caspase-3, and down-regulation of IAPs.	sanguinarine	57-69	caspase 3	Homo sapiens	161-170
17440103-9	2007	Taken together, our findings suggest that sanguinarine is a potent inducer of apoptosis of PEL cells via up-regulation of DR5 and raise the possibility that this agent may be of value in the development of novel therapeutic approaches for the treatment of PEL.	sanguinarine	42-54	TNF receptor superfamily member 10b	Homo sapiens	122-125
16954816-0	2006	Sanguinarine downregulates AT1a gene expression in a hypertensive rat model.	sanguinarine	0-12	angiotensin II receptor, type 1a	Rattus norvegicus	27-31
17305495-4	2007	We show in particular that: (i) Sanguinarine is not transformed to 3,4-benzacridine and that the literature reporting this compound as a metabolite of sanguinarine is based on artifacts and misinterpretations that in course of time have created a dogma; (ii) Sanguinarine is converted to dihydrosanguinarine in vivo, the conversion being tentatively a detoxication pathway; (iii) Aryl hydrocarbon receptor metabolic signaling pathways modulate sanguinarine biological activity.	sanguinarine	151-163	aryl hydrocarbon receptor	Homo sapiens	380-405
16781091-1	2006	Putative interactions between quaternary benzo[c]phenanthridine alkaloid sanguinarine (SA) and aryl hydrocarbon receptor/cytochrome P450 CYP1A (AhR/CYP1A) regulatory pathway are the subject of perpetual disputations.	sanguinarine	73-85	aryl hydrocarbon receptor	Rattus norvegicus	144-147
16781091-1	2006	Putative interactions between quaternary benzo[c]phenanthridine alkaloid sanguinarine (SA) and aryl hydrocarbon receptor/cytochrome P450 CYP1A (AhR/CYP1A) regulatory pathway are the subject of perpetual disputations.	sanguinarine	87-89	aryl hydrocarbon receptor	Rattus norvegicus	144-147
16782256-4	2006	In this work we analyzed the effects of sanguinarine and chelerythrine on AhR activity in rat hepatoma cells HII4E.luc stably transfected with dioxin responsive element fused to luciferase gene (DRE-LUC).	sanguinarine	40-52	aryl hydrocarbon receptor	Rattus norvegicus	74-77
16782256-10	2006	Regarding the concentrations of QBAs occurring in vivo, the use of products containing sanguinarine and/or chelerythrine has low toxicological potential in terms of the interactions with AhR signaling pathways.	sanguinarine	87-99	aryl hydrocarbon receptor	Rattus norvegicus	187-190
17011577-0	2006	Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.	sanguinarine	18-30	BCL2 like 1	Homo sapiens	57-62
16735106-7	2006	Thus, sanguinarine may overcome the phenomenon of Pgp-mediated MDR by inducing apoptosis through increasing the Bax/Bcl-2 ratio and activating caspase-3, and oncosis, which involved neither.	sanguinarine	6-18	BCL2 associated X, apoptosis regulator	Homo sapiens	112-115
16735106-7	2006	Thus, sanguinarine may overcome the phenomenon of Pgp-mediated MDR by inducing apoptosis through increasing the Bax/Bcl-2 ratio and activating caspase-3, and oncosis, which involved neither.	sanguinarine	6-18	BCL2 apoptosis regulator	Homo sapiens	116-121
16735106-7	2006	Thus, sanguinarine may overcome the phenomenon of Pgp-mediated MDR by inducing apoptosis through increasing the Bax/Bcl-2 ratio and activating caspase-3, and oncosis, which involved neither.	sanguinarine	6-18	caspase 3	Homo sapiens	143-152
16954816-1	2006	We studied the in vivo effects of sanguinarine in a hypertensive rat model and its effects on AT1a mRNA expression in kidney tissues.	sanguinarine	34-46	angiotensin II receptor, type 1a	Rattus norvegicus	94-98
16829183-3	2006	Both TNF-alpha and IL-1beta induced HUVEC platelet-activating factor (PAF) production and PAF was required for subsequent firm THP-1 monocyte adhesion since it was inhibited by both PAF receptor antagonists (BN-52021 or CV-6209) and a PAF synthesis inhibitor (sanguinarine).	sanguinarine	260-272	tumor necrosis factor	Homo sapiens	5-14
16829183-3	2006	Both TNF-alpha and IL-1beta induced HUVEC platelet-activating factor (PAF) production and PAF was required for subsequent firm THP-1 monocyte adhesion since it was inhibited by both PAF receptor antagonists (BN-52021 or CV-6209) and a PAF synthesis inhibitor (sanguinarine).	sanguinarine	260-272	interleukin 1 beta	Homo sapiens	19-27
16829183-3	2006	Both TNF-alpha and IL-1beta induced HUVEC platelet-activating factor (PAF) production and PAF was required for subsequent firm THP-1 monocyte adhesion since it was inhibited by both PAF receptor antagonists (BN-52021 or CV-6209) and a PAF synthesis inhibitor (sanguinarine).	sanguinarine	260-272	PCNA clamp associated factor	Homo sapiens	90-93
16829183-3	2006	Both TNF-alpha and IL-1beta induced HUVEC platelet-activating factor (PAF) production and PAF was required for subsequent firm THP-1 monocyte adhesion since it was inhibited by both PAF receptor antagonists (BN-52021 or CV-6209) and a PAF synthesis inhibitor (sanguinarine).	sanguinarine	260-272	PCNA clamp associated factor	Homo sapiens	90-93
16829183-3	2006	Both TNF-alpha and IL-1beta induced HUVEC platelet-activating factor (PAF) production and PAF was required for subsequent firm THP-1 monocyte adhesion since it was inhibited by both PAF receptor antagonists (BN-52021 or CV-6209) and a PAF synthesis inhibitor (sanguinarine).	sanguinarine	260-272	PCNA clamp associated factor	Homo sapiens	90-93
16585199-0	2006	Cyclooxygenase 2 rescues LNCaP prostate cancer cells from sanguinarine-induced apoptosis by a mechanism involving inhibition of nitric oxide synthase activity.	sanguinarine	58-70	prostaglandin-endoperoxide synthase 2	Homo sapiens	0-16
16585199-2	2006	The aim of this study was to investigate whether expression of Cox-2 is effective against prostate cancer cell apoptosis triggered by sanguinarine, the quaternary benzophenanthridine alkaloid with antineoplastic properties.	sanguinarine	134-146	prostaglandin-endoperoxide synthase 2	Homo sapiens	63-68
16585199-3	2006	Sanguinarine effectively induced apoptosis in LNCaP human prostate cancer epithelial cells as assessed by caspase-3 activation assay, Annexin V staining assay, or by visual analysis for the apoptotic morphology changes.	sanguinarine	0-12	caspase 3	Homo sapiens	106-115
16585199-3	2006	Sanguinarine effectively induced apoptosis in LNCaP human prostate cancer epithelial cells as assessed by caspase-3 activation assay, Annexin V staining assay, or by visual analysis for the apoptotic morphology changes.	sanguinarine	0-12	annexin A5	Homo sapiens	134-143
16585199-5	2006	Activation of NO synthase (NOS) activity was crucial for sanguinarine-induced cell death because NOS inhibitor L-NMMA efficiently protected cells from apoptosis.	sanguinarine	57-69	nitric oxide synthase 2	Homo sapiens	14-25
16585199-6	2006	Adenovirus-mediated transfer of Cox-2 into LNCaP cells inhibited sanguinarine-induced apoptosis and prevented an increase in NO production.	sanguinarine	65-77	prostaglandin-endoperoxide synthase 2	Homo sapiens	32-37
16585199-10	2006	These results suggest that Cox-2 expression rescues prostate cancer cells from sanguinarine-induced apoptosis by a mechanism involving inhibition of NOS activity, and that coadministration of Cox-2 inhibitors with sanguinarine may be developed as a strategy for the management of prostate cancer.	sanguinarine	79-91	prostaglandin-endoperoxide synthase 2	Homo sapiens	27-32
16585199-10	2006	These results suggest that Cox-2 expression rescues prostate cancer cells from sanguinarine-induced apoptosis by a mechanism involving inhibition of NOS activity, and that coadministration of Cox-2 inhibitors with sanguinarine may be developed as a strategy for the management of prostate cancer.	sanguinarine	214-226	prostaglandin-endoperoxide synthase 2	Homo sapiens	27-32
16585199-10	2006	These results suggest that Cox-2 expression rescues prostate cancer cells from sanguinarine-induced apoptosis by a mechanism involving inhibition of NOS activity, and that coadministration of Cox-2 inhibitors with sanguinarine may be developed as a strategy for the management of prostate cancer.	sanguinarine	214-226	prostaglandin-endoperoxide synthase 2	Homo sapiens	192-197
16290068-3	2006	Since angiogenesis is fundamental for follicle development, we also tested the impact of SA exposure on vascular endothelial growth factor (VEGF) production.	sanguinarine	89-91	vascular endothelial growth factor A	Sus scrofa	104-138
16290068-3	2006	Since angiogenesis is fundamental for follicle development, we also tested the impact of SA exposure on vascular endothelial growth factor (VEGF) production.	sanguinarine	89-91	vascular endothelial growth factor A	Sus scrofa	140-144
16290068-5	2006	SA addition to granulosa cell culture inhibited VEGF production and increased peroxidase and catalase activities at all tested concentrations while superoxide dismutase activity was increased only at 300 nM.	sanguinarine	0-2	vascular endothelial growth factor A	Sus scrofa	48-52
16290068-5	2006	SA addition to granulosa cell culture inhibited VEGF production and increased peroxidase and catalase activities at all tested concentrations while superoxide dismutase activity was increased only at 300 nM.	sanguinarine	0-2	catalase	Sus scrofa	93-101
16512916-0	2006	Disruption of nucleocytoplasmic trafficking of cyclin D1 and topoisomerase II by sanguinarine.	sanguinarine	81-93	cyclin D1	Homo sapiens	47-56
16289013-3	2006	Sanguinarine and chelerythrine elicited nuclear translocation of the p65 subunit of NF-kappaB.	sanguinarine	0-12	RELA proto-oncogene, NF-kB subunit	Homo sapiens	69-93
16505117-5	2006	These responses on UVB and/or sanguinarine treatments were associated with (a) decrease in Bcl-2 and Bcl-X(L) and (b) increase in Bax, Bid, and Bak protein levels.	sanguinarine	30-42	BCL2 apoptosis regulator	Homo sapiens	91-96
16115718-0	2006	Investigation of sanguinarine and chelerythrine effects on CYP1A1 expression and activity in human hepatoma cells.	sanguinarine	17-29	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	59-65
16115718-18	2006	In our work we examined the effects of sanguinarine and chelerythrine on CYP1A1 expression and catalytic activity in human hepatoma cells-HepG2.	sanguinarine	39-51	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	73-79
16115718-23	2006	The IC50 values for the inhibition of CYP1A1 by sanguinarine and chelerythrine were 2.1 and 1.9muM, respectively.	sanguinarine	48-60	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	38-44
16289013-7	2006	Sanguinarine and chelerythrine induced accumulation of GR in the nucleus with concomitant diminution of cytosolic GR.	sanguinarine	0-12	nuclear receptor subfamily 3 group C member 1	Homo sapiens	55-57
16505117-5	2006	These responses on UVB and/or sanguinarine treatments were associated with (a) decrease in Bcl-2 and Bcl-X(L) and (b) increase in Bax, Bid, and Bak protein levels.	sanguinarine	30-42	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133
16505117-5	2006	These responses on UVB and/or sanguinarine treatments were associated with (a) decrease in Bcl-2 and Bcl-X(L) and (b) increase in Bax, Bid, and Bak protein levels.	sanguinarine	30-42	BCL2 like 1	Homo sapiens	101-109
16505117-5	2006	These responses on UVB and/or sanguinarine treatments were associated with (a) decrease in Bcl-2 and Bcl-X(L) and (b) increase in Bax, Bid, and Bak protein levels.	sanguinarine	30-42	BH3 interacting domain death agonist	Homo sapiens	135-138
15993743-6	2005	Our results demonstrate that sanguinarine: (i) results in formation of the AhR-ARNT complex, (ii) induces AhR-associated gene expression, (iii) inhibits cytochrome P450 1A1 (CYP 1A1) microsomal oxidative activity and (iv) pretreatment upregulates CYP 1A1 function.	sanguinarine	29-41	aryl hydrocarbon receptor	Homo sapiens	75-78
16505117-5	2006	These responses on UVB and/or sanguinarine treatments were associated with (a) decrease in Bcl-2 and Bcl-X(L) and (b) increase in Bax, Bid, and Bak protein levels.	sanguinarine	30-42	BCL2 antagonist/killer 1	Homo sapiens	144-147
16505117-6	2006	Bax knockdown and Bcl-2 overexpression resulted in a rescue of HaCaT cells from sanguinarine-mediated apoptosis.	sanguinarine	80-92	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
16505117-6	2006	Bax knockdown and Bcl-2 overexpression resulted in a rescue of HaCaT cells from sanguinarine-mediated apoptosis.	sanguinarine	80-92	BCL2 apoptosis regulator	Homo sapiens	18-23
16505117-9	2006	Furthermore, sanguinarine treatment was found to result in significant modulations in p53, p66Shc, MsrA, and superoxide dismutase levels.	sanguinarine	13-25	tumor protein p53	Homo sapiens	86-89
16505117-9	2006	Furthermore, sanguinarine treatment was found to result in significant modulations in p53, p66Shc, MsrA, and superoxide dismutase levels.	sanguinarine	13-25	methionine sulfoxide reductase A	Homo sapiens	99-103
15981203-6	2005	The activities of cutaneous gamma-glutamyl transpeptidase (GGT) and glutathione-S-transferase P (GST-P), marker enzymes of tumorigenesis, were found to exhibit higher expression in AO or isolated sanguinarine/TPA treated groups when compared to control.	sanguinarine	196-208	inactive glutathione hydrolase 2	Homo sapiens	28-57
15981203-6	2005	The activities of cutaneous gamma-glutamyl transpeptidase (GGT) and glutathione-S-transferase P (GST-P), marker enzymes of tumorigenesis, were found to exhibit higher expression in AO or isolated sanguinarine/TPA treated groups when compared to control.	sanguinarine	196-208	inactive glutathione hydrolase 2	Homo sapiens	59-62
15981203-6	2005	The activities of cutaneous gamma-glutamyl transpeptidase (GGT) and glutathione-S-transferase P (GST-P), marker enzymes of tumorigenesis, were found to exhibit higher expression in AO or isolated sanguinarine/TPA treated groups when compared to control.	sanguinarine	196-208	glutathione S-transferase pi 1	Homo sapiens	68-95
15981203-6	2005	The activities of cutaneous gamma-glutamyl transpeptidase (GGT) and glutathione-S-transferase P (GST-P), marker enzymes of tumorigenesis, were found to exhibit higher expression in AO or isolated sanguinarine/TPA treated groups when compared to control.	sanguinarine	196-208	glutathione S-transferase pi 1	Homo sapiens	97-102
15981203-7	2005	The higher expression of p53 and p21/WAF1 in skin after single topical application of AO or isolated sanguinarine further confirms the tumorigenic response.	sanguinarine	101-113	tumor protein p53	Homo sapiens	25-28
15981203-7	2005	The higher expression of p53 and p21/WAF1 in skin after single topical application of AO or isolated sanguinarine further confirms the tumorigenic response.	sanguinarine	101-113	cyclin dependent kinase inhibitor 1A	Homo sapiens	33-36
15981203-7	2005	The higher expression of p53 and p21/WAF1 in skin after single topical application of AO or isolated sanguinarine further confirms the tumorigenic response.	sanguinarine	101-113	cyclin dependent kinase inhibitor 1A	Homo sapiens	37-41
15993743-6	2005	Our results demonstrate that sanguinarine: (i) results in formation of the AhR-ARNT complex, (ii) induces AhR-associated gene expression, (iii) inhibits cytochrome P450 1A1 (CYP 1A1) microsomal oxidative activity and (iv) pretreatment upregulates CYP 1A1 function.	sanguinarine	29-41	aryl hydrocarbon receptor nuclear translocator	Homo sapiens	79-83
15993743-6	2005	Our results demonstrate that sanguinarine: (i) results in formation of the AhR-ARNT complex, (ii) induces AhR-associated gene expression, (iii) inhibits cytochrome P450 1A1 (CYP 1A1) microsomal oxidative activity and (iv) pretreatment upregulates CYP 1A1 function.	sanguinarine	29-41	aryl hydrocarbon receptor	Homo sapiens	106-109
15993743-6	2005	Our results demonstrate that sanguinarine: (i) results in formation of the AhR-ARNT complex, (ii) induces AhR-associated gene expression, (iii) inhibits cytochrome P450 1A1 (CYP 1A1) microsomal oxidative activity and (iv) pretreatment upregulates CYP 1A1 function.	sanguinarine	29-41	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	153-172
15993743-6	2005	Our results demonstrate that sanguinarine: (i) results in formation of the AhR-ARNT complex, (ii) induces AhR-associated gene expression, (iii) inhibits cytochrome P450 1A1 (CYP 1A1) microsomal oxidative activity and (iv) pretreatment upregulates CYP 1A1 function.	sanguinarine	29-41	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	174-181
15993743-6	2005	Our results demonstrate that sanguinarine: (i) results in formation of the AhR-ARNT complex, (ii) induces AhR-associated gene expression, (iii) inhibits cytochrome P450 1A1 (CYP 1A1) microsomal oxidative activity and (iv) pretreatment upregulates CYP 1A1 function.	sanguinarine	29-41	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	247-254
15753082-6	2005	Sanguinarine also inhibited MKP-1 and the MKP-1 like phosphatase, MKP-L, in vitro with IC50 values of 17.3 and 12.5 microM, respectively, and showed 5-10-fold selectivity for MKP-3 and MKP-1 over VH-1-related phosphatase, Cdc25B2, or protein-tyrosine phosphatase 1B.	sanguinarine	0-12	dual specificity phosphatase 1	Homo sapiens	42-47
15753082-6	2005	Sanguinarine also inhibited MKP-1 and the MKP-1 like phosphatase, MKP-L, in vitro with IC50 values of 17.3 and 12.5 microM, respectively, and showed 5-10-fold selectivity for MKP-3 and MKP-1 over VH-1-related phosphatase, Cdc25B2, or protein-tyrosine phosphatase 1B.	sanguinarine	0-12	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	222-265
15753082-0	2005	The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1.	sanguinarine	37-49	dual specificity phosphatase 1	Homo sapiens	92-138
15753082-4	2005	Using two-dimensional Kolmogorov-Smirnov statistics, we identified sanguinarine, a plant alkaloid with known antibiotic and antitumor activity but no primary cellular target, as a potent and selective inhibitor of MKP-1.	sanguinarine	67-79	dual specificity phosphatase 1	Homo sapiens	214-219
15753082-5	2005	Sanguinarine inhibited cellular MKP-1 with an IC50 of 10 microM and showed selectivity for MKP-1 over MKP-3.	sanguinarine	0-12	dual specificity phosphatase 1	Homo sapiens	32-37
15753082-7	2005	In a human tumor cell line with high MKP-1 levels, sanguinarine caused enhanced ERK and JNK/SAPK phosphorylation.	sanguinarine	51-63	dual specificity phosphatase 1	Homo sapiens	37-42
15753082-5	2005	Sanguinarine inhibited cellular MKP-1 with an IC50 of 10 microM and showed selectivity for MKP-1 over MKP-3.	sanguinarine	0-12	dual specificity phosphatase 1	Homo sapiens	91-96
15753082-7	2005	In a human tumor cell line with high MKP-1 levels, sanguinarine caused enhanced ERK and JNK/SAPK phosphorylation.	sanguinarine	51-63	mitogen-activated protein kinase 1	Homo sapiens	80-83
15753082-5	2005	Sanguinarine inhibited cellular MKP-1 with an IC50 of 10 microM and showed selectivity for MKP-1 over MKP-3.	sanguinarine	0-12	dual specificity phosphatase 6	Homo sapiens	102-107
15753082-7	2005	In a human tumor cell line with high MKP-1 levels, sanguinarine caused enhanced ERK and JNK/SAPK phosphorylation.	sanguinarine	51-63	mitogen-activated protein kinase 8	Homo sapiens	88-91
15753082-6	2005	Sanguinarine also inhibited MKP-1 and the MKP-1 like phosphatase, MKP-L, in vitro with IC50 values of 17.3 and 12.5 microM, respectively, and showed 5-10-fold selectivity for MKP-3 and MKP-1 over VH-1-related phosphatase, Cdc25B2, or protein-tyrosine phosphatase 1B.	sanguinarine	0-12	dual specificity phosphatase 1	Homo sapiens	28-33
15753082-6	2005	Sanguinarine also inhibited MKP-1 and the MKP-1 like phosphatase, MKP-L, in vitro with IC50 values of 17.3 and 12.5 microM, respectively, and showed 5-10-fold selectivity for MKP-3 and MKP-1 over VH-1-related phosphatase, Cdc25B2, or protein-tyrosine phosphatase 1B.	sanguinarine	0-12	dual specificity phosphatase 1	Homo sapiens	42-47
15753082-7	2005	In a human tumor cell line with high MKP-1 levels, sanguinarine caused enhanced ERK and JNK/SAPK phosphorylation.	sanguinarine	51-63	mitogen-activated protein kinase 9	Homo sapiens	92-96
15753082-6	2005	Sanguinarine also inhibited MKP-1 and the MKP-1 like phosphatase, MKP-L, in vitro with IC50 values of 17.3 and 12.5 microM, respectively, and showed 5-10-fold selectivity for MKP-3 and MKP-1 over VH-1-related phosphatase, Cdc25B2, or protein-tyrosine phosphatase 1B.	sanguinarine	0-12	dual specificity phosphatase 14	Homo sapiens	66-71
15753082-6	2005	Sanguinarine also inhibited MKP-1 and the MKP-1 like phosphatase, MKP-L, in vitro with IC50 values of 17.3 and 12.5 microM, respectively, and showed 5-10-fold selectivity for MKP-3 and MKP-1 over VH-1-related phosphatase, Cdc25B2, or protein-tyrosine phosphatase 1B.	sanguinarine	0-12	dual specificity phosphatase 6	Homo sapiens	175-180
15753082-8	2005	A close congener of sanguinarine, chelerythrine, also inhibited MKP-1 in vitro and in whole cells, and activated ERK and JNK/SAPK.	sanguinarine	20-32	dual specificity phosphatase 1	Homo sapiens	64-69
15753082-8	2005	A close congener of sanguinarine, chelerythrine, also inhibited MKP-1 in vitro and in whole cells, and activated ERK and JNK/SAPK.	sanguinarine	20-32	mitogen-activated protein kinase 1	Homo sapiens	113-116
15753082-8	2005	A close congener of sanguinarine, chelerythrine, also inhibited MKP-1 in vitro and in whole cells, and activated ERK and JNK/SAPK.	sanguinarine	20-32	mitogen-activated protein kinase 8	Homo sapiens	121-129
15313406-4	2004	Our results provide evidence for a differential effect of chemopreventive agents such as beta-lapachone, emodin, sanguinarine and capsaicin, which significantly inhibit reporter gene expression as well as TNFalpha- and TPA-induced binding of AP-1 and NF-kappaB, whereas trans-anethole and silymarin do not produce any inhibitory effect.	sanguinarine	113-125	tumor necrosis factor	Homo sapiens	205-213
16711384-1	2005	A study was made of modulations of lysosome-phagosome fusion process and of fibrillar actin content in mouse peritoneal macrophages by an antitumor alkaloid sanguinarine and a derivative drug Ukrain.	sanguinarine	157-169	actin	Oryctolagus cuniculus	86-91
16711384-3	2005	Sanguinarine and Ukrain stimulated lysosome-phagosome fusion and increased the content of polymerized fibrillar form of actin in mouse macrophages.	sanguinarine	0-12	actin	Oryctolagus cuniculus	120-125
16711384-5	2005	Both sanguinarine and Ukrain induced in vitro polymerization of globular actin from rabbit muscle.	sanguinarine	5-17	actin	Oryctolagus cuniculus	73-78
15313406-4	2004	Our results provide evidence for a differential effect of chemopreventive agents such as beta-lapachone, emodin, sanguinarine and capsaicin, which significantly inhibit reporter gene expression as well as TNFalpha- and TPA-induced binding of AP-1 and NF-kappaB, whereas trans-anethole and silymarin do not produce any inhibitory effect.	sanguinarine	113-125	FosB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	242-246
15313406-4	2004	Our results provide evidence for a differential effect of chemopreventive agents such as beta-lapachone, emodin, sanguinarine and capsaicin, which significantly inhibit reporter gene expression as well as TNFalpha- and TPA-induced binding of AP-1 and NF-kappaB, whereas trans-anethole and silymarin do not produce any inhibitory effect.	sanguinarine	113-125	nuclear factor kappa B subunit 1	Homo sapiens	251-260
15063803-5	2004	In the present study, we examined the effect of sanguinarine on VEGF-induced angiogenesis in vitro and in vivo.	sanguinarine	48-60	vascular endothelial growth factor A	Mus musculus	64-68
15299076-9	2004	Immunoblot analysis showed that sanguinarine treatment of both LNCaP and DU145 cells resulted in significant (1) induction of cyclin kinase inhibitors p21/WAF1 and p27/KIP1; (2) down-regulation of cyclin E, D1, and D2; and (3) down-regulation of cyclin-dependent kinase 2, 4, and 6.	sanguinarine	32-44	cyclin dependent kinase inhibitor 1A	Homo sapiens	151-154
15299076-9	2004	Immunoblot analysis showed that sanguinarine treatment of both LNCaP and DU145 cells resulted in significant (1) induction of cyclin kinase inhibitors p21/WAF1 and p27/KIP1; (2) down-regulation of cyclin E, D1, and D2; and (3) down-regulation of cyclin-dependent kinase 2, 4, and 6.	sanguinarine	32-44	cyclin dependent kinase inhibitor 1A	Homo sapiens	155-159
15299076-9	2004	Immunoblot analysis showed that sanguinarine treatment of both LNCaP and DU145 cells resulted in significant (1) induction of cyclin kinase inhibitors p21/WAF1 and p27/KIP1; (2) down-regulation of cyclin E, D1, and D2; and (3) down-regulation of cyclin-dependent kinase 2, 4, and 6.	sanguinarine	32-44	dynactin subunit 6	Homo sapiens	164-167
15299076-9	2004	Immunoblot analysis showed that sanguinarine treatment of both LNCaP and DU145 cells resulted in significant (1) induction of cyclin kinase inhibitors p21/WAF1 and p27/KIP1; (2) down-regulation of cyclin E, D1, and D2; and (3) down-regulation of cyclin-dependent kinase 2, 4, and 6.	sanguinarine	32-44	cyclin dependent kinase inhibitor 1B	Homo sapiens	168-172
15299076-9	2004	Immunoblot analysis showed that sanguinarine treatment of both LNCaP and DU145 cells resulted in significant (1) induction of cyclin kinase inhibitors p21/WAF1 and p27/KIP1; (2) down-regulation of cyclin E, D1, and D2; and (3) down-regulation of cyclin-dependent kinase 2, 4, and 6.	sanguinarine	32-44	leiomodin 1	Homo sapiens	207-217
15299076-9	2004	Immunoblot analysis showed that sanguinarine treatment of both LNCaP and DU145 cells resulted in significant (1) induction of cyclin kinase inhibitors p21/WAF1 and p27/KIP1; (2) down-regulation of cyclin E, D1, and D2; and (3) down-regulation of cyclin-dependent kinase 2, 4, and 6.	sanguinarine	32-44	cyclin dependent kinase 2	Homo sapiens	246-281
15183462-4	2004	implicated rat hepatic cytochrome P450 (CYP) 1A2 as a likely modulator of SA toxicity.	sanguinarine	74-76	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	23-48
15183462-6	2004	Using microsomes containing recombinant CYP1A1 or CYP1A2 we show that SA causes non-competitive inhibition of the former and competitive inhibition of the latter as assessed by ethoxyresorufin de-ethylation (EROD).	sanguinarine	70-72	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	40-46
15183462-6	2004	Using microsomes containing recombinant CYP1A1 or CYP1A2 we show that SA causes non-competitive inhibition of the former and competitive inhibition of the latter as assessed by ethoxyresorufin de-ethylation (EROD).	sanguinarine	70-72	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	50-56
15183462-7	2004	In human hepatic microsomes SA exhibits competitive inhibition of EROD activity with apparent K(i) of 2 microM, a value identical to that observed for CYP1A2 inhibition in recombinant system.	sanguinarine	28-30	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	151-157
15183462-8	2004	Pre-incubation of SA with human liver microsomes resulted in time-dependent, but not dose-dependent decline in EROD activity suggesting CYP1A2 inhibition is not mechanism based.	sanguinarine	18-20	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	136-142
15063803-8	2004	Our biochemical assays indicated that sanguinarine strongly suppressed basal and VEGF-induced Akt phosphorylation, while it did not produce any changes in VEGF-induced activation of ERK1/2 and PLCgamma1.	sanguinarine	38-50	thymoma viral proto-oncogene 1	Mus musculus	94-97
15063803-9	2004	Therefore, we conclude that sanguinarine is a potent antiangiogenic natural product, and its mode of action could involve the blocking of VEGF-induced Akt activation.	sanguinarine	28-40	vascular endothelial growth factor A	Mus musculus	138-142
15063803-9	2004	Therefore, we conclude that sanguinarine is a potent antiangiogenic natural product, and its mode of action could involve the blocking of VEGF-induced Akt activation.	sanguinarine	28-40	thymoma viral proto-oncogene 1	Mus musculus	151-154
15063803-6	2004	Interestingly, sanguinarine markedly suppressed VEGF-induced endothelial cell migration, sprouting, and survival in vitro in a dose-dependent manner at nanomolar concentrations.	sanguinarine	15-27	vascular endothelial growth factor A	Mus musculus	48-52
15063803-8	2004	Our biochemical assays indicated that sanguinarine strongly suppressed basal and VEGF-induced Akt phosphorylation, while it did not produce any changes in VEGF-induced activation of ERK1/2 and PLCgamma1.	sanguinarine	38-50	vascular endothelial growth factor A	Mus musculus	81-85
14585282-3	2003	After incubation of mouse fibroblasts in culture with 100 microM sanguinarine an approximately 50% decrease in the activities of N-acetyl-beta,D-glucosaminidase (NAGA), beta-galactosidase (GAL), arylsulfatase and acid lipase was observed.	sanguinarine	65-77	O-GlcNAcase	Mus musculus	129-160
12912970-9	2003	Sanguinarine also resulted in significant increases in the proapoptotic members of Bcl-2 family proteins, i.e., Bak and Bid.	sanguinarine	0-12	BH3 interacting domain death agonist	Homo sapiens	120-123
12912970-11	2003	Taken together, our data showed the involvement of mitochondrial pathway and Bcl-2 family proteins during sanguinarine-mediated apoptosis of immortalized keratinocytes.	sanguinarine	106-118	BCL2 apoptosis regulator	Homo sapiens	77-82
12700925-8	2003	In PC3 cells, continuous treatment with 5 microM sanguinarine induced an early (within 10 min) cellular reduced glutathione depletion insensitive to dithiothreitol or N-acetylcysteine treatment, followed by a caspase 3/7-dependent apoptotic response within 2 h. Complementary assays suggested that the glutathione depletion was initiated by direct reactivity of sanguinarine with reduced glutathione.	sanguinarine	49-61	caspase 3	Homo sapiens	209-218
14726151-3	2004	SA inhibited both N-formyl-Met-Leu-Phe (fMLP) and phorbol 12-myristate 13-acetate (PMA)-induced oxidative burst with half-maximal concentration for inhibition (IC(50)) of 1.5 and 1.8 microM, respectively.	sanguinarine	0-2	formyl peptide receptor 1	Homo sapiens	18-38
14726151-3	2004	SA inhibited both N-formyl-Met-Leu-Phe (fMLP) and phorbol 12-myristate 13-acetate (PMA)-induced oxidative burst with half-maximal concentration for inhibition (IC(50)) of 1.5 and 1.8 microM, respectively.	sanguinarine	0-2	formyl peptide receptor 1	Homo sapiens	40-44
12912970-0	2003	Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes.	sanguinarine	84-96	BCL2 apoptosis regulator	Homo sapiens	23-28
12912970-6	2003	Sanguinarine treatment also resulted in a significant cleavage of poly(ADP-ribose) polymerase in HaCaT cells.	sanguinarine	0-12	poly(ADP-ribose) polymerase 1	Homo sapiens	66-93
12912970-8	2003	As shown by the immunoblot analysis, our data clearly demonstrated that sanguinarine treatment to HaCaT cells resulted in a dose-dependent (a) increase in the level of Bax with a concomitant decrease in Bcl-2 levels and (b) increase in Bax/Bcl-2 ratio.	sanguinarine	72-84	BCL2 associated X, apoptosis regulator	Homo sapiens	168-171
12912970-8	2003	As shown by the immunoblot analysis, our data clearly demonstrated that sanguinarine treatment to HaCaT cells resulted in a dose-dependent (a) increase in the level of Bax with a concomitant decrease in Bcl-2 levels and (b) increase in Bax/Bcl-2 ratio.	sanguinarine	72-84	BCL2 apoptosis regulator	Homo sapiens	203-208
12912970-8	2003	As shown by the immunoblot analysis, our data clearly demonstrated that sanguinarine treatment to HaCaT cells resulted in a dose-dependent (a) increase in the level of Bax with a concomitant decrease in Bcl-2 levels and (b) increase in Bax/Bcl-2 ratio.	sanguinarine	72-84	BCL2 associated X, apoptosis regulator	Homo sapiens	236-239
12912970-8	2003	As shown by the immunoblot analysis, our data clearly demonstrated that sanguinarine treatment to HaCaT cells resulted in a dose-dependent (a) increase in the level of Bax with a concomitant decrease in Bcl-2 levels and (b) increase in Bax/Bcl-2 ratio.	sanguinarine	72-84	BCL2 apoptosis regulator	Homo sapiens	240-245
12912970-9	2003	Sanguinarine also resulted in significant increases in the proapoptotic members of Bcl-2 family proteins, i.e., Bak and Bid.	sanguinarine	0-12	BCL2 apoptosis regulator	Homo sapiens	83-88
14585282-3	2003	After incubation of mouse fibroblasts in culture with 100 microM sanguinarine an approximately 50% decrease in the activities of N-acetyl-beta,D-glucosaminidase (NAGA), beta-galactosidase (GAL), arylsulfatase and acid lipase was observed.	sanguinarine	65-77	O-GlcNAcase	Mus musculus	162-166
14585282-3	2003	After incubation of mouse fibroblasts in culture with 100 microM sanguinarine an approximately 50% decrease in the activities of N-acetyl-beta,D-glucosaminidase (NAGA), beta-galactosidase (GAL), arylsulfatase and acid lipase was observed.	sanguinarine	65-77	galactosidase, beta 1	Mus musculus	169-187
14585282-3	2003	After incubation of mouse fibroblasts in culture with 100 microM sanguinarine an approximately 50% decrease in the activities of N-acetyl-beta,D-glucosaminidase (NAGA), beta-galactosidase (GAL), arylsulfatase and acid lipase was observed.	sanguinarine	65-77	galactosidase, beta 1	Mus musculus	189-192
14585282-4	2003	Because the biological activity of sanguinarine might arise from the interaction of its iminium cation with enzyme thiol groups, we compared its effect on NAGA, GAL and acid phosphatase (AcP) activities with the effects of SH-specific reagents p-chloromercuribenzoic acid (CPMA) and N-ethylmaleimide (NEM).	sanguinarine	35-47	O-GlcNAcase	Mus musculus	155-159
14585282-4	2003	Because the biological activity of sanguinarine might arise from the interaction of its iminium cation with enzyme thiol groups, we compared its effect on NAGA, GAL and acid phosphatase (AcP) activities with the effects of SH-specific reagents p-chloromercuribenzoic acid (CPMA) and N-ethylmaleimide (NEM).	sanguinarine	35-47	galactosidase, beta 1	Mus musculus	161-164
14585282-5	2003	Treatment of lysosomal fractions with millimolar concentrations of sanguinarine induces a dose-dependent inhibition of the enzymes; for example, 0.6 mM sanguinarine causes approximately a 40% decrease in AcP and NAGA activities.	sanguinarine	67-79	O-GlcNAcase	Mus musculus	212-216
14585282-5	2003	Treatment of lysosomal fractions with millimolar concentrations of sanguinarine induces a dose-dependent inhibition of the enzymes; for example, 0.6 mM sanguinarine causes approximately a 40% decrease in AcP and NAGA activities.	sanguinarine	152-164	O-GlcNAcase	Mus musculus	212-216
14989176-7	2003	Judging from the data obtained, sanguinarine and chelerythrine appear to exert similar inhibitory effects in this reaction, since sanguinarine and "Sanguirythrine" have similar values of bimolecular rate constants of their interaction with mitochondrial MAO.	sanguinarine	32-44	monoamine oxidase A	Rattus norvegicus	254-257
12790770-2	2003	The low-MW form of DPP-IV-like enzyme activity, corresponding most probably to DPP-8, observed only in glioma cells but not in human plasma, was inhibited preferentially by SA, CHE and EX, and only slightly by FA.	sanguinarine	173-175	dipeptidyl peptidase 4	Homo sapiens	19-25
12790770-2	2003	The low-MW form of DPP-IV-like enzyme activity, corresponding most probably to DPP-8, observed only in glioma cells but not in human plasma, was inhibited preferentially by SA, CHE and EX, and only slightly by FA.	sanguinarine	173-175	dipeptidyl peptidase 8	Homo sapiens	79-84
14989176-7	2003	Judging from the data obtained, sanguinarine and chelerythrine appear to exert similar inhibitory effects in this reaction, since sanguinarine and "Sanguirythrine" have similar values of bimolecular rate constants of their interaction with mitochondrial MAO.	sanguinarine	130-142	monoamine oxidase A	Rattus norvegicus	254-257
11522612-7	2001	A pretreatment with a CoA-IT and lyso-PAF-AT inhibitor (Sanguinarin; 500 nM) blocked VEGF-induced PAF synthesis by 95%, a specific CoA-IT inhibitor (SKF45905; 10 - 50 microM) was without effect, confirming the crucial role of the PLA2 and lyso-PAF-AT.	sanguinarine	56-67	vascular endothelial growth factor A	Homo sapiens	85-89
11807974-1	2002	Chelerythrine, sanguinarine and an alkaloid extract from Macleaya cordata--sanguiritrin--were found to be inhibitors of aminopeptidase A and dipeptidyl peptidase IV, while fagaronine inhibited dipeptidyl peptidase IV only.	sanguinarine	15-27	dipeptidyl peptidase 4	Bos taurus	141-164
11807974-1	2002	Chelerythrine, sanguinarine and an alkaloid extract from Macleaya cordata--sanguiritrin--were found to be inhibitors of aminopeptidase A and dipeptidyl peptidase IV, while fagaronine inhibited dipeptidyl peptidase IV only.	sanguinarine	15-27	dipeptidyl peptidase 4	Bos taurus	193-216
11807974-2	2002	At 50 microM, chelerythrine, sanguinarine and sanguiritrin inhibited aminopeptidase N by 82%, 82%, 88%, DPP IV by 38%, 62%, 57%, and fagaronine by 34%, respectively.	sanguinarine	29-41	alanyl aminopeptidase, membrane	Bos taurus	69-85
11807974-2	2002	At 50 microM, chelerythrine, sanguinarine and sanguiritrin inhibited aminopeptidase N by 82%, 82%, 88%, DPP IV by 38%, 62%, 57%, and fagaronine by 34%, respectively.	sanguinarine	29-41	dipeptidyl peptidase 4	Bos taurus	104-110
11807974-2	2002	At 50 microM, chelerythrine, sanguinarine and sanguiritrin inhibited aminopeptidase N by 82%, 82%, 88%, DPP IV by 38%, 62%, 57%, and fagaronine by 34%, respectively.	sanguinarine	46-58	alanyl aminopeptidase, membrane	Bos taurus	69-85
11807974-2	2002	At 50 microM, chelerythrine, sanguinarine and sanguiritrin inhibited aminopeptidase N by 82%, 82%, 88%, DPP IV by 38%, 62%, 57%, and fagaronine by 34%, respectively.	sanguinarine	46-58	dipeptidyl peptidase 4	Bos taurus	104-110
11996882-7	2002	Treatment with 2.12 or 4.24 microM sanguinarine induced death in most cells that was characterized as apoptosis using the criteria of cell surface blebbing, as determined by light and scanning electron microscopy, and proteolytic activation of caspase-3 and cleavage of the caspase-3 substrate poly(ADP-ribose) polymerase (PARP), as detected by Western blot analysis.	sanguinarine	35-47	caspase 3	Homo sapiens	244-253
11996882-7	2002	Treatment with 2.12 or 4.24 microM sanguinarine induced death in most cells that was characterized as apoptosis using the criteria of cell surface blebbing, as determined by light and scanning electron microscopy, and proteolytic activation of caspase-3 and cleavage of the caspase-3 substrate poly(ADP-ribose) polymerase (PARP), as detected by Western blot analysis.	sanguinarine	35-47	caspase 3	Homo sapiens	274-283
11996882-7	2002	Treatment with 2.12 or 4.24 microM sanguinarine induced death in most cells that was characterized as apoptosis using the criteria of cell surface blebbing, as determined by light and scanning electron microscopy, and proteolytic activation of caspase-3 and cleavage of the caspase-3 substrate poly(ADP-ribose) polymerase (PARP), as detected by Western blot analysis.	sanguinarine	35-47	poly(ADP-ribose) polymerase 1	Homo sapiens	294-321
11996882-7	2002	Treatment with 2.12 or 4.24 microM sanguinarine induced death in most cells that was characterized as apoptosis using the criteria of cell surface blebbing, as determined by light and scanning electron microscopy, and proteolytic activation of caspase-3 and cleavage of the caspase-3 substrate poly(ADP-ribose) polymerase (PARP), as detected by Western blot analysis.	sanguinarine	35-47	poly(ADP-ribose) polymerase 1	Homo sapiens	323-327
11996882-9	2002	This study provides the first evidence that sanguinarine is effective against MDR in cervical cells via bimodal cell death, which displays alternative mechanisms involving different morphologies and caspase-3 activation status.	sanguinarine	44-56	caspase 3	Homo sapiens	199-208
11522612-7	2001	A pretreatment with a CoA-IT and lyso-PAF-AT inhibitor (Sanguinarin; 500 nM) blocked VEGF-induced PAF synthesis by 95%, a specific CoA-IT inhibitor (SKF45905; 10 - 50 microM) was without effect, confirming the crucial role of the PLA2 and lyso-PAF-AT.	sanguinarine	56-67	phospholipase A2 group IIA	Homo sapiens	230-234
11787859-0	2001	Role of Bcl-2 family proteins and caspase-3 in sanguinarine-induced bimodal cell death.	sanguinarine	47-59	BCL2 apoptosis regulator	Homo sapiens	8-13
11502101-0	2001	Bax, Bcl-2, and NF-kappaB expression in sanguinarine induced bimodal cell death.	sanguinarine	40-52	BCL2 associated X, apoptosis regulator	Homo sapiens	0-3
11502101-0	2001	Bax, Bcl-2, and NF-kappaB expression in sanguinarine induced bimodal cell death.	sanguinarine	40-52	BCL2 apoptosis regulator	Homo sapiens	5-10
11502101-0	2001	Bax, Bcl-2, and NF-kappaB expression in sanguinarine induced bimodal cell death.	sanguinarine	40-52	nuclear factor kappa B subunit 1	Homo sapiens	16-25
11502101-1	2001	The apoptosis related proteins Bax, Bcl-2, and NF-kappaB were analyzed in sanguinarine induced apoptosis and blister cell death (BCD) of K562 erythroleukemia cells and in sanguinarine treated high Bcl-2 expressing JM1 pre-B lymphoblastic cells, utilizing immunofluorescence-flow cytometry.	sanguinarine	74-86	BCL2 associated X, apoptosis regulator	Homo sapiens	31-34
11502101-1	2001	The apoptosis related proteins Bax, Bcl-2, and NF-kappaB were analyzed in sanguinarine induced apoptosis and blister cell death (BCD) of K562 erythroleukemia cells and in sanguinarine treated high Bcl-2 expressing JM1 pre-B lymphoblastic cells, utilizing immunofluorescence-flow cytometry.	sanguinarine	74-86	BCL2 apoptosis regulator	Homo sapiens	36-41
11502101-1	2001	The apoptosis related proteins Bax, Bcl-2, and NF-kappaB were analyzed in sanguinarine induced apoptosis and blister cell death (BCD) of K562 erythroleukemia cells and in sanguinarine treated high Bcl-2 expressing JM1 pre-B lymphoblastic cells, utilizing immunofluorescence-flow cytometry.	sanguinarine	74-86	nuclear factor kappa B subunit 1	Homo sapiens	47-56
11502101-1	2001	The apoptosis related proteins Bax, Bcl-2, and NF-kappaB were analyzed in sanguinarine induced apoptosis and blister cell death (BCD) of K562 erythroleukemia cells and in sanguinarine treated high Bcl-2 expressing JM1 pre-B lymphoblastic cells, utilizing immunofluorescence-flow cytometry.	sanguinarine	74-86	BCL2 apoptosis regulator	Homo sapiens	197-202
11502101-1	2001	The apoptosis related proteins Bax, Bcl-2, and NF-kappaB were analyzed in sanguinarine induced apoptosis and blister cell death (BCD) of K562 erythroleukemia cells and in sanguinarine treated high Bcl-2 expressing JM1 pre-B lymphoblastic cells, utilizing immunofluorescence-flow cytometry.	sanguinarine	74-86	coiled-coil domain containing 22	Homo sapiens	214-217
11502101-2	2001	Sanguinarine induced apoptosis of K562 cells was found to have increased Bax expression and decreased NF-kappaB, whereas BCD showed a decrease in Bax expression and an increase in NF-kappaB.	sanguinarine	0-12	BCL2 associated X, apoptosis regulator	Homo sapiens	73-76
11502101-2	2001	Sanguinarine induced apoptosis of K562 cells was found to have increased Bax expression and decreased NF-kappaB, whereas BCD showed a decrease in Bax expression and an increase in NF-kappaB.	sanguinarine	0-12	nuclear factor kappa B subunit 1	Homo sapiens	102-111
11502101-2	2001	Sanguinarine induced apoptosis of K562 cells was found to have increased Bax expression and decreased NF-kappaB, whereas BCD showed a decrease in Bax expression and an increase in NF-kappaB.	sanguinarine	0-12	nuclear factor kappa B subunit 1	Homo sapiens	180-189
11502101-3	2001	In contrast, high Bcl-2 expressing JM1 cells, when exposed to the same concentrations (and duration) of sanguinarine that induced PCD and BCD in K562 cells, failed to show the respective morphologies while showing a concomitant increase in Bcl-2.	sanguinarine	104-116	BCL2 apoptosis regulator	Homo sapiens	18-23
11502101-3	2001	In contrast, high Bcl-2 expressing JM1 cells, when exposed to the same concentrations (and duration) of sanguinarine that induced PCD and BCD in K562 cells, failed to show the respective morphologies while showing a concomitant increase in Bcl-2.	sanguinarine	104-116	coiled-coil domain containing 22	Homo sapiens	35-38
11502101-3	2001	In contrast, high Bcl-2 expressing JM1 cells, when exposed to the same concentrations (and duration) of sanguinarine that induced PCD and BCD in K562 cells, failed to show the respective morphologies while showing a concomitant increase in Bcl-2.	sanguinarine	104-116	BCL2 apoptosis regulator	Homo sapiens	240-245
11301853-3	2001	Sanguinarine chloride (5) and isoliquiritigenin (13) were capable of lowering the levels of both ICAM-1 and VCAM-1.	sanguinarine	0-21	intercellular adhesion molecule 1	Mus musculus	97-103
11301853-3	2001	Sanguinarine chloride (5) and isoliquiritigenin (13) were capable of lowering the levels of both ICAM-1 and VCAM-1.	sanguinarine	0-21	vascular cell adhesion molecule 1	Mus musculus	108-114
11787859-8	2001	These results suggest that sanguinarine in K562 cells induces apoptosis through increasing Bax and activating caspase-3, whereas sanguinarine-induced BCD involves neither.	sanguinarine	27-39	BCL2 associated X, apoptosis regulator	Homo sapiens	91-94
11787859-8	2001	These results suggest that sanguinarine in K562 cells induces apoptosis through increasing Bax and activating caspase-3, whereas sanguinarine-induced BCD involves neither.	sanguinarine	27-39	caspase 3	Homo sapiens	110-119
11787859-0	2001	Role of Bcl-2 family proteins and caspase-3 in sanguinarine-induced bimodal cell death.	sanguinarine	47-59	caspase 3	Homo sapiens	34-43
11787859-2	2001	We previously demonstrated that sanguinarine treatment at a low level induced apoptosis or programmed cell death (PCD) in the Bcl-2 low-expressing K562 human erythroleukemia cells, and that a high level induced blister cell death (BCD); whereas Bcl-2 overexpressing, sanguinarine-treated JM1 pre-B lymphoblastic cells displayed neither apoptosis nor BCD morphologies.	sanguinarine	32-44	BCL2 apoptosis regulator	Homo sapiens	126-131
11787859-2	2001	We previously demonstrated that sanguinarine treatment at a low level induced apoptosis or programmed cell death (PCD) in the Bcl-2 low-expressing K562 human erythroleukemia cells, and that a high level induced blister cell death (BCD); whereas Bcl-2 overexpressing, sanguinarine-treated JM1 pre-B lymphoblastic cells displayed neither apoptosis nor BCD morphologies.	sanguinarine	32-44	BCL2 apoptosis regulator	Homo sapiens	245-250
11787859-2	2001	We previously demonstrated that sanguinarine treatment at a low level induced apoptosis or programmed cell death (PCD) in the Bcl-2 low-expressing K562 human erythroleukemia cells, and that a high level induced blister cell death (BCD); whereas Bcl-2 overexpressing, sanguinarine-treated JM1 pre-B lymphoblastic cells displayed neither apoptosis nor BCD morphologies.	sanguinarine	32-44	coiled-coil domain containing 22	Homo sapiens	288-291
11787859-3	2001	Here, we report that sanguinarine-treated K562 cells, when analyzed by western blot, showed significant increase in expression of the pro-apoptotic Bax protein in apoptosis, but not in BCD.	sanguinarine	21-33	BCL2 associated X, apoptosis regulator	Homo sapiens	148-151
11770015-1	2001	Our previous studies with low Bcl-2-expressing K562 cells have shown that, when treated with the putative anti-cancer drug sanguinarine, concentrations of 1.5 microg/ml induced the morphology of apoptosis or programmed cell death (PCD), while concentrations of 12.5 microg/ml induced a morphology of blister formation or blister cell death (BCD).	sanguinarine	123-135	BCL2 apoptosis regulator	Homo sapiens	30-35
10807666-5	2000	Sanguinarine induced Ca(2+) release from the actively loaded SR vesicles was blocked by ruthenium red and dithiothreitol (DTT), consistent with the ryanodine receptor (RyR) as the site of sanguinarine action.	sanguinarine	0-12	ryanodine receptor 1, skeletal muscle	Mus musculus	148-166
11770015-4	2001	Thus, the over-expression of anti-apoptotic Bcl-2 may have prevented sanguinarine from inducing PCD and BCD in JM1 cells.	sanguinarine	69-81	BCL2 apoptosis regulator	Homo sapiens	44-49
11770015-5	2001	These results indicate that the resistance of JM1 cells to the alkaloid sanguinarine may have been due to an anti-BCD role played by Bcl-2, in addition to its widely reported anti-apoptotic role.	sanguinarine	72-84	BCL2 apoptosis regulator	Homo sapiens	133-138
10807666-5	2000	Sanguinarine induced Ca(2+) release from the actively loaded SR vesicles was blocked by ruthenium red and dithiothreitol (DTT), consistent with the ryanodine receptor (RyR) as the site of sanguinarine action.	sanguinarine	0-12	ryanodine receptor 1, skeletal muscle	Mus musculus	168-171
10807666-5	2000	Sanguinarine induced Ca(2+) release from the actively loaded SR vesicles was blocked by ruthenium red and dithiothreitol (DTT), consistent with the ryanodine receptor (RyR) as the site of sanguinarine action.	sanguinarine	188-200	ryanodine receptor 1, skeletal muscle	Mus musculus	148-166
10807666-5	2000	Sanguinarine induced Ca(2+) release from the actively loaded SR vesicles was blocked by ruthenium red and dithiothreitol (DTT), consistent with the ryanodine receptor (RyR) as the site of sanguinarine action.	sanguinarine	188-200	ryanodine receptor 1, skeletal muscle	Mus musculus	168-171
10807666-6	2000	Sanguinarine altered [(3)H]-ryanodine binding to the RyR of isolated SR vesicles, potentiating [(3)H]-ryanodine binding at lower concentrations and inhibiting binding at higher concentrations.	sanguinarine	0-12	ryanodine receptor 1, skeletal muscle	Mus musculus	53-56
10807666-7	2000	All of these effects were reversed by DTT, suggesting that sanguinarine-induced Ca(2+) release from SR occurs through oxidation of critical SH groups of the RyR SR calcium release channel.	sanguinarine	59-71	ryanodine receptor 1, skeletal muscle	Mus musculus	157-160
10778985-6	2000	The induction of apoptosis by sanguinarine was also evident by confocal microscopy after labeling the cells with annexin V.	sanguinarine	30-42	annexin A5	Homo sapiens	113-122
9434598-6	1997	The inhibition of cAK, MLCK, and PKC by apomorphine and sanguinarine is competitive with respect to ATP as substrate.	sanguinarine	56-68	myosin light chain kinase	Rattus norvegicus	23-27
8794470-0	1996	Influence of sanguinarine on the GABA synthesizing enzyme glutamate decarboxylase in vitro.	sanguinarine	13-25	glutamate-ammonia ligase	Rattus norvegicus	58-81
9374492-9	1997	Overall, our results demonstrate that sanguinarine is a potent suppressor of NF-kappaB activation and it acts at a step prior to IkappaBalpha phosphorylation.	sanguinarine	38-50	nuclear factor kappa B subunit 1	Homo sapiens	77-86
9374492-9	1997	Overall, our results demonstrate that sanguinarine is a potent suppressor of NF-kappaB activation and it acts at a step prior to IkappaBalpha phosphorylation.	sanguinarine	38-50	NFKB inhibitor alpha	Homo sapiens	129-141
9374492-0	1997	Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-kappaB activation, IkappaBalpha phosphorylation, and degradation.	sanguinarine	0-12	nuclear factor kappa B subunit 1	Homo sapiens	60-69
9374492-0	1997	Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-kappaB activation, IkappaBalpha phosphorylation, and degradation.	sanguinarine	0-12	NFKB inhibitor alpha	Homo sapiens	82-94
9374492-0	1997	Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-kappaB activation, IkappaBalpha phosphorylation, and degradation.	sanguinarine	14-33	nuclear factor kappa B subunit 1	Homo sapiens	60-69
9374492-0	1997	Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-kappaB activation, IkappaBalpha phosphorylation, and degradation.	sanguinarine	14-33	NFKB inhibitor alpha	Homo sapiens	82-94
9374492-3	1997	In the present report we show that sanguinarine (a benzophenanthridine alkaloid), a known anti-inflammatory agent, is a potent inhibitor of NF-kappaB activation.	sanguinarine	35-47	nuclear factor kappa B subunit 1	Homo sapiens	140-149
9374492-4	1997	Treatment of human myeloid ML-1a cells with tumor necrosis factor rapidly activated NF-kappaB, this activation was completely suppressed by sanguinarine in a dose- and time-dependent manner.	sanguinarine	140-152	nuclear factor kappa B subunit 1	Homo sapiens	84-93
9374492-5	1997	Sanguinarine did not inhibit the binding of NF-kappaB protein to the DNA but rather inhibited the pathway leading to NF-kappaB activation.	sanguinarine	0-12	nuclear factor kappa B subunit 1	Homo sapiens	117-126
9374492-6	1997	The reversal of inhibitory effects of sanguinarine by reducing agents suggests a critical sulfhydryl group is involved in NF-kappaB activation.	sanguinarine	38-50	nuclear factor kappa B subunit 1	Homo sapiens	122-131
9374492-7	1997	Sanguinarine blocked the tumor necrosis factor-induced phosphorylation and degradation of IkappaBalpha, an inhibitory subunit of NF-kappaB, and inhibited translocation of p65 subunit to the nucleus.	sanguinarine	0-12	NFKB inhibitor alpha	Homo sapiens	90-102
9374492-7	1997	Sanguinarine blocked the tumor necrosis factor-induced phosphorylation and degradation of IkappaBalpha, an inhibitory subunit of NF-kappaB, and inhibited translocation of p65 subunit to the nucleus.	sanguinarine	0-12	nuclear factor kappa B subunit 1	Homo sapiens	129-138
9374492-7	1997	Sanguinarine blocked the tumor necrosis factor-induced phosphorylation and degradation of IkappaBalpha, an inhibitory subunit of NF-kappaB, and inhibited translocation of p65 subunit to the nucleus.	sanguinarine	0-12	RELA proto-oncogene, NF-kB subunit	Homo sapiens	171-174
9374492-8	1997	As sanguinarine also inhibited NF-kappaB activation induced by interleukin-1, phorbol ester, and okadaic acid but not that activated by hydrogen peroxide or ceramide, the pathway leading to NF-kappaB activation is likely different for different inducers.	sanguinarine	3-15	nuclear factor kappa B subunit 1	Homo sapiens	31-40
9374492-8	1997	As sanguinarine also inhibited NF-kappaB activation induced by interleukin-1, phorbol ester, and okadaic acid but not that activated by hydrogen peroxide or ceramide, the pathway leading to NF-kappaB activation is likely different for different inducers.	sanguinarine	3-15	nuclear factor kappa B subunit 1	Homo sapiens	190-199
9312909-18	1997	Sanguinarine, ellipticine and some of their derivatives, like other DNA-intercalators studied, inhibit also the enzymatic activities of cholinesterase systems due to hydrophobicity and positive charges of their molecules.	sanguinarine	0-12	butyrylcholinesterase	Homo sapiens	136-150
9005450-1	1996	The benzophenanthridine alkaloids sanguinarine and chelerythrine of Chelidonium majus, L. (Papaveraceae), are potent inhibitors of 5-lipoxygenase in polymorphonuclear leukocytes and 12-lipoxygenase in mouse epidermis, while the activity of soybean lipoxygenase is not influenced.	sanguinarine	34-46	arachidonate 5-lipoxygenase	Mus musculus	131-145
9005450-1	1996	The benzophenanthridine alkaloids sanguinarine and chelerythrine of Chelidonium majus, L. (Papaveraceae), are potent inhibitors of 5-lipoxygenase in polymorphonuclear leukocytes and 12-lipoxygenase in mouse epidermis, while the activity of soybean lipoxygenase is not influenced.	sanguinarine	34-46	linoleate 9S-lipoxygenase-4	Glycine max	133-145
9005450-1	1996	The benzophenanthridine alkaloids sanguinarine and chelerythrine of Chelidonium majus, L. (Papaveraceae), are potent inhibitors of 5-lipoxygenase in polymorphonuclear leukocytes and 12-lipoxygenase in mouse epidermis, while the activity of soybean lipoxygenase is not influenced.	sanguinarine	34-46	linoleate 9S-lipoxygenase-4	Glycine max	185-197
8794470-1	1996	The inhibitory activity of the quaternary benzophenanthridine alkaloid sanguinarine on rat brain glutamate decarboxylase (GAD; EC 4.1.1.15) was studied in vitro.	sanguinarine	71-83	glutamate-ammonia ligase	Rattus norvegicus	97-120
8794470-1	1996	The inhibitory activity of the quaternary benzophenanthridine alkaloid sanguinarine on rat brain glutamate decarboxylase (GAD; EC 4.1.1.15) was studied in vitro.	sanguinarine	71-83	glutamate-ammonia ligase	Rattus norvegicus	122-125
8794470-3	1996	The inhibition was irreversible and increased during the preincubation time of sanguinarine with the GAD preparation.	sanguinarine	79-91	glutamate-ammonia ligase	Rattus norvegicus	101-104
8794470-5	1996	As GAD catalyzes the rate-limiting step of GABA synthesis, its inhibition by sanguinarine may contribute to its physiological action in vivo.	sanguinarine	77-89	glutamate-ammonia ligase	Rattus norvegicus	3-6
34744004-6	2022	In addition, the genes, such as sox9b, myl7, nkx2.5 and bmp10, which play crucial parts in the development and the function of the heart, were changed after sanguinarine treatment.	sanguinarine	157-169	SRY-box transcription factor 9b	Danio rerio	32-37
34744004-6	2022	In addition, the genes, such as sox9b, myl7, nkx2.5 and bmp10, which play crucial parts in the development and the function of the heart, were changed after sanguinarine treatment.	sanguinarine	157-169	myosin, light chain 7, regulatory	Danio rerio	39-43
34744004-6	2022	In addition, the genes, such as sox9b, myl7, nkx2.5 and bmp10, which play crucial parts in the development and the function of the heart, were changed after sanguinarine treatment.	sanguinarine	157-169	NK2 homeobox 5	Danio rerio	45-51
34744004-6	2022	In addition, the genes, such as sox9b, myl7, nkx2.5 and bmp10, which play crucial parts in the development and the function of the heart, were changed after sanguinarine treatment.	sanguinarine	157-169	bone morphogenetic protein 10	Danio rerio	56-61
34744004-7	2022	caspase3, caspase9, bax and bcl2, apoptosis-related genes, were also altered by sanguinarine.	sanguinarine	80-92	caspase 3, apoptosis-related cysteine peptidase a	Danio rerio	0-8
34744004-7	2022	caspase3, caspase9, bax and bcl2, apoptosis-related genes, were also altered by sanguinarine.	sanguinarine	80-92	caspase 9, apoptosis-related cysteine peptidase	Danio rerio	10-18
34744004-7	2022	caspase3, caspase9, bax and bcl2, apoptosis-related genes, were also altered by sanguinarine.	sanguinarine	80-92	BCL2 associated X, apoptosis regulator a	Danio rerio	20-23
34744004-7	2022	caspase3, caspase9, bax and bcl2, apoptosis-related genes, were also altered by sanguinarine.	sanguinarine	80-92	BCL2 apoptosis regulator a	Danio rerio	28-32
34744004-10	2022	Moreover, the MAPK pathway (JNK and P38) were notably enhanced and involved in the cardiotoxicity induced by sanguinarine.	sanguinarine	109-121	mitogen-activated protein kinase 8b	Danio rerio	28-31
34744004-10	2022	Moreover, the MAPK pathway (JNK and P38) were notably enhanced and involved in the cardiotoxicity induced by sanguinarine.	sanguinarine	109-121	mitogen-activated protein kinase 14a	Danio rerio	36-39
35341731-7	2022	This study found sanguinarine (-10.7 kcal mol-1) to be the most potent inhibitor of EGFR as compared to erlotinib (-7.5 kcal mol-1).	sanguinarine	17-29	epidermal growth factor receptor	Homo sapiens	84-88
34024253-9	2021	More importantly, MKP1 inhibitor sanguinarine inhibited the dephosphorylation levels of p38, ERK1/2, and p66Shc caused by PTHrP.	sanguinarine	33-45	parathyroid hormone like hormone	Homo sapiens	122-127
34024253-9	2021	More importantly, MKP1 inhibitor sanguinarine inhibited the dephosphorylation levels of p38, ERK1/2, and p66Shc caused by PTHrP.	sanguinarine	33-45	dual specificity phosphatase 1	Homo sapiens	18-22
34024253-9	2021	More importantly, MKP1 inhibitor sanguinarine inhibited the dephosphorylation levels of p38, ERK1/2, and p66Shc caused by PTHrP.	sanguinarine	33-45	mitogen-activated protein kinase 1	Homo sapiens	88-91
34024253-9	2021	More importantly, MKP1 inhibitor sanguinarine inhibited the dephosphorylation levels of p38, ERK1/2, and p66Shc caused by PTHrP.	sanguinarine	33-45	mitogen-activated protein kinase 3	Homo sapiens	93-99
34956477-8	2021	Furthermore, OSA/AHA/sanguinarine/PDA-Bmkn2 hydrogel (less than 10 mug/mL BmKn2 and 0.2 mug/mL sanguinarine) had excellent biocompatibility.	sanguinarine	95-107	Osa protein	Escherichia coli	13-16
34467721-1	2021	Sanguinarine is the main active component of the Papaver plants, and protopine-6-hydroxylase(P6 H), involved in the sanguinarine biosynthetic pathway, can oxidize protopine to 6-hydroxyprotopine.	sanguinarine	0-12	protopine 6-monooxygenase	Papaver somniferum	93-97
34467721-1	2021	Sanguinarine is the main active component of the Papaver plants, and protopine-6-hydroxylase(P6 H), involved in the sanguinarine biosynthetic pathway, can oxidize protopine to 6-hydroxyprotopine.	sanguinarine	116-128	protopine 6-monooxygenase	Papaver somniferum	93-97
34467721-2	2021	The investigation on the diversity of P6 H genes in the medicinal Papaver plants contributes to the acquirement of P6 H with high activity to increase the biosynthesis of sanguinarine.	sanguinarine	171-183	protopine 6-monooxygenase	Papaver somniferum	38-42
34467721-2	2021	The investigation on the diversity of P6 H genes in the medicinal Papaver plants contributes to the acquirement of P6 H with high activity to increase the biosynthesis of sanguinarine.	sanguinarine	171-183	protopine 6-monooxygenase	Papaver somniferum	115-119
34467721-9	2021	The present study confirmed genetic diversity of P6 H in the three medicinal Papaver plants, which lays a basis for the research on the biosynthesis pathway and mechanism of sanguinarine in Papaver species.	sanguinarine	174-186	protopine 6-monooxygenase	Papaver somniferum	49-53
34124222-12	2021	Chelerythrine had a weak impact on NQO1 activity, but sanguinarine inhibited NQO1 activity Conclusion: Through studying the effects of cytosolic reductase inhibitors on chelerythrine reduction and the impact of chelerythrine and sanguinarine on the activity of NQO1 in vitro and in vivo, we clarified the potential drug interaction of Macleaya cordata extract in clinical application, so as to provide theoretical guidance for clinically safe medication.	sanguinarine	54-66	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	77-81
34124222-12	2021	Chelerythrine had a weak impact on NQO1 activity, but sanguinarine inhibited NQO1 activity Conclusion: Through studying the effects of cytosolic reductase inhibitors on chelerythrine reduction and the impact of chelerythrine and sanguinarine on the activity of NQO1 in vitro and in vivo, we clarified the potential drug interaction of Macleaya cordata extract in clinical application, so as to provide theoretical guidance for clinically safe medication.	sanguinarine	54-66	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	261-265
34124222-12	2021	Chelerythrine had a weak impact on NQO1 activity, but sanguinarine inhibited NQO1 activity Conclusion: Through studying the effects of cytosolic reductase inhibitors on chelerythrine reduction and the impact of chelerythrine and sanguinarine on the activity of NQO1 in vitro and in vivo, we clarified the potential drug interaction of Macleaya cordata extract in clinical application, so as to provide theoretical guidance for clinically safe medication.	sanguinarine	229-241	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	261-265
34409102-12	2021	In addition, sanguinarine inhibited the activation of microglia and decreased the expression of p-p38 and TNF-alpha, IL-1beta, and IL-6 in the spinal dorsal horn of the CCI group in a dose-dependent manner.	sanguinarine	13-25	mitogen activated protein kinase 14	Rattus norvegicus	98-101
34409102-12	2021	In addition, sanguinarine inhibited the activation of microglia and decreased the expression of p-p38 and TNF-alpha, IL-1beta, and IL-6 in the spinal dorsal horn of the CCI group in a dose-dependent manner.	sanguinarine	13-25	tumor necrosis factor	Rattus norvegicus	106-115
34409102-12	2021	In addition, sanguinarine inhibited the activation of microglia and decreased the expression of p-p38 and TNF-alpha, IL-1beta, and IL-6 in the spinal dorsal horn of the CCI group in a dose-dependent manner.	sanguinarine	13-25	interleukin 1 alpha	Rattus norvegicus	117-125
34409102-12	2021	In addition, sanguinarine inhibited the activation of microglia and decreased the expression of p-p38 and TNF-alpha, IL-1beta, and IL-6 in the spinal dorsal horn of the CCI group in a dose-dependent manner.	sanguinarine	13-25	interleukin 6	Rattus norvegicus	131-135
35546212-9	2022	Finally, we obtained 85.415 +- 11.887 ng mL-1 sanguinarine and 4.288 +- 1.395 ng mL-1 chelerytrine, which was more than 2-3 times the content in leaves of M. cordata.	sanguinarine	46-58	L1 cell adhesion molecule	Mus musculus	41-45
33636580-0	2021	Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1alpha pathways in breast cancer.	sanguinarine	0-12	EPH receptor B4	Homo sapiens	51-56
35176976-12	2022	Mechanistically, SAG decreased the protein stability of glutathione peroxide 4 (GPX4) through E3 ligase STUB1-mediated ubiquitination and degradation of endogenous GPX4.	sanguinarine	17-20	glutathione peroxidase 4	Homo sapiens	80-84
35176976-12	2022	Mechanistically, SAG decreased the protein stability of glutathione peroxide 4 (GPX4) through E3 ligase STUB1-mediated ubiquitination and degradation of endogenous GPX4.	sanguinarine	17-20	STIP1 homology and U-box containing protein 1	Homo sapiens	104-109
35176976-12	2022	Mechanistically, SAG decreased the protein stability of glutathione peroxide 4 (GPX4) through E3 ligase STUB1-mediated ubiquitination and degradation of endogenous GPX4.	sanguinarine	17-20	glutathione peroxidase 4	Homo sapiens	164-168
35176976-13	2022	GPX4 overexpression restored the proliferation and invasion of NSCLC cells treated with SAG through inhibiting ferroptosis.	sanguinarine	88-91	glutathione peroxidase 4	Homo sapiens	0-4
35176976-14	2022	CONCLUSIONS: SAG inhibits the growth and metastasis of NSCLC by regulating STUB1/GPX4-dependent ferroptosis.	sanguinarine	13-16	STIP1 homology and U-box containing protein 1	Homo sapiens	75-80
35176976-14	2022	CONCLUSIONS: SAG inhibits the growth and metastasis of NSCLC by regulating STUB1/GPX4-dependent ferroptosis.	sanguinarine	13-16	glutathione peroxidase 4	Homo sapiens	81-85
33570254-10	2021	Taken together, the results indicate that dietary administration of sanguinarine could enhance productive performance via improving nutrient digestibility, hepatic health indices and fortifying systemic antioxidant capacity in laying hens fed low-CP diets.	sanguinarine	68-80	ceruloplasmin	Gallus gallus	247-249
35243236-0	2022	Sanguinarine promotes healthspan and innate immunity through a conserved mechanism of ROS-mediated PMK-1/SKN-1 activation.	sanguinarine	0-12	Mitogen-activated protein kinase pmk-1	Caenorhabditis elegans	99-104
35243236-0	2022	Sanguinarine promotes healthspan and innate immunity through a conserved mechanism of ROS-mediated PMK-1/SKN-1 activation.	sanguinarine	0-12	BZIP domain-containing protein;Protein skinhead-1	Caenorhabditis elegans	105-110
35243236-6	2022	We further show that sanguinarine generates reactive oxygen species (ROS), which is followed by the activation of PMK-1/SKN-1pathway to extend healthspan.	sanguinarine	21-33	Mitogen-activated protein kinase pmk-1	Caenorhabditis elegans	114-119
35243236-6	2022	We further show that sanguinarine generates reactive oxygen species (ROS), which is followed by the activation of PMK-1/SKN-1pathway to extend healthspan.	sanguinarine	21-33	BZIP domain-containing protein;Protein skinhead-1	Caenorhabditis elegans	120-125
35243236-8	2022	In addition, we also find that sanguinarine enhances innate immunity through PMK-1/SKN-1 pathway.	sanguinarine	31-43	Mitogen-activated protein kinase pmk-1	Caenorhabditis elegans	77-82
35243236-8	2022	In addition, we also find that sanguinarine enhances innate immunity through PMK-1/SKN-1 pathway.	sanguinarine	31-43	BZIP domain-containing protein;Protein skinhead-1	Caenorhabditis elegans	83-88
6768879-0	1980	Inhibition of human pregnancy plasma diamine oxidase with alkaloids of Argemone mexicana--berberine and sanguinarine.	sanguinarine	104-116	amine oxidase copper containing 1	Homo sapiens	37-52
33636580-6	2021	Sanguinarine, a natural alkaloid, could effectively combat hypoxia-induced EphB4 and HIF-1alpha expression.	sanguinarine	0-12	EPH receptor B4	Homo sapiens	75-80
33636580-6	2021	Sanguinarine, a natural alkaloid, could effectively combat hypoxia-induced EphB4 and HIF-1alpha expression.	sanguinarine	0-12	hypoxia inducible factor 1 subunit alpha	Homo sapiens	85-95
33636580-7	2021	Sanguinarine inhibited the activation of downstream protein signal transducer and activator of transcription-3 (STAT3), thereby blocking hypoxia-induced HIF-1alpha/STAT3 interaction and downregulating the mRNA levels of their target genes.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	60-110
33636580-7	2021	Sanguinarine inhibited the activation of downstream protein signal transducer and activator of transcription-3 (STAT3), thereby blocking hypoxia-induced HIF-1alpha/STAT3 interaction and downregulating the mRNA levels of their target genes.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	112-117
33636580-0	2021	Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1alpha pathways in breast cancer.	sanguinarine	0-12	hypoxia inducible factor 1 subunit alpha	Homo sapiens	61-71
33636580-7	2021	Sanguinarine inhibited the activation of downstream protein signal transducer and activator of transcription-3 (STAT3), thereby blocking hypoxia-induced HIF-1alpha/STAT3 interaction and downregulating the mRNA levels of their target genes.	sanguinarine	0-12	hypoxia inducible factor 1 subunit alpha	Homo sapiens	153-163
33636580-7	2021	Sanguinarine inhibited the activation of downstream protein signal transducer and activator of transcription-3 (STAT3), thereby blocking hypoxia-induced HIF-1alpha/STAT3 interaction and downregulating the mRNA levels of their target genes.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	164-169
33636580-4	2021	PURPOSE: We explore the effect of sanguinarine on hypoxia-induced activation of Ephrin type-B receptor 4 (EphB4) and hypoxia inducible factor-1alpha (HIF-1alpha) pathways in breast cancer.	sanguinarine	34-46	EPH receptor B4	Homo sapiens	80-104
33636580-8	2021	Mechanically, sanguinarine attenuated HIF-1alpha protein levels via inhibition of MAPK/ERK pathways and promotion of HIF-1alpha proteasome degradation.	sanguinarine	14-26	hypoxia inducible factor 1 subunit alpha	Homo sapiens	38-48
33636580-4	2021	PURPOSE: We explore the effect of sanguinarine on hypoxia-induced activation of Ephrin type-B receptor 4 (EphB4) and hypoxia inducible factor-1alpha (HIF-1alpha) pathways in breast cancer.	sanguinarine	34-46	EPH receptor B4	Homo sapiens	106-111
33636580-4	2021	PURPOSE: We explore the effect of sanguinarine on hypoxia-induced activation of Ephrin type-B receptor 4 (EphB4) and hypoxia inducible factor-1alpha (HIF-1alpha) pathways in breast cancer.	sanguinarine	34-46	hypoxia inducible factor 1 subunit alpha	Homo sapiens	117-148
33636580-8	2021	Mechanically, sanguinarine attenuated HIF-1alpha protein levels via inhibition of MAPK/ERK pathways and promotion of HIF-1alpha proteasome degradation.	sanguinarine	14-26	EPH receptor B2	Homo sapiens	87-90
33636580-4	2021	PURPOSE: We explore the effect of sanguinarine on hypoxia-induced activation of Ephrin type-B receptor 4 (EphB4) and hypoxia inducible factor-1alpha (HIF-1alpha) pathways in breast cancer.	sanguinarine	34-46	hypoxia inducible factor 1 subunit alpha	Homo sapiens	150-160
33636580-8	2021	Mechanically, sanguinarine attenuated HIF-1alpha protein levels via inhibition of MAPK/ERK pathways and promotion of HIF-1alpha proteasome degradation.	sanguinarine	14-26	hypoxia inducible factor 1 subunit alpha	Homo sapiens	117-127
33790794-0	2021	The Antiangiogenic Effect of Sanguinarine Chloride on Experimental Choroidal Neovacularization in Mice via Inhibiting Vascular Endothelial Growth Factor.	sanguinarine	29-50	vascular endothelial growth factor A	Mus musculus	118-152
33636580-9	2021	Sanguinarine inhibited STAT3 activation through targeting its upstream EphB4 and accelerating STAT3 dephosphorylation.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	23-28
33636580-9	2021	Sanguinarine inhibited STAT3 activation through targeting its upstream EphB4 and accelerating STAT3 dephosphorylation.	sanguinarine	0-12	EPH receptor B4	Homo sapiens	71-76
33636580-9	2021	Sanguinarine inhibited STAT3 activation through targeting its upstream EphB4 and accelerating STAT3 dephosphorylation.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	94-99
33636580-11	2021	CONCLUSIONS: Our results may bring insights to the hypoxia-induced pathways in breast cancers, and suggest sanguinarine as a promising candidate for EphB4 and HIF-1alpha-targeted inhibition.	sanguinarine	107-119	EPH receptor B4	Homo sapiens	149-154
33636580-11	2021	CONCLUSIONS: Our results may bring insights to the hypoxia-induced pathways in breast cancers, and suggest sanguinarine as a promising candidate for EphB4 and HIF-1alpha-targeted inhibition.	sanguinarine	107-119	hypoxia inducible factor 1 subunit alpha	Homo sapiens	159-169
33272574-0	2021	Sanguinarine is an agonist of TRPA1 channel.	sanguinarine	0-12	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	30-35
32956692-8	2021	A pilot screening of a natural product library via this established FP screening assay identified sanguinarine analogues as potential beta-catenin/LEF1 interaction inhibitors.	sanguinarine	98-110	catenin beta 1	Homo sapiens	134-146
32956692-8	2021	A pilot screening of a natural product library via this established FP screening assay identified sanguinarine analogues as potential beta-catenin/LEF1 interaction inhibitors.	sanguinarine	98-110	lymphoid enhancer binding factor 1	Homo sapiens	147-151
32956692-9	2021	GST pull-down and surface plasmon resonance (SPR) assay demonstrated that beta-catenin/LEF1 interaction is a potential anticancer target of sanguinarine in vitro.	sanguinarine	140-152	catenin beta 1	Homo sapiens	74-86
32956692-9	2021	GST pull-down and surface plasmon resonance (SPR) assay demonstrated that beta-catenin/LEF1 interaction is a potential anticancer target of sanguinarine in vitro.	sanguinarine	140-152	lymphoid enhancer binding factor 1	Homo sapiens	87-91
33272574-2	2021	Here we demonstrate that TRPA1 channel (Transient receptor potential cation channel, member A1) is a potential target for sanguinarine.	sanguinarine	122-134	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	25-30
33272574-3	2021	Electrophysiological recordings show that sanguinarine activates TRPA1 channel potently with an EC50 0.09 (0.04-0.13) muM, but has no effects on other examined TRP channels.	sanguinarine	42-54	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	65-70
33272574-5	2021	Plantar injection of sanguinarine evokes nociceptive behaviors similar to that elicited by allyl isothiocyanate (AITC), a classic agonist of TRPA1.	sanguinarine	21-33	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	141-146
33272574-7	2021	Taken together, our data demonstrate that sanguinarine is a potent and relatively selective agonist of TRPA1 channel.	sanguinarine	42-54	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	103-108
32404582-7	2020	In addition, 0.5 muM SA immediately increased intracellular free calcium concentration ([Ca2+]i) and decreased the mRNA expression of contractile proteins such as calponin and alpha-smooth muscle actin after the treatment for 24 h. Furthermore, SA-mediated decrease in cell stiffness/traction force and increase in [Ca2+]i were significantly blunted by inhibiting the TAS2Rs signaling.	sanguinarine	21-23	actin gamma 2, smooth muscle	Rattus norvegicus	176-201
32234456-0	2020	Blocking Parkin/PINK1-mediated mitophagy sensitizes hepatocellular carcinoma cells to sanguinarine-induced mitochondrial apoptosis.	sanguinarine	86-98	PTEN induced kinase 1	Homo sapiens	16-21
32234456-4	2020	Sanguinarine triggers mitochondrial dysfunction and PTEN-induced putative kinase 1 (PINK1)/Parkin upregulation and recruitment to mitochondria.	sanguinarine	0-12	PTEN induced kinase 1	Homo sapiens	52-82
32234456-4	2020	Sanguinarine triggers mitochondrial dysfunction and PTEN-induced putative kinase 1 (PINK1)/Parkin upregulation and recruitment to mitochondria.	sanguinarine	0-12	PTEN induced kinase 1	Homo sapiens	84-89
32234456-5	2020	Elevated levels of p62 and LC3-II/I ratios suggest that sanguinarine is both an inducer of autophagy and a blocker of autolysosome formation, which is further confirmed by LC3-II conversion levels in presence of autophagy and mitophagy inhibitors, as well as an autophagy activator.	sanguinarine	56-68	nucleoporin 62	Homo sapiens	19-22
31591052-0	2019	Sanguinarine inhibits the tumorigenesis of gastric cancer by regulating the TOX/DNA-PKcs/ KU70/80 pathway.	sanguinarine	0-12	thymocyte selection associated high mobility group box	Homo sapiens	76-79
31931095-0	2020	Sanguinarine as a new chemical entity of thioredoxin reductase inhibitor to elicit oxidative stress and promote tumor cell apoptosis.	sanguinarine	0-12	peroxiredoxin 5	Homo sapiens	41-62
32065498-0	2020	Sanguinarine disrupts the colocalization and interaction of HIF-1alpha with tyrosine and serine phosphorylated-STAT3 in breast cancer.	sanguinarine	0-12	hypoxia inducible factor 1 subunit alpha	Homo sapiens	60-70
32065498-0	2020	Sanguinarine disrupts the colocalization and interaction of HIF-1alpha with tyrosine and serine phosphorylated-STAT3 in breast cancer.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	111-116
32065498-5	2020	The effects of a natural alkaloid, sanguinarine, on HIF-1alpha and STAT3 colocalization and interaction were evaluated in vitro and mouse xenograft models.	sanguinarine	35-47	hypoxia inducible factor 1, alpha subunit	Mus musculus	52-62
32065498-5	2020	The effects of a natural alkaloid, sanguinarine, on HIF-1alpha and STAT3 colocalization and interaction were evaluated in vitro and mouse xenograft models.	sanguinarine	35-47	signal transducer and activator of transcription 3	Mus musculus	67-72
32065498-7	2020	Sanguinarine could inhibit the nuclear colocalization and interaction of HIF-1alpha with p-STAT3-Tyr and p-STAT3-Ser in vivo and in vitro.	sanguinarine	0-12	hypoxia inducible factor 1 subunit alpha	Homo sapiens	73-83
32065498-7	2020	Sanguinarine could inhibit the nuclear colocalization and interaction of HIF-1alpha with p-STAT3-Tyr and p-STAT3-Ser in vivo and in vitro.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	91-96
32075082-6	2020	Sanguinarine was found to be the most potent inhibitor of IL-1beta secretion.	sanguinarine	0-12	interleukin 1 alpha	Homo sapiens	58-66
32104082-0	2020	IGFBP-3 Is the Key Target of Sanguinarine in Promoting Apoptosis in Hepatocellular Carcinoma.	sanguinarine	29-41	insulin like growth factor binding protein 3	Homo sapiens	0-7
32508048-0	2020	Sanguinarine suppresses migration and metastasis in colorectal carcinoma associated with the inversion of EMT through the Wnt/beta-catenin signaling.	sanguinarine	0-12	catenin beta 1	Homo sapiens	126-138
31819036-0	2019	Sanguinarine inhibits epithelial-mesenchymal transition via targeting HIF-1alpha/TGF-beta feed-forward loop in hepatocellular carcinoma.	sanguinarine	0-12	hypoxia inducible factor 1 subunit alpha	Homo sapiens	70-80
31819036-0	2019	Sanguinarine inhibits epithelial-mesenchymal transition via targeting HIF-1alpha/TGF-beta feed-forward loop in hepatocellular carcinoma.	sanguinarine	0-12	transforming growth factor alpha	Homo sapiens	81-89
31819036-6	2019	In hypoxic and TGF-beta cell models, sanguinarine inhibits HIF-1alpha signaling and the expression of EMT markers, translocation of Snail and activation of both Smad and PI3K-AKT pathways.	sanguinarine	37-49	transforming growth factor alpha	Homo sapiens	15-23
31819036-6	2019	In hypoxic and TGF-beta cell models, sanguinarine inhibits HIF-1alpha signaling and the expression of EMT markers, translocation of Snail and activation of both Smad and PI3K-AKT pathways.	sanguinarine	37-49	hypoxia inducible factor 1 subunit alpha	Homo sapiens	59-69
31819036-6	2019	In hypoxic and TGF-beta cell models, sanguinarine inhibits HIF-1alpha signaling and the expression of EMT markers, translocation of Snail and activation of both Smad and PI3K-AKT pathways.	sanguinarine	37-49	snail family transcriptional repressor 1	Homo sapiens	132-137
31819036-6	2019	In hypoxic and TGF-beta cell models, sanguinarine inhibits HIF-1alpha signaling and the expression of EMT markers, translocation of Snail and activation of both Smad and PI3K-AKT pathways.	sanguinarine	37-49	AKT serine/threonine kinase 1	Homo sapiens	175-178
31819036-7	2019	Sanguinarine could also inhibit TGF-beta-induced cell migration in HCC cells.	sanguinarine	0-12	transforming growth factor alpha	Homo sapiens	32-40
31819036-8	2019	In vivo studies reveal that the administration of sanguinarine inhibits tumor growth and HIF-1alpha signaling, inhibits the expression changes of EMT markers as well as Smad and PI3K-AKT pathway proteins.	sanguinarine	50-62	hypoxia inducible factor 1 subunit alpha	Homo sapiens	89-99
31819036-8	2019	In vivo studies reveal that the administration of sanguinarine inhibits tumor growth and HIF-1alpha signaling, inhibits the expression changes of EMT markers as well as Smad and PI3K-AKT pathway proteins.	sanguinarine	50-62	AKT serine/threonine kinase 1	Homo sapiens	183-186
31819036-9	2019	Our findings suggest that sanguinarine is a promising candidate targeting HIF-1alpha/TGF-beta signaling to improve the treatment for HCC patients.	sanguinarine	26-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	74-84
31819036-9	2019	Our findings suggest that sanguinarine is a promising candidate targeting HIF-1alpha/TGF-beta signaling to improve the treatment for HCC patients.	sanguinarine	26-38	transforming growth factor alpha	Homo sapiens	85-93
31568920-0	2019	Regulation of p21 expression for anti-apoptotic activity of DDX3 against sanguinarine-induced cell death on intrinsic pathway.	sanguinarine	73-85	H3 histone pseudogene 16	Homo sapiens	14-17
31568920-0	2019	Regulation of p21 expression for anti-apoptotic activity of DDX3 against sanguinarine-induced cell death on intrinsic pathway.	sanguinarine	73-85	DEAD-box helicase 3 X-linked	Homo sapiens	60-64
31568920-3	2019	PURPOSE: In this study, we aimed to study the bio-function of DDX3 anti-apoptotic activity in the intrinsic pathway using HeLa cells treated with sanguinarine.	sanguinarine	146-158	DEAD-box helicase 3 X-linked	Homo sapiens	62-66
31568920-9	2019	DDX3 upregulated anti-apoptotic gene expression (Bcl-xL, cyclin D1, cyclin E, and cyclin B1) and downregulated pro-apoptotic gene expression (caspase-3, Bax) after sanguinarine treatment.	sanguinarine	164-176	DEAD-box helicase 3 X-linked	Homo sapiens	0-4
32696742-7	2020	The PP2C inhibitor sanguinarine reversed PA-induced decrease of eNOS Ser1177 phosphorylation level and NO content.	sanguinarine	19-31	nitric oxide synthase 3	Homo sapiens	64-68
31931095-3	2020	We reported herein the natural product sanguinarine (SAN) as a potent inhibitor of TrxR with a new chemical scaffold.	sanguinarine	39-51	peroxiredoxin 5	Homo sapiens	83-87
31931095-3	2020	We reported herein the natural product sanguinarine (SAN) as a potent inhibitor of TrxR with a new chemical scaffold.	sanguinarine	53-56	peroxiredoxin 5	Homo sapiens	83-87
31931095-5	2020	Further synthesis of different model compounds of SAN demonstrated that the phenanthridinium unit is responsible for the TrxR inhibition.	sanguinarine	50-53	peroxiredoxin 5	Homo sapiens	121-125
31931095-6	2020	The core structure of SAN, e.g., the phenanthridinium moiety, is different from those of known TrxR inhibitors, and thus SAN is a new chemical entity of TrxR inhibitors and may serve a lead for further development.	sanguinarine	22-25	peroxiredoxin 5	Homo sapiens	153-157
31931095-6	2020	The core structure of SAN, e.g., the phenanthridinium moiety, is different from those of known TrxR inhibitors, and thus SAN is a new chemical entity of TrxR inhibitors and may serve a lead for further development.	sanguinarine	121-124	peroxiredoxin 5	Homo sapiens	153-157
32065498-7	2020	Sanguinarine could inhibit the nuclear colocalization and interaction of HIF-1alpha with p-STAT3-Tyr and p-STAT3-Ser in vivo and in vitro.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	107-112
32065498-8	2020	Our results may bring insights to the HIF-1alpha/STAT3 interaction in breast cancers and suggest sanguinarine as a promising candidate for HIF-alpha/STAT3 inhibition.	sanguinarine	97-109	hypoxia inducible factor 1 subunit alpha	Homo sapiens	38-48
32065498-8	2020	Our results may bring insights to the HIF-1alpha/STAT3 interaction in breast cancers and suggest sanguinarine as a promising candidate for HIF-alpha/STAT3 inhibition.	sanguinarine	97-109	signal transducer and activator of transcription 3	Homo sapiens	149-154
31512406-6	2020	Apoptosis-inducing effect of sanguinarine alone and in combination with cisplatin was evaluated by annexin V/PI assay and DAPI staining.	sanguinarine	29-41	annexin A5	Homo sapiens	99-108
31568920-11	2019	The results implied that p21 might be involved in the toxicity of sanguinarine to HeLa cells.	sanguinarine	66-78	H3 histone pseudogene 16	Homo sapiens	25-28
31568920-12	2019	Overexpression and knockdown of DDX3 under sanguinarine-treated conditions showed that DDX3 inhibited p21 expression in sanguinarine-treated HeLa cells.	sanguinarine	43-55	DEAD-box helicase 3 X-linked	Homo sapiens	32-36
31568920-12	2019	Overexpression and knockdown of DDX3 under sanguinarine-treated conditions showed that DDX3 inhibited p21 expression in sanguinarine-treated HeLa cells.	sanguinarine	43-55	DEAD-box helicase 3 X-linked	Homo sapiens	87-91
31568920-12	2019	Overexpression and knockdown of DDX3 under sanguinarine-treated conditions showed that DDX3 inhibited p21 expression in sanguinarine-treated HeLa cells.	sanguinarine	43-55	H3 histone pseudogene 16	Homo sapiens	102-105
31568920-12	2019	Overexpression and knockdown of DDX3 under sanguinarine-treated conditions showed that DDX3 inhibited p21 expression in sanguinarine-treated HeLa cells.	sanguinarine	120-132	DEAD-box helicase 3 X-linked	Homo sapiens	32-36
31568920-12	2019	Overexpression and knockdown of DDX3 under sanguinarine-treated conditions showed that DDX3 inhibited p21 expression in sanguinarine-treated HeLa cells.	sanguinarine	120-132	DEAD-box helicase 3 X-linked	Homo sapiens	87-91
31568920-12	2019	Overexpression and knockdown of DDX3 under sanguinarine-treated conditions showed that DDX3 inhibited p21 expression in sanguinarine-treated HeLa cells.	sanguinarine	120-132	H3 histone pseudogene 16	Homo sapiens	102-105
31568920-14	2019	CONCLUSION: Taken together, the results suggest that the S90E residue is important for the regulation of p21 expression responsible for the anti-apoptotic activity of DDX3 in HeLa cells treated with sanguinarine.	sanguinarine	199-211	H3 histone pseudogene 16	Homo sapiens	105-108
31568920-14	2019	CONCLUSION: Taken together, the results suggest that the S90E residue is important for the regulation of p21 expression responsible for the anti-apoptotic activity of DDX3 in HeLa cells treated with sanguinarine.	sanguinarine	199-211	DEAD-box helicase 3 X-linked	Homo sapiens	167-171
31568920-15	2019	A model of the antiapoptotic function of DDX3 on sanguinarine-treated HeLa cells was proposed to understand the molecular mechanism of the intrinsic apoptosis inhibition in cervical cancer cells.	sanguinarine	49-61	DEAD-box helicase 3 X-linked	Homo sapiens	41-45
31591052-5	2019	We identified 9 collective targets of SAG and GC, of which TOX expression levels were dramatically downregulated in GC tissues compared with adjacent normal tissues, and a low expression of TOX served as an independent prognostic factor of poor survival in patients with GC.	sanguinarine	38-41	thymocyte selection associated high mobility group box	Homo sapiens	59-62
31591052-5	2019	We identified 9 collective targets of SAG and GC, of which TOX expression levels were dramatically downregulated in GC tissues compared with adjacent normal tissues, and a low expression of TOX served as an independent prognostic factor of poor survival in patients with GC.	sanguinarine	38-41	thymocyte selection associated high mobility group box	Homo sapiens	190-193
31591052-7	2019	Furthermore, SAG increased the expression levels of TOX but decreased those of DNA-PKcs and KU70/80 in GC cells.	sanguinarine	13-16	thymocyte selection associated high mobility group box	Homo sapiens	52-55
31591052-7	2019	Furthermore, SAG increased the expression levels of TOX but decreased those of DNA-PKcs and KU70/80 in GC cells.	sanguinarine	13-16	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	79-87
31591052-7	2019	Furthermore, SAG increased the expression levels of TOX but decreased those of DNA-PKcs and KU70/80 in GC cells.	sanguinarine	13-16	X-ray repair cross complementing 6	Homo sapiens	92-96
31591052-8	2019	Our findings indicate that SAG inhibits the tumorigenesis of GC cells by regulating TOX/DNA-PKcs/KU70/80 signaling and may provide therapeutic strategies for the treatment of GC.	sanguinarine	27-30	thymocyte selection associated high mobility group box	Homo sapiens	84-87
31591052-8	2019	Our findings indicate that SAG inhibits the tumorigenesis of GC cells by regulating TOX/DNA-PKcs/KU70/80 signaling and may provide therapeutic strategies for the treatment of GC.	sanguinarine	27-30	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	88-96
31591052-8	2019	Our findings indicate that SAG inhibits the tumorigenesis of GC cells by regulating TOX/DNA-PKcs/KU70/80 signaling and may provide therapeutic strategies for the treatment of GC.	sanguinarine	27-30	X-ray repair cross complementing 6	Homo sapiens	97-101
31591052-0	2019	Sanguinarine inhibits the tumorigenesis of gastric cancer by regulating the TOX/DNA-PKcs/ KU70/80 pathway.	sanguinarine	0-12	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	80-88
31591052-0	2019	Sanguinarine inhibits the tumorigenesis of gastric cancer by regulating the TOX/DNA-PKcs/ KU70/80 pathway.	sanguinarine	0-12	X-ray repair cross complementing 6	Homo sapiens	90-94
31058086-0	2019	Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling.	sanguinarine	0-12	Janus kinase 2	Homo sapiens	92-96
31402318-3	2019	Utilizing a screening system based on wild-type eIF4AI and its L243G mutant with a changed linker domain, we discovered an eIF4AI inhibitor, sanguinarine (SAN) and used it to study the catalytic mechanism of eIF4AI.	sanguinarine	141-153	eukaryotic translation initiation factor 4A1	Homo sapiens	48-54
31402318-3	2019	Utilizing a screening system based on wild-type eIF4AI and its L243G mutant with a changed linker domain, we discovered an eIF4AI inhibitor, sanguinarine (SAN) and used it to study the catalytic mechanism of eIF4AI.	sanguinarine	141-153	eukaryotic translation initiation factor 4A1	Homo sapiens	123-129
31402318-3	2019	Utilizing a screening system based on wild-type eIF4AI and its L243G mutant with a changed linker domain, we discovered an eIF4AI inhibitor, sanguinarine (SAN) and used it to study the catalytic mechanism of eIF4AI.	sanguinarine	141-153	eukaryotic translation initiation factor 4A1	Homo sapiens	123-129
31163195-0	2019	p53-dependent upregulation of miR-16-2 by sanguinarine induces cell cycle arrest and apoptosis in hepatocellular carcinoma.	sanguinarine	42-54	tumor protein p53	Homo sapiens	0-3
31163195-0	2019	p53-dependent upregulation of miR-16-2 by sanguinarine induces cell cycle arrest and apoptosis in hepatocellular carcinoma.	sanguinarine	42-54	microRNA 16-2	Homo sapiens	30-38
31163195-4	2019	One compound, sanguinarine (SG), was capable of activating miR-16 in HCC cells with wildtype or mutated p53 expression but not in p53-deleted HCC cells.	sanguinarine	14-26	glycerophosphodiester phosphodiesterase 1	Homo sapiens	59-65
31163195-4	2019	One compound, sanguinarine (SG), was capable of activating miR-16 in HCC cells with wildtype or mutated p53 expression but not in p53-deleted HCC cells.	sanguinarine	14-26	tumor protein p53	Homo sapiens	104-107
31616177-0	2019	Sanguinarine exhibits potent efficacy against cervical cancer cells through inhibiting the STAT3 pathway in vitro and in vivo.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	91-96
31616177-10	2019	Western blot analysis results revealed that SNG-induced antitumor effect might be mediated by STAT3 inhibition.	sanguinarine	44-47	signal transducer and activator of transcription 3	Homo sapiens	94-99
31616177-11	2019	SNG increased the expression of the proapoptotic protein Bax and reduced the expression of the antiapoptotic protein Bcl-2.	sanguinarine	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	57-60
31616177-11	2019	SNG increased the expression of the proapoptotic protein Bax and reduced the expression of the antiapoptotic protein Bcl-2.	sanguinarine	0-3	BCL2 apoptosis regulator	Homo sapiens	117-122
28489960-4	2019	The putative inhibitor of SWAP70 sanguinarine blocked phagocytosis and F-actin polymerization, supporting a key role for SWAP70 in phagocytosis as demonstrated previously with knock-down.	sanguinarine	33-45	switching B cell complex subunit SWAP70	Homo sapiens	26-32
28489960-4	2019	The putative inhibitor of SWAP70 sanguinarine blocked phagocytosis and F-actin polymerization, supporting a key role for SWAP70 in phagocytosis as demonstrated previously with knock-down.	sanguinarine	33-45	switching B cell complex subunit SWAP70	Homo sapiens	121-127
30942394-11	2019	Sanguinarine also significantly increased the phosphorylation levels of c-Jun N-terminal kinase and p38, which indicated the involvement of the mitogen-activated protein kinase signaling pathway.	sanguinarine	0-12	mitogen-activated protein kinase 14	Homo sapiens	100-103
31058086-0	2019	Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	97-102
30735839-0	2019	Critical role of H2O2 in mediating sanguinarine-induced apoptosis in prostate cancer cells via facilitating ceramide generation, ERK1/2 phosphorylation, and Par-4 cleavage.	sanguinarine	35-47	mitogen-activated protein kinase 3	Homo sapiens	129-135
30735839-0	2019	Critical role of H2O2 in mediating sanguinarine-induced apoptosis in prostate cancer cells via facilitating ceramide generation, ERK1/2 phosphorylation, and Par-4 cleavage.	sanguinarine	35-47	pro-apoptotic WT1 regulator	Homo sapiens	157-162
30350369-12	2019	administration, the clearance (CL) of SA was 6.79 +- 0.63 (L h-1  kg-1 ) with a t1/2 of 0.34 +- 0.13 hr.	sanguinarine	38-40	procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1	Gallus gallus	59-70
29571014-0	2018	Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-kappaB signaling or PI3K/AKT/mTOR pathway.	sanguinarine	0-12	cancer susceptibility 2	Homo sapiens	95-100
30718974-11	2019	CYP1A1 and CYP1A2 expressions increased after sanguinarine-containing solution, fulvic acid, and drinking water acidifier treatment.	sanguinarine	46-58	cytochrome P450 family 1 subfamily A member 1	Sus scrofa	0-6
30718974-11	2019	CYP1A1 and CYP1A2 expressions increased after sanguinarine-containing solution, fulvic acid, and drinking water acidifier treatment.	sanguinarine	46-58	cytochrome P450 family 1 subfamily A member 2	Sus scrofa	11-17
29571014-0	2018	Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-kappaB signaling or PI3K/AKT/mTOR pathway.	sanguinarine	0-12	eukaryotic translation initiation factor 4A3	Homo sapiens	101-107
29571014-0	2018	Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-kappaB signaling or PI3K/AKT/mTOR pathway.	sanguinarine	0-12	AKT serine/threonine kinase 1	Homo sapiens	159-162
29571014-0	2018	Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-kappaB signaling or PI3K/AKT/mTOR pathway.	sanguinarine	0-12	mechanistic target of rapamycin kinase	Homo sapiens	163-167
29571014-6	2018	Moreover, sanguinarine induced CASC2 expression and silencing of CASC2 reversed the effects of sanguinarine in epithelial ovarian cancer cells.	sanguinarine	10-22	cancer susceptibility 2	Homo sapiens	31-36
29571014-6	2018	Moreover, sanguinarine induced CASC2 expression and silencing of CASC2 reversed the effects of sanguinarine in epithelial ovarian cancer cells.	sanguinarine	95-107	cancer susceptibility 2	Homo sapiens	65-70
29571014-9	2018	Knockdown of EIF4A3 reversed the effects of sanguinarine plus CASC2 silencing.	sanguinarine	44-56	eukaryotic translation initiation factor 4A3	Homo sapiens	13-19
29571014-10	2018	Besides, sanguinarine markedly inhibited the activation of NF-kappaB signaling or PI3K/AKT/mTOR pathway, which was reversed by CASC2 silencing.	sanguinarine	9-21	AKT serine/threonine kinase 1	Homo sapiens	87-90
29571014-10	2018	Besides, sanguinarine markedly inhibited the activation of NF-kappaB signaling or PI3K/AKT/mTOR pathway, which was reversed by CASC2 silencing.	sanguinarine	9-21	mechanistic target of rapamycin kinase	Homo sapiens	91-95
29571014-10	2018	Besides, sanguinarine markedly inhibited the activation of NF-kappaB signaling or PI3K/AKT/mTOR pathway, which was reversed by CASC2 silencing.	sanguinarine	9-21	cancer susceptibility 2	Homo sapiens	127-132
29571014-11	2018	And the effects of sanguinarine plus CASC2 silencing on the activation of these pathways were further reversed after knockdown of EIF4A3 at the same time.	sanguinarine	19-31	eukaryotic translation initiation factor 4A3	Homo sapiens	130-136
29571014-12	2018	CONCLUSIONS: Our findings reveal that sanguinarine exhibits antitumor effects in epithelial ovarian cancer cells possible via regulating CASC2-EIF4A3 axis and/or inhibiting NF-kappaB signaling or PI3K/AKT/mTOR pathway.	sanguinarine	38-50	cancer susceptibility 2	Homo sapiens	137-142
29571014-12	2018	CONCLUSIONS: Our findings reveal that sanguinarine exhibits antitumor effects in epithelial ovarian cancer cells possible via regulating CASC2-EIF4A3 axis and/or inhibiting NF-kappaB signaling or PI3K/AKT/mTOR pathway.	sanguinarine	38-50	eukaryotic translation initiation factor 4A3	Homo sapiens	143-149
29571014-12	2018	CONCLUSIONS: Our findings reveal that sanguinarine exhibits antitumor effects in epithelial ovarian cancer cells possible via regulating CASC2-EIF4A3 axis and/or inhibiting NF-kappaB signaling or PI3K/AKT/mTOR pathway.	sanguinarine	38-50	AKT serine/threonine kinase 1	Homo sapiens	201-204
29571014-12	2018	CONCLUSIONS: Our findings reveal that sanguinarine exhibits antitumor effects in epithelial ovarian cancer cells possible via regulating CASC2-EIF4A3 axis and/or inhibiting NF-kappaB signaling or PI3K/AKT/mTOR pathway.	sanguinarine	38-50	mechanistic target of rapamycin kinase	Homo sapiens	205-209
28926099-7	2018	In conclusion, these results indicate that Sanguinarine induces the differentiation of MC3T3-E1 cells through the activation of the AMPK/Smad1 signaling pathway.	sanguinarine	43-55	SMAD family member 1	Mus musculus	137-142
30074177-0	2018	Sanguinarine Attenuates Lipopolysaccharide-induced Inflammation and Apoptosis by Inhibiting the TLR4/NF-kappaB Pathway in H9c2 Cardiomyocytes.	sanguinarine	0-12	toll like receptor 4	Homo sapiens	96-100
29731961-9	2018	The NFkappaB inhibitor Sanguinarine resulted in a decrease in MMP7 protein expression and both NFkappaB inhibitor Sanguinarine and MMP inhibitor Batimastat prevented occludin degradation and budding.	sanguinarine	23-35	nuclear factor kappa B subunit 1	Homo sapiens	4-12
29731961-9	2018	The NFkappaB inhibitor Sanguinarine resulted in a decrease in MMP7 protein expression and both NFkappaB inhibitor Sanguinarine and MMP inhibitor Batimastat prevented occludin degradation and budding.	sanguinarine	23-35	matrix metallopeptidase 7	Homo sapiens	62-66
29731961-9	2018	The NFkappaB inhibitor Sanguinarine resulted in a decrease in MMP7 protein expression and both NFkappaB inhibitor Sanguinarine and MMP inhibitor Batimastat prevented occludin degradation and budding.	sanguinarine	23-35	nuclear factor kappa B subunit 1	Homo sapiens	95-103
29731961-9	2018	The NFkappaB inhibitor Sanguinarine resulted in a decrease in MMP7 protein expression and both NFkappaB inhibitor Sanguinarine and MMP inhibitor Batimastat prevented occludin degradation and budding.	sanguinarine	114-126	nuclear factor kappa B subunit 1	Homo sapiens	95-103
29783958-0	2018	Sanguinarine triggers intrinsic apoptosis to suppress colorectal cancer growth through disassociation between STRAP and MELK.	sanguinarine	0-12	serine/threonine kinase receptor associated protein	Homo sapiens	110-115
29783958-0	2018	Sanguinarine triggers intrinsic apoptosis to suppress colorectal cancer growth through disassociation between STRAP and MELK.	sanguinarine	0-12	maternal embryonic leucine zipper kinase	Homo sapiens	120-124
29783958-14	2018	The intrinsic apoptosis induced by sanguinarine was Bax-dependent.	sanguinarine	35-47	BCL2 associated X, apoptosis regulator	Homo sapiens	52-55
29783958-16	2018	Sanguinarine dephosphorylated STRAP and MELK and disrupted the association between them in HCT116 and SW480 cells.	sanguinarine	0-12	serine/threonine kinase receptor associated protein	Homo sapiens	30-35
29783958-16	2018	Sanguinarine dephosphorylated STRAP and MELK and disrupted the association between them in HCT116 and SW480 cells.	sanguinarine	0-12	maternal embryonic leucine zipper kinase	Homo sapiens	40-44
29783958-17	2018	The expression and association between STRAP and MELK were also attenuated by sanguinarine in the tumor tissues.	sanguinarine	78-90	serine/threonine kinase receptor associated protein	Homo sapiens	39-44
29783958-17	2018	The expression and association between STRAP and MELK were also attenuated by sanguinarine in the tumor tissues.	sanguinarine	78-90	maternal embryonic leucine zipper kinase	Homo sapiens	49-53
29783958-20	2018	CONCLUSIONS: Sanguinarine dephosphorelates STRAP and MELK and disassociates the interaction between them to trigger intrinsic apoptosis.	sanguinarine	13-25	serine/threonine kinase receptor associated protein	Homo sapiens	43-48
29783958-20	2018	CONCLUSIONS: Sanguinarine dephosphorelates STRAP and MELK and disassociates the interaction between them to trigger intrinsic apoptosis.	sanguinarine	13-25	maternal embryonic leucine zipper kinase	Homo sapiens	53-57
29761161-5	2018	While developing the T3SS screening method, we discovered that sanguinarine chloride, a natural compound, could decrease the production of the SPI-1 type III secretion system main virulence proteins SipA and SipB and prevent the invasion of HeLa cells by Salmonella enterica serovar Typhimurium without affecting the growth of Salmonella.	sanguinarine	63-84	Spi-1 proto-oncogene	Homo sapiens	143-148
29761161-6	2018	Furthermore, sanguinarine chloride downregulated the transcription of HilA and consequently regulated the expression of the SPI-1 apparatus and effector genes.	sanguinarine	13-34	Spi-1 proto-oncogene	Homo sapiens	124-129
30074177-0	2018	Sanguinarine Attenuates Lipopolysaccharide-induced Inflammation and Apoptosis by Inhibiting the TLR4/NF-kappaB Pathway in H9c2 Cardiomyocytes.	sanguinarine	0-12	nuclear factor kappa B subunit 1	Homo sapiens	101-110
28968696-0	2017	Sanguinarine inhibits pancreatic cancer stem cell characteristics by inducing oxidative stress and suppressing sonic hedgehog-Gli-Nanog pathway.	sanguinarine	0-12	GLI family zinc finger 1	Homo sapiens	126-129
29535628-8	2018	Interestingly, P-gp overexpressing cells were hypersensitive to sanguinarine.	sanguinarine	64-76	phosphoglycolate phosphatase	Homo sapiens	15-19
29535628-9	2018	Doxorubicin uptake assay carried by flow cytometry revealed that sanguinarine is a potent inhibitor of the P-gp transporter.	sanguinarine	65-77	phosphoglycolate phosphatase	Homo sapiens	107-111
29535628-10	2018	Moreover, immunoblotting analysis proved that P-gp was downregulated in a dose dependent manner after treating P-gp overexpressing cells with sanguinarine.	sanguinarine	142-154	phosphoglycolate phosphatase	Homo sapiens	46-50
29535628-10	2018	Moreover, immunoblotting analysis proved that P-gp was downregulated in a dose dependent manner after treating P-gp overexpressing cells with sanguinarine.	sanguinarine	142-154	phosphoglycolate phosphatase	Homo sapiens	111-115
28968696-9	2017	Furthermore, sanguinarine inhibited Shh-Gli pathway leading to modulation of Gli target genes in pancreatic CSCs.	sanguinarine	13-25	GLI family zinc finger 1	Homo sapiens	40-43
28968696-9	2017	Furthermore, sanguinarine inhibited Shh-Gli pathway leading to modulation of Gli target genes in pancreatic CSCs.	sanguinarine	13-25	GLI family zinc finger 1	Homo sapiens	77-80
28968696-10	2017	Chromatin immunoprecipitation assay demonstrated that Nanog directly binds to promoters of Cdk2, Cdk6, FGF4, c-Myc and Oct4, and sanguinarine inhibits the binding of Nanog with these genes, suggesting the direct involvement of Nanog in cell cycle, pluripotency and self-renewal.	sanguinarine	129-141	Nanog homeobox	Homo sapiens	54-59
28968696-10	2017	Chromatin immunoprecipitation assay demonstrated that Nanog directly binds to promoters of Cdk2, Cdk6, FGF4, c-Myc and Oct4, and sanguinarine inhibits the binding of Nanog with these genes, suggesting the direct involvement of Nanog in cell cycle, pluripotency and self-renewal.	sanguinarine	129-141	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	109-114
28968696-10	2017	Chromatin immunoprecipitation assay demonstrated that Nanog directly binds to promoters of Cdk2, Cdk6, FGF4, c-Myc and Oct4, and sanguinarine inhibits the binding of Nanog with these genes, suggesting the direct involvement of Nanog in cell cycle, pluripotency and self-renewal.	sanguinarine	129-141	POU class 5 homeobox 1	Homo sapiens	119-123
30962774-11	2018	Caspase assays demonstrated that sanguinarine treatment of C-33A cells resulted in an induction of caspase-3/7 when compared with vehicle-treated controls.	sanguinarine	33-45	caspase 3	Homo sapiens	99-108
28968696-0	2017	Sanguinarine inhibits pancreatic cancer stem cell characteristics by inducing oxidative stress and suppressing sonic hedgehog-Gli-Nanog pathway.	sanguinarine	0-12	Nanog homeobox	Homo sapiens	130-135
28968696-6	2017	Furthermore, sanguinarine suppressed epithelial-mesenchymal transition (EMT) by up-regulating E-cadherin and inhibiting N-cadherin.	sanguinarine	13-25	cadherin 1	Homo sapiens	94-104
28968696-6	2017	Furthermore, sanguinarine suppressed epithelial-mesenchymal transition (EMT) by up-regulating E-cadherin and inhibiting N-cadherin.	sanguinarine	13-25	cadherin 2	Homo sapiens	120-130
28968696-10	2017	Chromatin immunoprecipitation assay demonstrated that Nanog directly binds to promoters of Cdk2, Cdk6, FGF4, c-Myc and Oct4, and sanguinarine inhibits the binding of Nanog with these genes, suggesting the direct involvement of Nanog in cell cycle, pluripotency and self-renewal.	sanguinarine	129-141	Nanog homeobox	Homo sapiens	166-171
28968696-10	2017	Chromatin immunoprecipitation assay demonstrated that Nanog directly binds to promoters of Cdk2, Cdk6, FGF4, c-Myc and Oct4, and sanguinarine inhibits the binding of Nanog with these genes, suggesting the direct involvement of Nanog in cell cycle, pluripotency and self-renewal.	sanguinarine	129-141	Nanog homeobox	Homo sapiens	166-171
28968696-7	2017	Significant decrease in expression level of Snail, Slug and Zeb1 corroborated the suppression of EMT in sanguinarine treated pancreatic CSCS.	sanguinarine	104-116	snail family transcriptional repressor 1	Homo sapiens	44-49
28968696-12	2017	Enforced activation of Shh or overexpression of Nanog counteracted the inhibitory effects of sanguinarine on pancreatic CSC proliferation, suggesting the actions of sanguinarine are mediated, at least in part, through Shh-Gli-Nanog pathway.	sanguinarine	93-105	Nanog homeobox	Homo sapiens	48-53
28968696-12	2017	Enforced activation of Shh or overexpression of Nanog counteracted the inhibitory effects of sanguinarine on pancreatic CSC proliferation, suggesting the actions of sanguinarine are mediated, at least in part, through Shh-Gli-Nanog pathway.	sanguinarine	93-105	GLI family zinc finger 1	Homo sapiens	222-225
28968696-12	2017	Enforced activation of Shh or overexpression of Nanog counteracted the inhibitory effects of sanguinarine on pancreatic CSC proliferation, suggesting the actions of sanguinarine are mediated, at least in part, through Shh-Gli-Nanog pathway.	sanguinarine	93-105	Nanog homeobox	Homo sapiens	226-231
28968696-7	2017	Significant decrease in expression level of Snail, Slug and Zeb1 corroborated the suppression of EMT in sanguinarine treated pancreatic CSCS.	sanguinarine	104-116	snail family transcriptional repressor 2	Homo sapiens	51-55
28968696-12	2017	Enforced activation of Shh or overexpression of Nanog counteracted the inhibitory effects of sanguinarine on pancreatic CSC proliferation, suggesting the actions of sanguinarine are mediated, at least in part, through Shh-Gli-Nanog pathway.	sanguinarine	165-177	Nanog homeobox	Homo sapiens	48-53
28968696-12	2017	Enforced activation of Shh or overexpression of Nanog counteracted the inhibitory effects of sanguinarine on pancreatic CSC proliferation, suggesting the actions of sanguinarine are mediated, at least in part, through Shh-Gli-Nanog pathway.	sanguinarine	165-177	sonic hedgehog signaling molecule	Homo sapiens	218-221
28968696-12	2017	Enforced activation of Shh or overexpression of Nanog counteracted the inhibitory effects of sanguinarine on pancreatic CSC proliferation, suggesting the actions of sanguinarine are mediated, at least in part, through Shh-Gli-Nanog pathway.	sanguinarine	165-177	GLI family zinc finger 1	Homo sapiens	222-225
28968696-7	2017	Significant decrease in expression level of Snail, Slug and Zeb1 corroborated the suppression of EMT in sanguinarine treated pancreatic CSCS.	sanguinarine	104-116	zinc finger E-box binding homeobox 1	Homo sapiens	60-64
28968696-12	2017	Enforced activation of Shh or overexpression of Nanog counteracted the inhibitory effects of sanguinarine on pancreatic CSC proliferation, suggesting the actions of sanguinarine are mediated, at least in part, through Shh-Gli-Nanog pathway.	sanguinarine	165-177	Nanog homeobox	Homo sapiens	226-231
28968696-9	2017	Furthermore, sanguinarine inhibited Shh-Gli pathway leading to modulation of Gli target genes in pancreatic CSCs.	sanguinarine	13-25	sonic hedgehog signaling molecule	Homo sapiens	36-39
28381458-4	2017	Sanguinarine, a specific protein phosphatase (PP) 2C inhibitor, but not inhibitors of PP1, PP2A (okadaic acid), or PP2B (cyclosporine), abolished VP-induced S261 dephosphorylation.	sanguinarine	0-12	arginine vasopressin	Homo sapiens	146-148
28677733-10	2017	Importantly, the IFN-gamma-induced increase in the expression levels of MIG, IP-10 and I-TAC in the INS-1 cells was strongly inhibited by SFN, but not by other natural substances, such as curcumin, sanguinarine, resveratrol, triptolide and epigallocatechin gallate (EGCG), suggesting the specificity of SFN in downregulating the levels of these chemokines.	sanguinarine	198-210	interferon gamma	Rattus norvegicus	17-26
28677733-10	2017	Importantly, the IFN-gamma-induced increase in the expression levels of MIG, IP-10 and I-TAC in the INS-1 cells was strongly inhibited by SFN, but not by other natural substances, such as curcumin, sanguinarine, resveratrol, triptolide and epigallocatechin gallate (EGCG), suggesting the specificity of SFN in downregulating the levels of these chemokines.	sanguinarine	198-210	C-X-C motif chemokine ligand 9	Rattus norvegicus	72-75
28677733-10	2017	Importantly, the IFN-gamma-induced increase in the expression levels of MIG, IP-10 and I-TAC in the INS-1 cells was strongly inhibited by SFN, but not by other natural substances, such as curcumin, sanguinarine, resveratrol, triptolide and epigallocatechin gallate (EGCG), suggesting the specificity of SFN in downregulating the levels of these chemokines.	sanguinarine	198-210	insulin 1	Rattus norvegicus	100-105
28381458-5	2017	However, sanguinarine and VP significantly increased phosphorylation of ERK, a kinase that can phosphorylate S261; inhibition of ERK by PD98059 partially decreased baseline S261 phosphorylation.	sanguinarine	9-21	mitogen-activated protein kinase 1	Homo sapiens	72-75
28381458-7	2017	We also found that sanguinarine abolished VP-induced S261 dephosphorylation in cells expressing mutated AQP2 S256A, suggesting that the phosphorylation state of S261 is independent of S256.	sanguinarine	19-31	arginine vasopressin	Homo sapiens	42-44
28381458-7	2017	We also found that sanguinarine abolished VP-induced S261 dephosphorylation in cells expressing mutated AQP2 S256A, suggesting that the phosphorylation state of S261 is independent of S256.	sanguinarine	19-31	aquaporin 2	Homo sapiens	104-108
27420038-3	2016	Sanguinarine, chelerythrine and chelidonine depolymerized the microtubule network in living cancer cells (Hela cells and human osteosarcoma U2OS cells) and inhibited tubulin polymerization in vitro with IC50 values of 48.41 +- 3.73, 206.39 +- 4.20 and 34.51 +- 9.47 muM, respectively.	sanguinarine	0-12	latexin	Homo sapiens	266-269
28296008-0	2017	Sanguinarine exhibits antitumor activity via up-regulation of Fas-associated factor 1 in non-small cell lung cancer.	sanguinarine	0-12	Fas associated factor 1	Homo sapiens	62-85
28621943-9	2017	Two compounds, sanguinarine (1) and celastrol (2), were found to be cytostatic against lung and prostate cancer cell lines and cytotoxic against prostate cancer cell lines in vitro, although the dependence of RGS17 on these phenomena remains elusive, a result that is perhaps not surprising given the multimodal cytostatic and cytotoxic activities of many natural products.	sanguinarine	15-27	regulator of G protein signaling 17	Homo sapiens	209-214
28551880-10	2017	Insulin increased while sanguinarine attenuated phosphorylation of MKP-1 at 10 min reperfusion.	sanguinarine	24-36	dual specificity phosphatase 1	Rattus norvegicus	67-72
28551880-11	2017	CONCLUSION: Inhibition of MKP-1 with sanguinarine abolished the insulin-induced improvement in functional recovery, but reduced infarct size.	sanguinarine	37-49	dual specificity phosphatase 1	Rattus norvegicus	26-31
28176854-5	2017	Targeted depletion of PPM1A by shRNA or inhibition of PPM1A activity by sanguinarine restored JNK activation, resulting in increased apoptosis of Mtb-infected macrophages.	sanguinarine	72-84	mitogen-activated protein kinase 8	Homo sapiens	94-97
27565766-3	2017	The interaction mechanism between the G-quadruplex of KRAS promoter and three isoquinoline alkaloids (jatrorrhizine, berberine and sanguinarine) has been investigated by UV-visible, fluorescence and circular dichroism spectroscopic methods.	sanguinarine	131-143	KRAS proto-oncogene, GTPase	Homo sapiens	54-58
27565766-4	2017	The results showed that the three alkaloids can form complexes with G-quadruplex KRAS promoter with the molecular ratio of 1:1, and the binding constants were (0.90+-0.16)x106Lmol-1, (0.93+-0.21)x106Lmol-1 and (1.16+-0.45)x106Lmol-1 for jatrorrhizine, berberine and sanguinarine.	sanguinarine	266-278	KRAS proto-oncogene, GTPase	Homo sapiens	81-85
27565766-6	2017	Sanguinarine was more beneficial to maintain the stability and parallel conformation of KRAS promoter G-quadruplex.	sanguinarine	0-12	KRAS proto-oncogene, GTPase	Homo sapiens	88-92
27957827-0	2017	Sanguinarine inhibits growth and invasion of gastric cancer cells via regulation of the DUSP4/ERK pathway.	sanguinarine	0-12	dual specificity phosphatase 4	Homo sapiens	88-93
27957827-0	2017	Sanguinarine inhibits growth and invasion of gastric cancer cells via regulation of the DUSP4/ERK pathway.	sanguinarine	0-12	mitogen-activated protein kinase 1	Homo sapiens	94-97
27957827-5	2017	Functional experiments including CCK-8, Transwell and flow cytometry analysis indicated that sanguinarine or DUSP4 overexpression inhibited GC cell viability and invasive potential, and induced cell apoptosis and cycle arrest in S phase, but DUSP4 knockdown attenuated the antitumour activity of sanguinarine.	sanguinarine	93-105	dual specificity phosphatase 4	Homo sapiens	242-247
27957827-5	2017	Functional experiments including CCK-8, Transwell and flow cytometry analysis indicated that sanguinarine or DUSP4 overexpression inhibited GC cell viability and invasive potential, and induced cell apoptosis and cycle arrest in S phase, but DUSP4 knockdown attenuated the antitumour activity of sanguinarine.	sanguinarine	296-308	dual specificity phosphatase 4	Homo sapiens	109-114
27957827-6	2017	Further observation demonstrated that sanguinarine up-regulated the expression of DUSP4 and Bcl-2-associated X protein (Bax), but down-regulated phosphorylated extracellular signal-regulated kinase (p-ERK), proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 2 (MMP-2) and B-cell lymphoma 2 (Bcl-2) expression.	sanguinarine	38-50	dual specificity phosphatase 4	Homo sapiens	82-87
27957827-6	2017	Further observation demonstrated that sanguinarine up-regulated the expression of DUSP4 and Bcl-2-associated X protein (Bax), but down-regulated phosphorylated extracellular signal-regulated kinase (p-ERK), proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 2 (MMP-2) and B-cell lymphoma 2 (Bcl-2) expression.	sanguinarine	38-50	BCL2 associated X, apoptosis regulator	Homo sapiens	92-118
27957827-6	2017	Further observation demonstrated that sanguinarine up-regulated the expression of DUSP4 and Bcl-2-associated X protein (Bax), but down-regulated phosphorylated extracellular signal-regulated kinase (p-ERK), proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 2 (MMP-2) and B-cell lymphoma 2 (Bcl-2) expression.	sanguinarine	38-50	BCL2 associated X, apoptosis regulator	Homo sapiens	120-123
27957827-6	2017	Further observation demonstrated that sanguinarine up-regulated the expression of DUSP4 and Bcl-2-associated X protein (Bax), but down-regulated phosphorylated extracellular signal-regulated kinase (p-ERK), proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 2 (MMP-2) and B-cell lymphoma 2 (Bcl-2) expression.	sanguinarine	38-50	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	199-204
27957827-6	2017	Further observation demonstrated that sanguinarine up-regulated the expression of DUSP4 and Bcl-2-associated X protein (Bax), but down-regulated phosphorylated extracellular signal-regulated kinase (p-ERK), proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 2 (MMP-2) and B-cell lymphoma 2 (Bcl-2) expression.	sanguinarine	38-50	proliferating cell nuclear antigen	Homo sapiens	207-241
27957827-6	2017	Further observation demonstrated that sanguinarine up-regulated the expression of DUSP4 and Bcl-2-associated X protein (Bax), but down-regulated phosphorylated extracellular signal-regulated kinase (p-ERK), proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 2 (MMP-2) and B-cell lymphoma 2 (Bcl-2) expression.	sanguinarine	38-50	proliferating cell nuclear antigen	Homo sapiens	243-247
27957827-6	2017	Further observation demonstrated that sanguinarine up-regulated the expression of DUSP4 and Bcl-2-associated X protein (Bax), but down-regulated phosphorylated extracellular signal-regulated kinase (p-ERK), proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 2 (MMP-2) and B-cell lymphoma 2 (Bcl-2) expression.	sanguinarine	38-50	matrix metallopeptidase 2	Homo sapiens	250-276
27957827-6	2017	Further observation demonstrated that sanguinarine up-regulated the expression of DUSP4 and Bcl-2-associated X protein (Bax), but down-regulated phosphorylated extracellular signal-regulated kinase (p-ERK), proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 2 (MMP-2) and B-cell lymphoma 2 (Bcl-2) expression.	sanguinarine	38-50	matrix metallopeptidase 2	Homo sapiens	278-283
27957827-6	2017	Further observation demonstrated that sanguinarine up-regulated the expression of DUSP4 and Bcl-2-associated X protein (Bax), but down-regulated phosphorylated extracellular signal-regulated kinase (p-ERK), proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 2 (MMP-2) and B-cell lymphoma 2 (Bcl-2) expression.	sanguinarine	38-50	BCL2 apoptosis regulator	Homo sapiens	289-306
27957827-6	2017	Further observation demonstrated that sanguinarine up-regulated the expression of DUSP4 and Bcl-2-associated X protein (Bax), but down-regulated phosphorylated extracellular signal-regulated kinase (p-ERK), proliferating cell nuclear antigen (PCNA), matrix metalloproteinase 2 (MMP-2) and B-cell lymphoma 2 (Bcl-2) expression.	sanguinarine	38-50	BCL2 apoptosis regulator	Homo sapiens	92-97
27957827-7	2017	Taken together, our findings indicate that sanguinarine inhibits growth and invasion of GC cells through regulation of the DUSP4/ERK pathway, suggesting that sanguinarine may have potential for use in GC treatment.	sanguinarine	43-55	dual specificity phosphatase 4	Homo sapiens	123-128
27957827-7	2017	Taken together, our findings indicate that sanguinarine inhibits growth and invasion of GC cells through regulation of the DUSP4/ERK pathway, suggesting that sanguinarine may have potential for use in GC treatment.	sanguinarine	43-55	mitogen-activated protein kinase 1	Homo sapiens	129-132
27957827-7	2017	Taken together, our findings indicate that sanguinarine inhibits growth and invasion of GC cells through regulation of the DUSP4/ERK pathway, suggesting that sanguinarine may have potential for use in GC treatment.	sanguinarine	158-170	dual specificity phosphatase 4	Homo sapiens	123-128
27957827-7	2017	Taken together, our findings indicate that sanguinarine inhibits growth and invasion of GC cells through regulation of the DUSP4/ERK pathway, suggesting that sanguinarine may have potential for use in GC treatment.	sanguinarine	158-170	mitogen-activated protein kinase 1	Homo sapiens	129-132
27357344-9	2017	These dephosphorylating and prosurvival actions of PTHrP (1-37) were prevented by a phosphatase inhibitor cocktail, the phosphatase MKP1 inhibitor sanguinarine or a MKP1 siRNA.	sanguinarine	147-159	parathyroid hormone like hormone	Homo sapiens	51-56
28123499-9	2017	In addition, western blot analysis demonstrated that the ratio of B-cell lymphoma 2/Bcl-2-associated X protein was significantly increased following treatment with sanguinarine (P<0.05).	sanguinarine	164-176	BCL2, apoptosis regulator	Rattus norvegicus	84-89
27485114-7	2016	Investigation of the molecular mechanisms of the effects of sanguinarine revealed that it significantly inhibited lung CSC proliferation, invasion, and apoptosis, possibly via downregulation of the Wnt/beta-catenin signaling pathway.	sanguinarine	60-72	catenin (cadherin associated protein), beta 1	Mus musculus	202-214
27363951-0	2016	Sanguinarine Induces Apoptosis of Human Oral Squamous Cell Carcinoma KB Cells via Inactivation of the PI3K/Akt Signaling Pathway.	sanguinarine	0-12	AKT serine/threonine kinase 1	Homo sapiens	107-110
27363951-3	2016	Sanguinarine treatment increased DR5/TRAILR2 (death receptor 5/TRAIL receptor 2) expression and enhanced the activation of caspase-8 and cleavage of its substrate, Bid.	sanguinarine	0-12	TNF receptor superfamily member 10b	Homo sapiens	33-36
27363951-3	2016	Sanguinarine treatment increased DR5/TRAILR2 (death receptor 5/TRAIL receptor 2) expression and enhanced the activation of caspase-8 and cleavage of its substrate, Bid.	sanguinarine	0-12	TNF receptor superfamily member 10b	Homo sapiens	37-44
27363951-3	2016	Sanguinarine treatment increased DR5/TRAILR2 (death receptor 5/TRAIL receptor 2) expression and enhanced the activation of caspase-8 and cleavage of its substrate, Bid.	sanguinarine	0-12	TNF receptor superfamily member 10b	Homo sapiens	46-62
27363951-3	2016	Sanguinarine treatment increased DR5/TRAILR2 (death receptor 5/TRAIL receptor 2) expression and enhanced the activation of caspase-8 and cleavage of its substrate, Bid.	sanguinarine	0-12	caspase 8	Homo sapiens	123-132
27363951-3	2016	Sanguinarine treatment increased DR5/TRAILR2 (death receptor 5/TRAIL receptor 2) expression and enhanced the activation of caspase-8 and cleavage of its substrate, Bid.	sanguinarine	0-12	BH3 interacting domain death agonist	Homo sapiens	164-167
27363951-4	2016	Sanguinarine also induced the mitochondrial translocation of pro-apoptotic Bax, mitochondrial dysfunction, cytochrome c release to the cytosol, and activation of caspase-9 and -3.	sanguinarine	0-12	BCL2 associated X, apoptosis regulator	Homo sapiens	75-78
27363951-4	2016	Sanguinarine also induced the mitochondrial translocation of pro-apoptotic Bax, mitochondrial dysfunction, cytochrome c release to the cytosol, and activation of caspase-9 and -3.	sanguinarine	0-12	cytochrome c, somatic	Homo sapiens	107-119
27363951-4	2016	Sanguinarine also induced the mitochondrial translocation of pro-apoptotic Bax, mitochondrial dysfunction, cytochrome c release to the cytosol, and activation of caspase-9 and -3.	sanguinarine	0-12	caspase 9	Homo sapiens	162-178
27363951-6	2016	Sanguinarine also suppressed the phosphorylation of phosphoinositide 3-kinase (PI3K) and Akt in KB cells, while co-treatment of cells with sanguinarine and a PI3K inhibitor revealed synergistic apoptotic effects.	sanguinarine	0-12	AKT serine/threonine kinase 1	Homo sapiens	89-92
27363951-8	2016	Collectively, these findings indicate that the pro-apoptotic effects of sanguinarine in KB cells may be regulated by a caspase-dependent cascade via activation of both intrinsic and extrinsic signaling pathways and inactivation of PI3K/Akt signaling.	sanguinarine	72-84	AKT serine/threonine kinase 1	Homo sapiens	236-239
26103139-6	2016	This phenotype was reverted when sanguinarine, a putative SWAP-70 inhibitor, was added.	sanguinarine	33-45	SWA-70 protein	Mus musculus	58-65
27154977-0	2016	Hydrogen peroxide/ceramide/Akt signaling axis play a critical role in the antileukemic potential of sanguinarine.	sanguinarine	100-112	AKT serine/threonine kinase 1	Homo sapiens	27-30
27053523-8	2016	Inhibition of MKP-1 with sanguinarine blocked the Bis-dependent increase of MAP kinase activity.	sanguinarine	25-37	dual specificity phosphatase 1	Sus scrofa	14-19
27053523-9	2016	Sanguinarine alone increased MAP kinase activity due to its effects on MKP-1.	sanguinarine	0-12	dual specificity phosphatase 1	Sus scrofa	71-76
27053523-10	2016	Sanguinarine increased MKP-1 phosphorylation, which was inhibited by inhibition of MAP kinase.	sanguinarine	0-12	dual specificity phosphatase 1	Sus scrofa	23-28
25929337-11	2015	Further validation by qRT-PCR and immunoblot analyses demonstrated that the dual specificity phosphatase-4 (DUSP4) was significantly upregulated by sanguinarine in BxPC-3 and MIA PaCa-2 cells.	sanguinarine	148-160	dual specificity phosphatase 4	Homo sapiens	76-106
26528827-6	2016	Interestingly, only NOX3 was upregulated by sanguinarine, a pharmacological agent to elevate ROS, and resulted in EGFR overoxidation, degradation, and apoptosis.	sanguinarine	44-56	NADPH oxidase 3	Homo sapiens	20-24
26528827-6	2016	Interestingly, only NOX3 was upregulated by sanguinarine, a pharmacological agent to elevate ROS, and resulted in EGFR overoxidation, degradation, and apoptosis.	sanguinarine	44-56	epidermal growth factor receptor	Homo sapiens	114-118
26733987-11	2015	However, BAY11-7082, BAY11-7085, sanguinarine chloride hydrate and ellipticine were cytotoxic to hGF cells at low concentrations.	sanguinarine	33-62	hepatocyte growth factor	Homo sapiens	97-100
26733987-13	2015	Four of the compounds identified, BAY11-7082, BAY11-7085, sanguinarine chloride hydrate and ellipticine, had toxic effects on Candida strains and hGF cells.	sanguinarine	58-87	hepatocyte growth factor	Homo sapiens	146-149
25929337-11	2015	Further validation by qRT-PCR and immunoblot analyses demonstrated that the dual specificity phosphatase-4 (DUSP4) was significantly upregulated by sanguinarine in BxPC-3 and MIA PaCa-2 cells.	sanguinarine	148-160	dual specificity phosphatase 4	Homo sapiens	108-113
25929337-12	2015	Sanguinarine treatment also caused down-regulation of HIF1alpha and PCNA, and increased cleavage of PARP and Caspase-7.	sanguinarine	0-12	hypoxia inducible factor 1 subunit alpha	Homo sapiens	54-63
25929337-12	2015	Sanguinarine treatment also caused down-regulation of HIF1alpha and PCNA, and increased cleavage of PARP and Caspase-7.	sanguinarine	0-12	proliferating cell nuclear antigen	Homo sapiens	68-72
25929337-12	2015	Sanguinarine treatment also caused down-regulation of HIF1alpha and PCNA, and increased cleavage of PARP and Caspase-7.	sanguinarine	0-12	collagen type XI alpha 2 chain	Homo sapiens	100-104
25929337-12	2015	Sanguinarine treatment also caused down-regulation of HIF1alpha and PCNA, and increased cleavage of PARP and Caspase-7.	sanguinarine	0-12	caspase 7	Homo sapiens	109-118
25481375-4	2015	Our data show that hydroalcoholic extracts of greater celandine and its alkaloids, especially berberine, chelidonine and sanguinarine have a significant hERG potassium channel blocking effect.	sanguinarine	121-133	ETS transcription factor ERG	Homo sapiens	153-157
26223712-8	2015	According to the annexin-V apoptosis detection results, we found that sanguinarine caused 3.9% apoptosis and 1.3% necrosis, while CDDP caused 2.9% apoptosis and 20% necrosis on HEI-OC1 cells.	sanguinarine	70-82	annexin A5	Homo sapiens	17-26
25544362-10	2015	Treatment with sanguinarine, but not berberine, inhibited the proliferation of Rac1b cells, which was accompanied by significantly increased the level of PARP-89, and decreased both the level of cyclin-D1 and the percentage of BrdU positive cells.	sanguinarine	15-27	cyclin D1	Homo sapiens	195-204
25022545-3	2014	It was recently observed in our lab while using sanguinarine, an MKP-1 inhibitor, that there were differences in outcomes depending on the mode of recirculation used.	sanguinarine	48-60	dual specificity phosphatase 1	Rattus norvegicus	65-70
25704029-0	2015	BCL2 promotor methylation and miR-15a/16-1 upregulation is associated with sanguinarine-induced apoptotic death in rat HSC-T6 cells.	sanguinarine	75-87	BCL2, apoptosis regulator	Rattus norvegicus	0-4
25704029-0	2015	BCL2 promotor methylation and miR-15a/16-1 upregulation is associated with sanguinarine-induced apoptotic death in rat HSC-T6 cells.	sanguinarine	75-87	microRNA mir-15a	Rattus norvegicus	30-37
25704029-1	2015	Previous studies show that several pathways are involved in sanguinarine-induced apoptotic cell death, including AKT downregulation, inhibition of NF-kB activation, mediation of ROS production, downregulation of anti-apoptosis proteins XIAP and cIAP-1, upregulation of BAX, and downregulation of BCL2.	sanguinarine	60-72	AKT serine/threonine kinase 1	Rattus norvegicus	113-116
25704029-1	2015	Previous studies show that several pathways are involved in sanguinarine-induced apoptotic cell death, including AKT downregulation, inhibition of NF-kB activation, mediation of ROS production, downregulation of anti-apoptosis proteins XIAP and cIAP-1, upregulation of BAX, and downregulation of BCL2.	sanguinarine	60-72	nuclear factor kappa B subunit 1	Rattus norvegicus	147-152
25704029-1	2015	Previous studies show that several pathways are involved in sanguinarine-induced apoptotic cell death, including AKT downregulation, inhibition of NF-kB activation, mediation of ROS production, downregulation of anti-apoptosis proteins XIAP and cIAP-1, upregulation of BAX, and downregulation of BCL2.	sanguinarine	60-72	X-linked inhibitor of apoptosis	Rattus norvegicus	236-240
25704029-1	2015	Previous studies show that several pathways are involved in sanguinarine-induced apoptotic cell death, including AKT downregulation, inhibition of NF-kB activation, mediation of ROS production, downregulation of anti-apoptosis proteins XIAP and cIAP-1, upregulation of BAX, and downregulation of BCL2.	sanguinarine	60-72	BCL2 associated X, apoptosis regulator	Rattus norvegicus	269-272
25704029-1	2015	Previous studies show that several pathways are involved in sanguinarine-induced apoptotic cell death, including AKT downregulation, inhibition of NF-kB activation, mediation of ROS production, downregulation of anti-apoptosis proteins XIAP and cIAP-1, upregulation of BAX, and downregulation of BCL2.	sanguinarine	60-72	BCL2, apoptosis regulator	Rattus norvegicus	296-300
25704029-4	2015	We showed that sanguinarine-induced down regulation of BCL2 was associated with the increased methylation rate of BCL2 promotor district and the increased expression of miR-15a/16-1.	sanguinarine	15-27	BCL2, apoptosis regulator	Rattus norvegicus	55-59
25704029-4	2015	We showed that sanguinarine-induced down regulation of BCL2 was associated with the increased methylation rate of BCL2 promotor district and the increased expression of miR-15a/16-1.	sanguinarine	15-27	BCL2, apoptosis regulator	Rattus norvegicus	114-118
25704029-4	2015	We showed that sanguinarine-induced down regulation of BCL2 was associated with the increased methylation rate of BCL2 promotor district and the increased expression of miR-15a/16-1.	sanguinarine	15-27	microRNA mir-15a	Rattus norvegicus	169-176
25704029-5	2015	HSC-T6 cells treatment with 5-Aza-2"-deoxycytidine (5"-Aza-CdR) impeded sanguinarine-induced BCL2 promotor district methylation and recovered BCL2"s expression.	sanguinarine	72-84	BCL2, apoptosis regulator	Rattus norvegicus	93-97
25704029-6	2015	Over expression of BCL2 using pEGFP-N1 vector decreased sanguinarine-induced HSC-T6 cells apoptotic death significantly but not completely.	sanguinarine	56-68	BCL2, apoptosis regulator	Rattus norvegicus	19-23
25704029-7	2015	These observations clearly showed that BCL2 down regulation was associated with its promoter methylation and miR-15a/16-1 upregulation in sanguinarine-induced Rat HSC-T6 cells.	sanguinarine	138-150	BCL2, apoptosis regulator	Rattus norvegicus	39-43
25704029-7	2015	These observations clearly showed that BCL2 down regulation was associated with its promoter methylation and miR-15a/16-1 upregulation in sanguinarine-induced Rat HSC-T6 cells.	sanguinarine	138-150	microRNA mir-15a	Rattus norvegicus	109-116
25354369-0	2014	Binding of the iminium and alkanolamine forms of sanguinarine to lysozyme: spectroscopic analysis, thermodynamics, and molecular modeling studies.	sanguinarine	49-61	lysozyme	Homo sapiens	65-73
25354369-4	2014	Both forms of sanguinarine quenched the intrinsic fluorescence of Lyz, but the quenching efficiencies varied on the basis of binding that was derived after correction for an inner-filter effect.	sanguinarine	14-26	lysozyme	Homo sapiens	66-69
25354369-14	2014	This study advances our knowledge of the structural nature and thermodynamic aspects of binding between the putative anticancer alkaloid sanguinarine and lysozyme.	sanguinarine	137-149	lysozyme	Homo sapiens	154-162
25299846-0	2014	Involvement of heme oxygenase-1 in neuroprotection by sanguinarine against glutamate-triggered apoptosis in HT22 neuronal cells.	sanguinarine	54-66	heme oxygenase 1	Mus musculus	15-31
25299846-2	2014	In the present study, we demonstrated that sanguinarine markedly induces the expression of HO-1 which leads to a neuroprotective response in mouse hippocampus-derived neuronal HT22 cells from apoptotic cell death induced by glutamate.	sanguinarine	43-55	heme oxygenase 1	Mus musculus	91-95
25299846-7	2014	Sanguinarine also induced HO-1, NQO-1 expression via activation of Nrf2.	sanguinarine	0-12	heme oxygenase 1	Mus musculus	26-30
25299846-7	2014	Sanguinarine also induced HO-1, NQO-1 expression via activation of Nrf2.	sanguinarine	0-12	NAD(P)H dehydrogenase, quinone 1	Mus musculus	32-37
25299846-7	2014	Sanguinarine also induced HO-1, NQO-1 expression via activation of Nrf2.	sanguinarine	0-12	nuclear factor, erythroid derived 2, like 2	Mus musculus	67-71
25299846-8	2014	Additionally, we found that si RNA mediated knock-down of Nrf2 or HO-1 significantly inhibited sanguinarine-induced neuroprotective response.	sanguinarine	95-107	nuclear factor, erythroid derived 2, like 2	Mus musculus	58-62
25299846-8	2014	Additionally, we found that si RNA mediated knock-down of Nrf2 or HO-1 significantly inhibited sanguinarine-induced neuroprotective response.	sanguinarine	95-107	heme oxygenase 1	Mus musculus	66-70
24253595-5	2014	Inhibition of MKP-1 activity with a pharmacological inhibitor, sanguinarine (SA), increased JNK1/2, p38, and ERK1/2 activities without causing apoptosis.	sanguinarine	63-75	dual specificity phosphatase 1	Rattus norvegicus	14-19
25063710-0	2014	Protective effect of sanguinarine on LPS-induced endotoxic shock in mice and its effect on LPS-induced COX-2 expression and COX-2 associated PGE2 release from peritoneal macrophages.	sanguinarine	21-33	cytochrome c oxidase II, mitochondrial	Mus musculus	103-108
25063710-0	2014	Protective effect of sanguinarine on LPS-induced endotoxic shock in mice and its effect on LPS-induced COX-2 expression and COX-2 associated PGE2 release from peritoneal macrophages.	sanguinarine	21-33	cytochrome c oxidase II, mitochondrial	Mus musculus	124-129
24794108-2	2014	Sanguinarine, a natural quaternary benzophenanthridine alkaloid (QBA), was reported to be inhibitor of rat DDC and possessed a different inhibitory mechanism.	sanguinarine	0-12	dopa decarboxylase	Rattus norvegicus	107-110
24253595-13	2014	Following inhibition by SA, MKP-1 localized in the cytoplasm, while basal and CPT-induced MKP-1 remained in the nuclear fraction.	sanguinarine	24-26	dual specificity phosphatase 1	Rattus norvegicus	28-33
25895393-8	2014	CTX, sanguinarine (20 and 40 mg/kg) and combination significantly reduced the expression of MVD and VEGF compared with the control group (P < 0.01, P < 0.05).	sanguinarine	5-17	vascular endothelial growth factor A	Mus musculus	100-104
25895393-9	2014	CONCLUSION: Sanguinarine can effectively inhibit the growth of S180 implanted tumors via reducing MVD and the expression of VEGF, which is associated with its anti-angiogenesis.	sanguinarine	12-24	vascular endothelial growth factor A	Mus musculus	124-128
24875448-0	2014	Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition.	sanguinarine	0-12	dihydrofolate reductase	Homo sapiens	64-87
24875448-5	2014	Western blotting analysis revealed that suppression of BLBC growth by sanguinarine was correlated with a concurrent upregulation of p27 and downregulation of cyclin D1 and with the inhibition of STAT3 activation.	sanguinarine	70-82	interferon alpha inducible protein 27	Homo sapiens	132-135
24875448-5	2014	Western blotting analysis revealed that suppression of BLBC growth by sanguinarine was correlated with a concurrent upregulation of p27 and downregulation of cyclin D1 and with the inhibition of STAT3 activation.	sanguinarine	70-82	cyclin D1	Homo sapiens	158-167
24875448-5	2014	Western blotting analysis revealed that suppression of BLBC growth by sanguinarine was correlated with a concurrent upregulation of p27 and downregulation of cyclin D1 and with the inhibition of STAT3 activation.	sanguinarine	70-82	signal transducer and activator of transcription 3	Homo sapiens	195-200
24875448-6	2014	In addition, we identified sanguinarine as a potent inhibitor of dihydrofolate reductase (DHFR), able to impair enzyme activity even in methotrexate resistant MDA-MB-231 cells.	sanguinarine	27-39	dihydrofolate reductase	Homo sapiens	65-88
24875448-6	2014	In addition, we identified sanguinarine as a potent inhibitor of dihydrofolate reductase (DHFR), able to impair enzyme activity even in methotrexate resistant MDA-MB-231 cells.	sanguinarine	27-39	dihydrofolate reductase	Homo sapiens	90-94
24253595-5	2014	Inhibition of MKP-1 activity with a pharmacological inhibitor, sanguinarine (SA), increased JNK1/2, p38, and ERK1/2 activities without causing apoptosis.	sanguinarine	63-75	mitogen activated protein kinase 14	Rattus norvegicus	100-103
24253595-5	2014	Inhibition of MKP-1 activity with a pharmacological inhibitor, sanguinarine (SA), increased JNK1/2, p38, and ERK1/2 activities without causing apoptosis.	sanguinarine	63-75	mitogen activated protein kinase 3	Rattus norvegicus	109-115
24253595-5	2014	Inhibition of MKP-1 activity with a pharmacological inhibitor, sanguinarine (SA), increased JNK1/2, p38, and ERK1/2 activities without causing apoptosis.	sanguinarine	77-79	dual specificity phosphatase 1	Rattus norvegicus	14-19
24253595-5	2014	Inhibition of MKP-1 activity with a pharmacological inhibitor, sanguinarine (SA), increased JNK1/2, p38, and ERK1/2 activities without causing apoptosis.	sanguinarine	77-79	mitogen activated protein kinase 14	Rattus norvegicus	100-103
24253595-5	2014	Inhibition of MKP-1 activity with a pharmacological inhibitor, sanguinarine (SA), increased JNK1/2, p38, and ERK1/2 activities without causing apoptosis.	sanguinarine	77-79	mitogen activated protein kinase 3	Rattus norvegicus	109-115
24300172-0	2014	NQO1 involves in the imine bond reduction of sanguinarine and recombinant adeno-associated virus mediated NQO1 overexpression decreases sanguinarine-induced cytotoxicity in rat BRL cells.	sanguinarine	45-57	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	0-4
24345465-5	2014	Drug combination experiments indicated that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) treatment improved arsenic trioxide/sanguinarine efficacy, a feature associated with a striking apoptosis induction, particularly in the cisplatin-resistant variant.	sanguinarine	144-156	TNF superfamily member 10	Homo sapiens	44-99
24345465-5	2014	Drug combination experiments indicated that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) treatment improved arsenic trioxide/sanguinarine efficacy, a feature associated with a striking apoptosis induction, particularly in the cisplatin-resistant variant.	sanguinarine	144-156	TNF superfamily member 10	Homo sapiens	101-106
24345465-6	2014	Thus, a synergistic interaction between sanguinarine and arsenic trioxide could be obtained independent of relative cell sensitivity to arsenic trioxide, and an enhanced apoptosis induction could be achieved in combination with TRAIL through modulation of the extrinsic apoptotic pathway.	sanguinarine	40-52	TNF superfamily member 10	Homo sapiens	228-233
24300172-6	2014	SANG-induced apoptosis was correlated with the up-regulation of Bax/Bcl2 ratio and the down-regulation of Bcl2.	sanguinarine	0-4	BCL2, apoptosis regulator	Rattus norvegicus	106-110
24300172-0	2014	NQO1 involves in the imine bond reduction of sanguinarine and recombinant adeno-associated virus mediated NQO1 overexpression decreases sanguinarine-induced cytotoxicity in rat BRL cells.	sanguinarine	136-148	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	0-4
24300172-10	2014	These data illustrated that NQO1 involved in the imine bond reduction of sanguinarine and this was a less toxic metabolizing pathway than CYP1A1-metabolizing pathway.	sanguinarine	73-85	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	28-32
24300172-10	2014	These data illustrated that NQO1 involved in the imine bond reduction of sanguinarine and this was a less toxic metabolizing pathway than CYP1A1-metabolizing pathway.	sanguinarine	73-85	cytochrome P450, family 1, subfamily a, polypeptide 1	Rattus norvegicus	138-144
24300172-0	2014	NQO1 involves in the imine bond reduction of sanguinarine and recombinant adeno-associated virus mediated NQO1 overexpression decreases sanguinarine-induced cytotoxicity in rat BRL cells.	sanguinarine	136-148	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	106-110
24300172-6	2014	SANG-induced apoptosis was correlated with the up-regulation of Bax/Bcl2 ratio and the down-regulation of Bcl2.	sanguinarine	0-4	BCL2 associated X, apoptosis regulator	Rattus norvegicus	64-67
24300172-6	2014	SANG-induced apoptosis was correlated with the up-regulation of Bax/Bcl2 ratio and the down-regulation of Bcl2.	sanguinarine	0-4	BCL2, apoptosis regulator	Rattus norvegicus	68-72
24220687-0	2014	Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression.	sanguinarine	0-12	matrix metallopeptidase 9	Homo sapiens	43-48
25422239-9	2014	Sanguinarine treatment did not affect apoptototic gene expression but decreased levels of anti-apoptotic genes NOL3 and BCL2L2 in SH-SY5Y cells.	sanguinarine	0-12	nucleolar protein 3	Homo sapiens	111-115
25422239-9	2014	Sanguinarine treatment did not affect apoptototic gene expression but decreased levels of anti-apoptotic genes NOL3 and BCL2L2 in SH-SY5Y cells.	sanguinarine	0-12	BCL2 like 2	Homo sapiens	120-126
25422239-10	2014	Caspase and TNF related gene expression was affected by the sanguinarine-cisplatin combination in SH-SY5Y cells.	sanguinarine	60-72	tumor necrosis factor	Homo sapiens	12-15
24220687-10	2014	We also demonstrated that sanguinarine induced HO-1 expression, and that the inhibition of MMP-9 and COX-2 expression and the enzymatic activity of sanguinarine were abrogated by siRNA-mediated knockdown of HO-1 expression.	sanguinarine	26-38	heme oxygenase 1	Homo sapiens	47-51
24220687-10	2014	We also demonstrated that sanguinarine induced HO-1 expression, and that the inhibition of MMP-9 and COX-2 expression and the enzymatic activity of sanguinarine were abrogated by siRNA-mediated knockdown of HO-1 expression.	sanguinarine	26-38	matrix metallopeptidase 9	Homo sapiens	91-96
24220687-10	2014	We also demonstrated that sanguinarine induced HO-1 expression, and that the inhibition of MMP-9 and COX-2 expression and the enzymatic activity of sanguinarine were abrogated by siRNA-mediated knockdown of HO-1 expression.	sanguinarine	26-38	heme oxygenase 1	Homo sapiens	207-211
24220687-10	2014	We also demonstrated that sanguinarine induced HO-1 expression, and that the inhibition of MMP-9 and COX-2 expression and the enzymatic activity of sanguinarine were abrogated by siRNA-mediated knockdown of HO-1 expression.	sanguinarine	148-160	heme oxygenase 1	Homo sapiens	207-211
24220687-12	2014	Overall, the results of the present study demonstrate that HO-1 plays a pivotal role in the anti-invasive response of sanguinarine in TPA-stimulated breast cancer cells.	sanguinarine	118-130	heme oxygenase 1	Homo sapiens	59-63
24220687-0	2014	Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression.	sanguinarine	0-12	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	53-58
24220687-0	2014	Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression.	sanguinarine	0-12	heme oxygenase 1	Homo sapiens	117-121
24220687-4	2014	In the present study, we investigated the anti-invasive mechanism of sanguinarine by focusing on its role in inducing HO-1 in breast cancer cells.	sanguinarine	69-81	heme oxygenase 1	Homo sapiens	118-122
24220687-5	2014	The results showed that sanguinarine inhibited TPA-induced MMP-9 and COX-2 mRNA and protein expression in a dose-dependent manner at non-cytotoxic concentrations.	sanguinarine	24-36	matrix metallopeptidase 9	Homo sapiens	59-64
24220687-5	2014	The results showed that sanguinarine inhibited TPA-induced MMP-9 and COX-2 mRNA and protein expression in a dose-dependent manner at non-cytotoxic concentrations.	sanguinarine	24-36	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	69-74
24220687-7	2014	TIMP-1 and TIMP-2, specific endogenous inhibitors of MMP-9, were slightly induced by sanguinarine.	sanguinarine	85-97	TIMP metallopeptidase inhibitor 1	Homo sapiens	0-6
24220687-7	2014	TIMP-1 and TIMP-2, specific endogenous inhibitors of MMP-9, were slightly induced by sanguinarine.	sanguinarine	85-97	TIMP metallopeptidase inhibitor 2	Homo sapiens	11-17
24220687-7	2014	TIMP-1 and TIMP-2, specific endogenous inhibitors of MMP-9, were slightly induced by sanguinarine.	sanguinarine	85-97	matrix metallopeptidase 9	Homo sapiens	53-58
24220687-8	2014	Subsequent studies revealed that sanguinarine suppressed TPA-induced NF-kappaB and AP-1 activation, as well as the phosphorylation of Akt and ERK.	sanguinarine	33-45	AKT serine/threonine kinase 1	Homo sapiens	134-137
24220687-8	2014	Subsequent studies revealed that sanguinarine suppressed TPA-induced NF-kappaB and AP-1 activation, as well as the phosphorylation of Akt and ERK.	sanguinarine	33-45	mitogen-activated protein kinase 1	Homo sapiens	142-145
23562763-0	2013	Molecular basis of recognition of quadruplexes human telomere and c-myc promoter by the putative anticancer agent sanguinarine.	sanguinarine	114-126	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	66-71
23641325-6	2013	For both the compounds, a concentration of 10 muM (equivalent to 1.88 mug/ml for plumbagin and 3.68 mug/ml for sanguinarine) resulted in 100% mortality at 48 h, which meets the World Health Organization"s (WHO) criterion of "hit" compounds for the control of schistosomiasis.	sanguinarine	111-123	latexin	Homo sapiens	46-49
23993687-0	2013	Inhibitory effect of sanguinarine on PKC-CPI-17 pathway mediating by muscarinic receptors in dispersed intestinal smooth muscle cells.	sanguinarine	21-33	protein phosphatase 1, regulatory (inhibitor) subunit 14A	Rattus norvegicus	41-47
23993687-1	2013	This study investigated the inhibitory effects of sanguinarine (SA) on PKC-CPI-17 pathway in rat intestinal smooth muscle cells (ISMC).	sanguinarine	50-62	protein phosphatase 1, regulatory (inhibitor) subunit 14A	Rattus norvegicus	75-81
23993687-1	2013	This study investigated the inhibitory effects of sanguinarine (SA) on PKC-CPI-17 pathway in rat intestinal smooth muscle cells (ISMC).	sanguinarine	64-66	protein phosphatase 1, regulatory (inhibitor) subunit 14A	Rattus norvegicus	75-81
23993687-4	2013	ISMC treated with 1 or 3 muM SA for 30 min significantly decreased the mRNA expression of PKC-delta, PKC-epsilon, PKC-eta, and CPI-17.	sanguinarine	29-31	protein phosphatase 1, regulatory (inhibitor) subunit 14A	Rattus norvegicus	127-133
23993687-5	2013	1 muM SA could markedly inhibit carbachol (CCh)-mediated increase PKC-delta, PKC-eta, and CPI-17 mRNA but had no effect in PKC-epsilon.Treatment of ISMC with SA (1 muM, 30 min) caused a decrease in protein expression of PKC-delta.	sanguinarine	6-8	protein phosphatase 1, regulatory (inhibitor) subunit 14A	Rattus norvegicus	90-96
23993687-5	2013	1 muM SA could markedly inhibit carbachol (CCh)-mediated increase PKC-delta, PKC-eta, and CPI-17 mRNA but had no effect in PKC-epsilon.Treatment of ISMC with SA (1 muM, 30 min) caused a decrease in protein expression of PKC-delta.	sanguinarine	158-160	protein phosphatase 1, regulatory (inhibitor) subunit 14A	Rattus norvegicus	90-96
23562763-1	2013	BACKGROUND: Interaction of putative anticancer agent sanguinarine with two quadruplex forming sequences, human telomeric DNA (H24) and NHE III1 upstream of the P1 promoter of c-myc (Pu27), has been studied to understand the structural basis of the recognition.	sanguinarine	53-65	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	175-180
23180022-14	2013	CONCLUSION: There is an increase in concentration of sanguinarine and diethylnitrosamine in CaGB blood and tissue in comparison to the cholelithiasis group suggesting an association with carcinoma of the gallbladder.	sanguinarine	53-65	S100 calcium binding protein A9	Homo sapiens	92-96
23500771-4	2013	The results showed that SAG was a potent noncompetitive inhibitor of CYP2C8 activity (Ki=8.9 muM), and competitive inhibitor of CYP1A2, CYP2C9 and CYP3A4 activities (Ki=2.7, 3.8 and 2.0 muM, respectively).	sanguinarine	24-27	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	69-75
23500771-4	2013	The results showed that SAG was a potent noncompetitive inhibitor of CYP2C8 activity (Ki=8.9 muM), and competitive inhibitor of CYP1A2, CYP2C9 and CYP3A4 activities (Ki=2.7, 3.8 and 2.0 muM, respectively).	sanguinarine	24-27	latexin	Homo sapiens	93-96
23500771-4	2013	The results showed that SAG was a potent noncompetitive inhibitor of CYP2C8 activity (Ki=8.9 muM), and competitive inhibitor of CYP1A2, CYP2C9 and CYP3A4 activities (Ki=2.7, 3.8 and 2.0 muM, respectively).	sanguinarine	24-27	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	128-134
23500771-4	2013	The results showed that SAG was a potent noncompetitive inhibitor of CYP2C8 activity (Ki=8.9 muM), and competitive inhibitor of CYP1A2, CYP2C9 and CYP3A4 activities (Ki=2.7, 3.8 and 2.0 muM, respectively).	sanguinarine	24-27	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	136-142
23500771-4	2013	The results showed that SAG was a potent noncompetitive inhibitor of CYP2C8 activity (Ki=8.9 muM), and competitive inhibitor of CYP1A2, CYP2C9 and CYP3A4 activities (Ki=2.7, 3.8 and 2.0 muM, respectively).	sanguinarine	24-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	147-153
23500771-4	2013	The results showed that SAG was a potent noncompetitive inhibitor of CYP2C8 activity (Ki=8.9 muM), and competitive inhibitor of CYP1A2, CYP2C9 and CYP3A4 activities (Ki=2.7, 3.8 and 2.0 muM, respectively).	sanguinarine	24-27	latexin	Homo sapiens	186-189
23500771-5	2013	Furthermore, SAG exhibited time- and NADPH-dependent inhibition towards CYP1A2 and CYP3A4 with KI/kinact values of 13.3/0.087 and 5.58/0.029 min(-1) muM(-1), respectively.	sanguinarine	13-16	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	72-78
23500771-5	2013	Furthermore, SAG exhibited time- and NADPH-dependent inhibition towards CYP1A2 and CYP3A4 with KI/kinact values of 13.3/0.087 and 5.58/0.029 min(-1) muM(-1), respectively.	sanguinarine	13-16	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
23500771-5	2013	Furthermore, SAG exhibited time- and NADPH-dependent inhibition towards CYP1A2 and CYP3A4 with KI/kinact values of 13.3/0.087 and 5.58/0.029 min(-1) muM(-1), respectively.	sanguinarine	13-16	PWWP domain containing 3A, DNA repair factor	Homo sapiens	149-155
23500771-6	2013	Weak inhibition of SAG against CYP2E1, CYP2D6 and CYP2A6 was also observed.	sanguinarine	19-22	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	31-37
23500771-6	2013	Weak inhibition of SAG against CYP2E1, CYP2D6 and CYP2A6 was also observed.	sanguinarine	19-22	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	39-45
23500771-6	2013	Weak inhibition of SAG against CYP2E1, CYP2D6 and CYP2A6 was also observed.	sanguinarine	19-22	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	50-56
23500771-7	2013	In vitro-in vivo extrapolation (IV-IVE) from HLM data showed that more than 35.9% of CYP1A2, CYP2C9, CYP2C8 and CYP3A4 activities in vivo could be inhibited by SAG, suggesting that harmful DDIs could occur when SAG or its medical preparations are co-administered with drugs primarily cleared by these CYP isoforms.	sanguinarine	160-163	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	85-91
23500771-7	2013	In vitro-in vivo extrapolation (IV-IVE) from HLM data showed that more than 35.9% of CYP1A2, CYP2C9, CYP2C8 and CYP3A4 activities in vivo could be inhibited by SAG, suggesting that harmful DDIs could occur when SAG or its medical preparations are co-administered with drugs primarily cleared by these CYP isoforms.	sanguinarine	160-163	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	93-99
23500771-7	2013	In vitro-in vivo extrapolation (IV-IVE) from HLM data showed that more than 35.9% of CYP1A2, CYP2C9, CYP2C8 and CYP3A4 activities in vivo could be inhibited by SAG, suggesting that harmful DDIs could occur when SAG or its medical preparations are co-administered with drugs primarily cleared by these CYP isoforms.	sanguinarine	160-163	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	101-107
23500771-7	2013	In vitro-in vivo extrapolation (IV-IVE) from HLM data showed that more than 35.9% of CYP1A2, CYP2C9, CYP2C8 and CYP3A4 activities in vivo could be inhibited by SAG, suggesting that harmful DDIs could occur when SAG or its medical preparations are co-administered with drugs primarily cleared by these CYP isoforms.	sanguinarine	160-163	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
23500771-7	2013	In vitro-in vivo extrapolation (IV-IVE) from HLM data showed that more than 35.9% of CYP1A2, CYP2C9, CYP2C8 and CYP3A4 activities in vivo could be inhibited by SAG, suggesting that harmful DDIs could occur when SAG or its medical preparations are co-administered with drugs primarily cleared by these CYP isoforms.	sanguinarine	211-214	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	85-91
23500771-7	2013	In vitro-in vivo extrapolation (IV-IVE) from HLM data showed that more than 35.9% of CYP1A2, CYP2C9, CYP2C8 and CYP3A4 activities in vivo could be inhibited by SAG, suggesting that harmful DDIs could occur when SAG or its medical preparations are co-administered with drugs primarily cleared by these CYP isoforms.	sanguinarine	211-214	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	93-99
23500771-7	2013	In vitro-in vivo extrapolation (IV-IVE) from HLM data showed that more than 35.9% of CYP1A2, CYP2C9, CYP2C8 and CYP3A4 activities in vivo could be inhibited by SAG, suggesting that harmful DDIs could occur when SAG or its medical preparations are co-administered with drugs primarily cleared by these CYP isoforms.	sanguinarine	211-214	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	101-107
23500771-7	2013	In vitro-in vivo extrapolation (IV-IVE) from HLM data showed that more than 35.9% of CYP1A2, CYP2C9, CYP2C8 and CYP3A4 activities in vivo could be inhibited by SAG, suggesting that harmful DDIs could occur when SAG or its medical preparations are co-administered with drugs primarily cleared by these CYP isoforms.	sanguinarine	211-214	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
23660334-0	2013	Sanguinarine induces apoptosis in human colorectal cancer HCT-116 cells through ROS-mediated Egr-1 activation and mitochondrial dysfunction.	sanguinarine	0-12	early growth response 1	Homo sapiens	93-98
23660334-2	2013	Sanguinarine generated ROS, which was followed by a decrease in the mitochondrial membrane potential (MMP), the activation of caspase-9 and -3, and the down-regulation of anti-apoptotic proteins, such as Bcl2, XIAP and cIAP-1.	sanguinarine	0-12	caspase 9	Homo sapiens	126-142
23660334-2	2013	Sanguinarine generated ROS, which was followed by a decrease in the mitochondrial membrane potential (MMP), the activation of caspase-9 and -3, and the down-regulation of anti-apoptotic proteins, such as Bcl2, XIAP and cIAP-1.	sanguinarine	0-12	BCL2 apoptosis regulator	Homo sapiens	204-208
23660334-2	2013	Sanguinarine generated ROS, which was followed by a decrease in the mitochondrial membrane potential (MMP), the activation of caspase-9 and -3, and the down-regulation of anti-apoptotic proteins, such as Bcl2, XIAP and cIAP-1.	sanguinarine	0-12	X-linked inhibitor of apoptosis	Homo sapiens	210-214
23660334-2	2013	Sanguinarine generated ROS, which was followed by a decrease in the mitochondrial membrane potential (MMP), the activation of caspase-9 and -3, and the down-regulation of anti-apoptotic proteins, such as Bcl2, XIAP and cIAP-1.	sanguinarine	0-12	baculoviral IAP repeat containing 2	Homo sapiens	219-225
23660334-3	2013	Sanguinarine also promoted the activation of caspase-8 and truncation of Bid (tBid).	sanguinarine	0-12	caspase 8	Homo sapiens	45-54
23660334-3	2013	Sanguinarine also promoted the activation of caspase-8 and truncation of Bid (tBid).	sanguinarine	0-12	BH3 interacting domain death agonist	Homo sapiens	73-76
23660334-4	2013	However, the quenching of ROS generation by N-acetyl-l-cysteine, a scavenger of ROS, reversed the sanguinarine-induced apoptosis effects via inhibition of the MMP collapse, tBid expression, and activation of caspases.	sanguinarine	98-110	caspase 8	Homo sapiens	208-216
23660334-5	2013	Sanguinarine also markedly induced the expression of the early growth response gene-1 (Egr-1) during the early period, after which expression level was decreased.	sanguinarine	0-12	early growth response 1	Homo sapiens	87-92
23660334-6	2013	In addition, HCT-116 cells transfected with Egr-1 siRNA displayed significant blockage of sanguinarine-induced apoptotic activity in a ROS-dependent manner.	sanguinarine	90-102	early growth response 1	Homo sapiens	44-49
23660334-7	2013	These observations clearly indicate that ROS, which are key mediators of Egr-1 activation and MMP collapse, are involved in the early molecular events in the sanguinarine-induced apoptotic pathway acting in HCT-116 cells.	sanguinarine	158-170	early growth response 1	Homo sapiens	73-78
23823128-7	2013	A pharmacological blockade of MKP-1 by intra-hippocampal sanguinarine (SA) infusion prevented the development of depressive-like behaviors and resulted in relatively normal levels of MKP-1 and phospho-ERK after withdrawal.	sanguinarine	57-69	dual specificity phosphatase 1	Mus musculus	30-35
23823128-7	2013	A pharmacological blockade of MKP-1 by intra-hippocampal sanguinarine (SA) infusion prevented the development of depressive-like behaviors and resulted in relatively normal levels of MKP-1 and phospho-ERK after withdrawal.	sanguinarine	71-73	dual specificity phosphatase 1	Mus musculus	30-35
23261473-0	2013	Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-kappaB and ERK signaling pathways.	sanguinarine	0-12	TNF superfamily member 11	Homo sapiens	79-84
23717422-4	2013	Sanguinarine-induced apoptosis was correlated with the up-regulation of Bax, the down-regulation of Bid and XIAP, the activation of caspases (-3, -8, and -9), and the generation of increased reactive oxygen species (ROS).	sanguinarine	0-12	BCL2 associated X, apoptosis regulator	Homo sapiens	72-75
23717422-4	2013	Sanguinarine-induced apoptosis was correlated with the up-regulation of Bax, the down-regulation of Bid and XIAP, the activation of caspases (-3, -8, and -9), and the generation of increased reactive oxygen species (ROS).	sanguinarine	0-12	BH3 interacting domain death agonist	Homo sapiens	100-103
23717422-4	2013	Sanguinarine-induced apoptosis was correlated with the up-regulation of Bax, the down-regulation of Bid and XIAP, the activation of caspases (-3, -8, and -9), and the generation of increased reactive oxygen species (ROS).	sanguinarine	0-12	X-linked inhibitor of apoptosis	Homo sapiens	108-112
23717422-6	2013	In addition, sanguinarine effectively increased the activation of the c-Jun N-terminal kinase (JNK) and the expression of the early growth response gene-1 (Egr-1), which was recovered by pretreatment with NAC.	sanguinarine	13-25	mitogen-activated protein kinase 8	Homo sapiens	70-93
23717422-6	2013	In addition, sanguinarine effectively increased the activation of the c-Jun N-terminal kinase (JNK) and the expression of the early growth response gene-1 (Egr-1), which was recovered by pretreatment with NAC.	sanguinarine	13-25	mitogen-activated protein kinase 8	Homo sapiens	95-98
23717422-6	2013	In addition, sanguinarine effectively increased the activation of the c-Jun N-terminal kinase (JNK) and the expression of the early growth response gene-1 (Egr-1), which was recovered by pretreatment with NAC.	sanguinarine	13-25	early growth response 1	Homo sapiens	156-161
23717422-7	2013	Furthermore, knockdown of Egr-1 expression by small interfering RNA attenuated sanguinarine-induced apoptosis, but not the JNK inhibitor, indicating that the interception of ROS generation blocked the sanguinarine-induced apoptotic effects via deregulation of the expression of Egr-1 proteins.	sanguinarine	79-91	early growth response 1	Homo sapiens	26-31
23717422-7	2013	Furthermore, knockdown of Egr-1 expression by small interfering RNA attenuated sanguinarine-induced apoptosis, but not the JNK inhibitor, indicating that the interception of ROS generation blocked the sanguinarine-induced apoptotic effects via deregulation of the expression of Egr-1 proteins.	sanguinarine	201-213	early growth response 1	Homo sapiens	26-31
23499690-5	2013	Sanguinarine treatment also induced an increase in intracellular calcium concentration, which was inhibited by dantrolene, and promoted cleavage of BAP-31, thus suggesting a putative role for Ca(2+) release from endoplasmic reticulum and a cross-talk between endoplasmic reticulum and mitochondria in the anti-melanoma action of sanguinarine.	sanguinarine	0-12	B cell receptor associated protein 31	Homo sapiens	148-154
23499690-6	2013	Sanguinarine disrupted the mitochondrial transmembrane potential (DeltaPsim), released cytochrome c and Smac/DIABLO from mitochondria to cytosol, and induced oxidative stress.	sanguinarine	0-12	cytochrome c, somatic	Homo sapiens	87-99
23499690-6	2013	Sanguinarine disrupted the mitochondrial transmembrane potential (DeltaPsim), released cytochrome c and Smac/DIABLO from mitochondria to cytosol, and induced oxidative stress.	sanguinarine	0-12	diablo IAP-binding mitochondrial protein	Homo sapiens	104-108
23499690-6	2013	Sanguinarine disrupted the mitochondrial transmembrane potential (DeltaPsim), released cytochrome c and Smac/DIABLO from mitochondria to cytosol, and induced oxidative stress.	sanguinarine	0-12	diablo IAP-binding mitochondrial protein	Homo sapiens	109-115
23499690-8	2013	However, preincubation with N-acetyl-l-cysteine (NAC) prevented sanguinarine-induced oxidative stress, PARP cleavage, release of apoptogenic mitochondrial proteins, and cell death.	sanguinarine	64-76	X-linked Kx blood group	Homo sapiens	49-52
23499690-8	2013	However, preincubation with N-acetyl-l-cysteine (NAC) prevented sanguinarine-induced oxidative stress, PARP cleavage, release of apoptogenic mitochondrial proteins, and cell death.	sanguinarine	64-76	poly(ADP-ribose) polymerase 1	Homo sapiens	103-107
23499690-10	2013	Thus, pretreatment with the thiol antioxidants NAC and GSH abrogated the killing activity of sanguinarine.	sanguinarine	93-105	X-linked Kx blood group	Homo sapiens	47-50
24649171-0	2013	Sanguinarine is a novel VEGF inhibitor involved in the suppression of angiogenesis and cell migration.	sanguinarine	0-12	vascular endothelial growth factor A	Homo sapiens	24-28
24649171-2	2013	In the present study, it was demonstrated that sanguinarine, an alkaloid obtained from the bloodroot plant, markedly repressed the VEGF-induced tube formation of human microvascular endothelial cells (HMVECs) and the migration of human A549 lung cancer cells.	sanguinarine	47-59	vascular endothelial growth factor A	Homo sapiens	131-135
24649171-3	2013	Furthermore, sanguinarine decreased VEGF secretion and expression in HMVECs and A549 lung cancer cells in a dose- and time-dependent manner.	sanguinarine	13-25	vascular endothelial growth factor A	Homo sapiens	36-40
24649171-4	2013	Additionally, sanguinarine inhibited the activation of serum starvation- and hypoxia-induced VEGF promoter activity.	sanguinarine	14-26	vascular endothelial growth factor A	Homo sapiens	93-97
24649171-5	2013	Sanguinarine also inhibited the VEGF-mediated Akt and p38 activation, as well as VE-cadherin protein phosphorylation.	sanguinarine	0-12	vascular endothelial growth factor A	Homo sapiens	32-36
24649171-5	2013	Sanguinarine also inhibited the VEGF-mediated Akt and p38 activation, as well as VE-cadherin protein phosphorylation.	sanguinarine	0-12	AKT serine/threonine kinase 1	Homo sapiens	46-49
24649171-5	2013	Sanguinarine also inhibited the VEGF-mediated Akt and p38 activation, as well as VE-cadherin protein phosphorylation.	sanguinarine	0-12	mitogen-activated protein kinase 14	Homo sapiens	54-57
24649171-5	2013	Sanguinarine also inhibited the VEGF-mediated Akt and p38 activation, as well as VE-cadherin protein phosphorylation.	sanguinarine	0-12	cadherin 5	Homo sapiens	81-92
24649171-6	2013	To the best of our knowledge, this is the first study demonstrating that VEGF inhibition appears to be an important mechanism involved in the antiangiogenic and anti-invasive activities of sanguinarine in lung cancer treatment.	sanguinarine	189-201	vascular endothelial growth factor A	Homo sapiens	73-77
23430963-5	2013	Conversely, low doses of chelerythrine and sanguinarine, two inhibitors of PKC, reversed PMA inhibition and enhanced ionophore-stimulated deimination.	sanguinarine	43-55	protein kinase C alpha	Homo sapiens	75-78
23430963-7	2013	At higher doses, chelerythrine, sanguinarine, and structurally unrelated PKC inhibitors blocked histone deimination, suggesting that a different PKC isoform activates histone deimination.	sanguinarine	32-44	protein kinase C alpha	Homo sapiens	145-148
23261473-4	2013	Sanguinarine diminished the expression of osteoclast marker genes, including TRAP, cathepsin K, calcitonin receptor, DC-STAMP, V-ATPase d2, NFATc1 and c-fos.	sanguinarine	0-12	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	151-156
23261473-5	2013	Further investigation revealed that sanguinarine attenuated RANKL-mediated IkappaBalpha phosphorylation and degradation, leading to the impairment of NF-kappaB signaling pathway during osteoclast differentiation.	sanguinarine	36-48	TNF superfamily member 11	Homo sapiens	60-65
23261473-5	2013	Further investigation revealed that sanguinarine attenuated RANKL-mediated IkappaBalpha phosphorylation and degradation, leading to the impairment of NF-kappaB signaling pathway during osteoclast differentiation.	sanguinarine	36-48	NFKB inhibitor alpha	Homo sapiens	75-87
23261473-6	2013	In addition, sanguinarine also affected the ERK signaling pathway by inhibiting RANKL-induced ERK phosphorylation.	sanguinarine	13-25	TNF superfamily member 11	Homo sapiens	80-85
23261473-4	2013	Sanguinarine diminished the expression of osteoclast marker genes, including TRAP, cathepsin K, calcitonin receptor, DC-STAMP, V-ATPase d2, NFATc1 and c-fos.	sanguinarine	0-12	TRAP	Homo sapiens	77-81
23261473-4	2013	Sanguinarine diminished the expression of osteoclast marker genes, including TRAP, cathepsin K, calcitonin receptor, DC-STAMP, V-ATPase d2, NFATc1 and c-fos.	sanguinarine	0-12	cathepsin K	Homo sapiens	83-94
23261473-4	2013	Sanguinarine diminished the expression of osteoclast marker genes, including TRAP, cathepsin K, calcitonin receptor, DC-STAMP, V-ATPase d2, NFATc1 and c-fos.	sanguinarine	0-12	calcitonin receptor	Homo sapiens	96-115
23261473-4	2013	Sanguinarine diminished the expression of osteoclast marker genes, including TRAP, cathepsin K, calcitonin receptor, DC-STAMP, V-ATPase d2, NFATc1 and c-fos.	sanguinarine	0-12	nuclear factor of activated T cells 1	Homo sapiens	140-146
22965493-4	2012	Sanguinarine caused a dose-dependent decrease in Bcl-2 and NF-kappaB protein             expression and a significant increase in Bax protein expression.	sanguinarine	0-12	BCL2 apoptosis regulator	Homo sapiens	49-54
23762849-1	2013	The inhibitory action and the possible mechanism of anticancer compound Sanguinarine (SAN) on vascular endothelial growth factor (VEGF) in human mammary adenocarcinoma cells MCF-7 were evaluated in this study.	sanguinarine	72-84	vascular endothelial growth factor A	Homo sapiens	94-128
23762849-1	2013	The inhibitory action and the possible mechanism of anticancer compound Sanguinarine (SAN) on vascular endothelial growth factor (VEGF) in human mammary adenocarcinoma cells MCF-7 were evaluated in this study.	sanguinarine	72-84	vascular endothelial growth factor A	Homo sapiens	130-134
23762849-6	2013	High concentration of SAN inhibited VEGF mRNA expression in MCF-7 cultures, suggesting an effect at transcriptional level, and was also abolished by antioxidant.	sanguinarine	22-25	vascular endothelial growth factor A	Homo sapiens	36-40
23682786-4	2013	Further, treatment of TOCO and NAC either alone or in combination to AO/TPA- or SANG/TPA-induced mice significantly decreased lipid peroxidation, along with significant revival in glutathione (GSH) content and activities of tyrosinase, histidase, catalase, SOD, GSH peroxidase, and GSH reductase in skin.	sanguinarine	80-84	tyrosinase	Mus musculus	224-234
23682786-4	2013	Further, treatment of TOCO and NAC either alone or in combination to AO/TPA- or SANG/TPA-induced mice significantly decreased lipid peroxidation, along with significant revival in glutathione (GSH) content and activities of tyrosinase, histidase, catalase, SOD, GSH peroxidase, and GSH reductase in skin.	sanguinarine	80-84	histidine ammonia lyase	Mus musculus	236-245
23682786-4	2013	Further, treatment of TOCO and NAC either alone or in combination to AO/TPA- or SANG/TPA-induced mice significantly decreased lipid peroxidation, along with significant revival in glutathione (GSH) content and activities of tyrosinase, histidase, catalase, SOD, GSH peroxidase, and GSH reductase in skin.	sanguinarine	80-84	catalase	Mus musculus	247-255
23762849-0	2013	Sanguinarine inhibits vascular endothelial growth factor release by generation of reactive oxygen species in MCF-7 human mammary adenocarcinoma cells.	sanguinarine	0-12	vascular endothelial growth factor A	Homo sapiens	22-56
22965493-4	2012	Sanguinarine caused a dose-dependent decrease in Bcl-2 and NF-kappaB protein             expression and a significant increase in Bax protein expression.	sanguinarine	0-12	nuclear factor kappa B subunit 1	Homo sapiens	59-68
22965493-4	2012	Sanguinarine caused a dose-dependent decrease in Bcl-2 and NF-kappaB protein             expression and a significant increase in Bax protein expression.	sanguinarine	0-12	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133
22592163-8	2012	Two hours after LPS stimulation, cells influenced by sanguinarine and chelerythrine significantly declined the CCL-2 expression by a factors of 3.5 (p<0.001) and 1.9 (p<0.01); for those treated with prednisone the factor was 5.3 (p<0.001).	sanguinarine	53-65	C-C motif chemokine ligand 2	Homo sapiens	111-116
22592163-11	2012	Two hours after LPS stimulation, cells treated with sanguinarine decreased the IL-6 mRNA level by a factor of 3.9 (p<0.001) compared with cells treated with the vehicle.	sanguinarine	52-64	interleukin 6	Homo sapiens	79-83
22592163-13	2012	Sanguinarine decreased gene expression of CCL-2 and IL-6 more than chelerythrine and its effect was quite similar to prednisone.	sanguinarine	0-12	C-C motif chemokine ligand 2	Homo sapiens	42-47
22592163-13	2012	Sanguinarine decreased gene expression of CCL-2 and IL-6 more than chelerythrine and its effect was quite similar to prednisone.	sanguinarine	0-12	interleukin 6	Homo sapiens	52-56
22592163-14	2012	Four hours after LPS stimulation, cells pre-treated with sanguinarine exhibited significantly higher expression (a factor of 1.7, p<0.001) of IL-1RA than cells without sanguinarine treatment.	sanguinarine	57-69	interleukin 1 receptor antagonist	Homo sapiens	145-151
22215411-0	2012	Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway.	sanguinarine	0-12	BCL2 associated X, apoptosis regulator	Homo sapiens	87-90
22166397-2	2012	In this study, we examined whether M. cordata extract and/or its major alkaloid constituents, protopine, allocryptopine, sanguinarine and chelerythrine activate the Nrf2 signalling pathway which regulates the expression of cytoprotective enzymes including heme oxygenase-1 (HO-1) and thioredoxin 1.	sanguinarine	121-133	nuclear factor, erythroid derived 2, like 2	Mus musculus	165-169
22166397-5	2012	At the concentration of 2 muM, sanguinarine induced nuclear accumulation of Nrf2, increased the expression of Hmox1 gene encoding HO-1 and elevated HO-1 protein levels.	sanguinarine	31-43	nuclear factor, erythroid derived 2, like 2	Mus musculus	76-80
22166397-5	2012	At the concentration of 2 muM, sanguinarine induced nuclear accumulation of Nrf2, increased the expression of Hmox1 gene encoding HO-1 and elevated HO-1 protein levels.	sanguinarine	31-43	heme oxygenase 1	Mus musculus	110-115
22166397-5	2012	At the concentration of 2 muM, sanguinarine induced nuclear accumulation of Nrf2, increased the expression of Hmox1 gene encoding HO-1 and elevated HO-1 protein levels.	sanguinarine	31-43	heme oxygenase 1	Mus musculus	130-134
22166397-5	2012	At the concentration of 2 muM, sanguinarine induced nuclear accumulation of Nrf2, increased the expression of Hmox1 gene encoding HO-1 and elevated HO-1 protein levels.	sanguinarine	31-43	heme oxygenase 1	Mus musculus	148-152
22166397-6	2012	Sanguinarine-induced Hmox1 mRNA expression was suppressed by SB203580, a pharmacologic inhibitor of p38 mitogen-activated protein kinases (p38 MAPKs).	sanguinarine	0-12	heme oxygenase 1	Mus musculus	21-26
22166397-6	2012	Sanguinarine-induced Hmox1 mRNA expression was suppressed by SB203580, a pharmacologic inhibitor of p38 mitogen-activated protein kinases (p38 MAPKs).	sanguinarine	0-12	mitogen-activated protein kinase 14	Mus musculus	139-148
22166397-7	2012	The upregulation of HO-1 in RAW264.7 cells by sanguinarine was, however, accompanied by decrease in cell viability.	sanguinarine	46-58	heme oxygenase 1	Mus musculus	20-24
22166397-8	2012	Nonetheless, sanguinarine at micromolar, non-cytotoxic concentrations elevated protein levels of HO-1 and thioredoxin 1 in primary cultures of human hepatocytes.	sanguinarine	13-25	heme oxygenase 1	Homo sapiens	97-101
22166397-9	2012	We conclude that sanguinarine may, under appropriate conditions, increase the capacity of the enzymatic antioxidant defence system via activation of the p38 MAPK/Nrf2 pathway.	sanguinarine	17-29	mitogen-activated protein kinase 14	Mus musculus	153-161
22166397-9	2012	We conclude that sanguinarine may, under appropriate conditions, increase the capacity of the enzymatic antioxidant defence system via activation of the p38 MAPK/Nrf2 pathway.	sanguinarine	17-29	nuclear factor, erythroid derived 2, like 2	Mus musculus	162-166
22155096-0	2012	Microinjection of sanguinarine into the ventrolateral orbital cortex inhibits Mkp-1 and exerts an antidepressant-like effect in rats.	sanguinarine	18-30	dual specificity phosphatase 1	Rattus norvegicus	78-83
22155096-1	2012	We investigated the antidepressant effects of bilateral intra-the ventrolateral orbital cortex (VLO) administration of sanguinarine (SA), a selective mitogen-activated protein kinase phosphatase-1 (Mkp-1) inhibitor, in rats that had been subjected to a forced swimming test (FST) which is a classic animal model of depression.	sanguinarine	119-131	dual specificity phosphatase 1	Rattus norvegicus	150-196
22155096-6	2012	In addition, a decrease in the expression of Mkp-1 and a correlative increase in ERK activation were involved in the antidepressant effects of the bilateral SA administration into the VLO.	sanguinarine	157-159	dual specificity phosphatase 1	Rattus norvegicus	45-50
22155096-6	2012	In addition, a decrease in the expression of Mkp-1 and a correlative increase in ERK activation were involved in the antidepressant effects of the bilateral SA administration into the VLO.	sanguinarine	157-159	Eph receptor B1	Rattus norvegicus	81-84
22215411-0	2012	Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway.	sanguinarine	0-12	BCL2 apoptosis regulator	Homo sapiens	91-96
22215411-0	2012	Sanguinarine induces apoptosis of HT-29 human colon cancer cells via the regulation of Bax/Bcl-2 ratio and caspase-9-dependent pathway.	sanguinarine	0-12	caspase 9	Homo sapiens	107-116
22215411-5	2012	We also investigated the effects of sanguinarine on the expression of apoptosis-associated proteins, and the results revealed that there was an increase in Bax and a decrease in B-cell lymphoma 2 (Bcl-2) protein levels.	sanguinarine	36-48	BCL2 associated X, apoptosis regulator	Homo sapiens	156-159
22215411-6	2012	Moreover, sanguinarine treatment significantly increases the activation of caspases 3 and 9 that are the key executioners in apoptosis.	sanguinarine	10-22	caspase 9	Homo sapiens	75-83
21494677-0	2011	Interaction of the anticancer plant alkaloid sanguinarine with bovine serum albumin.	sanguinarine	45-57	albumin	Homo sapiens	70-83
21538419-0	2012	Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion.	sanguinarine	34-46	signal transducer and activator of transcription 3	Homo sapiens	14-19
21538419-7	2012	RESULTS: In this study, we identified sanguinarine as a potent inhibitor of Stat3 activation which was able to suppress prostate cancer growth, migration, and invasion.	sanguinarine	38-50	signal transducer and activator of transcription 3	Homo sapiens	76-81
21538419-8	2012	Sanguinarine inhibits constitutive as well as IL6-induced phosphorylation of Stat3 at both Tyr705 and Ser727 in prostate cancer cells.	sanguinarine	0-12	interleukin 6	Homo sapiens	46-49
21538419-8	2012	Sanguinarine inhibits constitutive as well as IL6-induced phosphorylation of Stat3 at both Tyr705 and Ser727 in prostate cancer cells.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	77-82
21538419-9	2012	The inhibition of Stat3 phosphorylation by sanguinarine correlates with reduction of Janus-activated Kinase 2 (Jak2) and Src phosphorylation.	sanguinarine	43-55	signal transducer and activator of transcription 3	Homo sapiens	18-23
21538419-9	2012	The inhibition of Stat3 phosphorylation by sanguinarine correlates with reduction of Janus-activated Kinase 2 (Jak2) and Src phosphorylation.	sanguinarine	43-55	Janus kinase 2	Homo sapiens	85-109
21538419-9	2012	The inhibition of Stat3 phosphorylation by sanguinarine correlates with reduction of Janus-activated Kinase 2 (Jak2) and Src phosphorylation.	sanguinarine	43-55	Janus kinase 2	Homo sapiens	111-115
21538419-9	2012	The inhibition of Stat3 phosphorylation by sanguinarine correlates with reduction of Janus-activated Kinase 2 (Jak2) and Src phosphorylation.	sanguinarine	43-55	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	121-124
21538419-10	2012	Sanguinarine downregulates the expression of Stat3-mediated genes such as c-myc and survivin and inhibits the Stat3 responsive element luciferase reporter activity.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	45-50
21538419-10	2012	Sanguinarine downregulates the expression of Stat3-mediated genes such as c-myc and survivin and inhibits the Stat3 responsive element luciferase reporter activity.	sanguinarine	0-12	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	74-79
21538419-10	2012	Sanguinarine downregulates the expression of Stat3-mediated genes such as c-myc and survivin and inhibits the Stat3 responsive element luciferase reporter activity.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	110-115
21538419-11	2012	Sanguinarine inhibits the anchorage-independent growth of DU145 and LN-S17 cells expressing constitutively activated Stat3.	sanguinarine	0-12	signal transducer and activator of transcription 3	Homo sapiens	117-122
21538419-13	2012	CONCLUSIONS: These data demonstrate that sanguinarine is a potent Stat3 inhibitor and it could be developed as a therapeutic agent for prostate cancer with constitutive activation of Stat3.	sanguinarine	41-53	signal transducer and activator of transcription 3	Homo sapiens	66-71
21538419-13	2012	CONCLUSIONS: These data demonstrate that sanguinarine is a potent Stat3 inhibitor and it could be developed as a therapeutic agent for prostate cancer with constitutive activation of Stat3.	sanguinarine	41-53	signal transducer and activator of transcription 3	Homo sapiens	183-188
21884681-1	2011	We found that a natural product, Sanguinarine, directly interacts with AMPK and enhances its enzymatic activity.	sanguinarine	33-45	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	71-75
21884681-2	2011	Cell-based assays confirmed that cellular AMPK and the downstream acetyl-CoA carboxylase (ACC) were phosphorylated after Sanguinarine treatment.	sanguinarine	121-133	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	42-46
21884681-3	2011	Sanguinarine was shown to exclusively activate AMPK holoenzymes containing alpha1gamma1 complexes, and it activated both beta1- and beta2-containing isotypes of AMPK.	sanguinarine	0-12	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	47-51
21884681-3	2011	Sanguinarine was shown to exclusively activate AMPK holoenzymes containing alpha1gamma1 complexes, and it activated both beta1- and beta2-containing isotypes of AMPK.	sanguinarine	0-12	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	121-137
21884681-3	2011	Sanguinarine was shown to exclusively activate AMPK holoenzymes containing alpha1gamma1 complexes, and it activated both beta1- and beta2-containing isotypes of AMPK.	sanguinarine	0-12	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	161-165
21884681-4	2011	Furthermore, a docking study suggested that Sanguinarine binds AMPK at the cleft between the beta and gamma domains whereas the physiological activator, AMP, binds at the well-characterized gamma domain pocket.	sanguinarine	44-56	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	63-67
21884681-5	2011	In summary, we report that Sanguinarine is a novel, direct activator of AMPK that binds by a unique allosteric mechanism different from that of the natural AMPK ligand, AMP, and other known AMPK activators.	sanguinarine	27-39	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	72-76
21884681-5	2011	In summary, we report that Sanguinarine is a novel, direct activator of AMPK that binds by a unique allosteric mechanism different from that of the natural AMPK ligand, AMP, and other known AMPK activators.	sanguinarine	27-39	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	156-160
21884681-5	2011	In summary, we report that Sanguinarine is a novel, direct activator of AMPK that binds by a unique allosteric mechanism different from that of the natural AMPK ligand, AMP, and other known AMPK activators.	sanguinarine	27-39	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	156-160
21868527-5	2011	Finally, sanguinarine induced apoptotic cell death by activating caspase and altering the Bcl-2/Bax ratio.	sanguinarine	9-21	BCL2 apoptosis regulator	Homo sapiens	90-95
21868527-5	2011	Finally, sanguinarine induced apoptotic cell death by activating caspase and altering the Bcl-2/Bax ratio.	sanguinarine	9-21	BCL2 associated X, apoptosis regulator	Homo sapiens	96-99
21628956-4	2011	Sanguinarine antimicrobial activity was assessed by broth dilution method; its mechanism of action was investigated by bacteriolysis, detergent or ATPase inhibitors and transmission electron microscopy were used to monitor the survival characteristics and the changes in bacteria morphology.	sanguinarine	0-12	AT695_RS06370	Staphylococcus aureus	147-153
21494677-1	2011	BACKGROUND: Interaction of the iminium and alkanolamine forms of sanguinarine with bovine serum albumin (BSA) was characterized by spectroscopic and calorimetric techniques.	sanguinarine	65-77	albumin	Homo sapiens	90-103
21182530-2	2011	The quantum yields Phi(Delta) of singlet molecular oxygen formation of berberine, palmatine and sanguinarine are moderate in dichloromethane (0.2-0.6) and much smaller in acetonitrile or trifluoroethanol.	sanguinarine	96-108	glucose-6-phosphate isomerase	Homo sapiens	19-22
20150630-9	2010	CONCLUSION: NSC 95397, brefeldin A, bortezomib and sanguinarine induced caspase-3 activation with modest changes in nuclear morphology.	sanguinarine	51-63	caspase 3	Homo sapiens	72-81
21152038-0	2010	A mutant of SWAP-70, a phosphatidylinositoltrisphosphate binding protein, transforms mouse embryo fibroblasts, which is inhibited by sanguinarine.	sanguinarine	133-145	SWA-70 protein	Mus musculus	12-19
21152038-8	2010	Among various drugs, sanguinarine was found to inhibit transformation of MEFs by SWAP-70-374.	sanguinarine	21-33	SWA-70 protein	Mus musculus	81-88
19804952-0	2010	Metabolism of sanguinarine in human and in rat: characterization of oxidative metabolites produced by human CYP1A1 and CYP1A2 and rat liver microsomes using liquid chromatography-tandem mass spectrometry.	sanguinarine	14-26	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	108-114
19804952-0	2010	Metabolism of sanguinarine in human and in rat: characterization of oxidative metabolites produced by human CYP1A1 and CYP1A2 and rat liver microsomes using liquid chromatography-tandem mass spectrometry.	sanguinarine	14-26	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	119-125
19804952-3	2010	The goal of this study is to investigate the oxidative metabolites of SA formed during incubations with rat liver microsomes (RLM) and recombinant human cytochrome P450 (CYP) and to tentatively identify the CYP isoforms involved in SA detoxification.	sanguinarine	70-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	153-168
19804952-3	2010	The goal of this study is to investigate the oxidative metabolites of SA formed during incubations with rat liver microsomes (RLM) and recombinant human cytochrome P450 (CYP) and to tentatively identify the CYP isoforms involved in SA detoxification.	sanguinarine	70-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	170-173
19804952-3	2010	The goal of this study is to investigate the oxidative metabolites of SA formed during incubations with rat liver microsomes (RLM) and recombinant human cytochrome P450 (CYP) and to tentatively identify the CYP isoforms involved in SA detoxification.	sanguinarine	70-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-210
19804952-3	2010	The goal of this study is to investigate the oxidative metabolites of SA formed during incubations with rat liver microsomes (RLM) and recombinant human cytochrome P450 (CYP) and to tentatively identify the CYP isoforms involved in SA detoxification.	sanguinarine	232-234	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	207-210
19804952-10	2010	Oxidative biotransformation of SA was investigated using eight human CYPs: only CYP1A1 and CYP1A2 displayed activity.	sanguinarine	31-33	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	80-86
19804952-10	2010	Oxidative biotransformation of SA was investigated using eight human CYPs: only CYP1A1 and CYP1A2 displayed activity.	sanguinarine	31-33	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	91-97
19959817-4	2010	The increase was reduced by the p38 MAP kinase (p38) inhibitor SB203580, by the cytosolic phospholipase A2 (cPLA(2)) inhibitor AACOCF3, and by the lyso-PAF acetyltransferase inhibitor sanguinarin, indicating that capsaicin-induced PAF production may be mediated by activation of cPLA(2), p38, and lyso-PAF acetyltransferase.	sanguinarine	184-195	mitogen-activated protein kinase 14	Homo sapiens	32-46
19959817-4	2010	The increase was reduced by the p38 MAP kinase (p38) inhibitor SB203580, by the cytosolic phospholipase A2 (cPLA(2)) inhibitor AACOCF3, and by the lyso-PAF acetyltransferase inhibitor sanguinarin, indicating that capsaicin-induced PAF production may be mediated by activation of cPLA(2), p38, and lyso-PAF acetyltransferase.	sanguinarine	184-195	mitogen-activated protein kinase 14	Homo sapiens	32-35
19959817-4	2010	The increase was reduced by the p38 MAP kinase (p38) inhibitor SB203580, by the cytosolic phospholipase A2 (cPLA(2)) inhibitor AACOCF3, and by the lyso-PAF acetyltransferase inhibitor sanguinarin, indicating that capsaicin-induced PAF production may be mediated by activation of cPLA(2), p38, and lyso-PAF acetyltransferase.	sanguinarine	184-195	phospholipase A2 group IVA	Homo sapiens	108-115
21151985-9	2010	The ecs mutants had higher susceptibility to ribosomal antibiotics and plant alkaloids chelerythrine and sanguinarine.	sanguinarine	105-117	epistatic circling SWR/J	Mus musculus	4-7
19959817-4	2010	The increase was reduced by the p38 MAP kinase (p38) inhibitor SB203580, by the cytosolic phospholipase A2 (cPLA(2)) inhibitor AACOCF3, and by the lyso-PAF acetyltransferase inhibitor sanguinarin, indicating that capsaicin-induced PAF production may be mediated by activation of cPLA(2), p38, and lyso-PAF acetyltransferase.	sanguinarine	184-195	lysophosphatidylcholine acyltransferase 1	Homo sapiens	147-173
19959817-4	2010	The increase was reduced by the p38 MAP kinase (p38) inhibitor SB203580, by the cytosolic phospholipase A2 (cPLA(2)) inhibitor AACOCF3, and by the lyso-PAF acetyltransferase inhibitor sanguinarin, indicating that capsaicin-induced PAF production may be mediated by activation of cPLA(2), p38, and lyso-PAF acetyltransferase.	sanguinarine	184-195	PCNA clamp associated factor	Homo sapiens	152-155
19959817-4	2010	The increase was reduced by the p38 MAP kinase (p38) inhibitor SB203580, by the cytosolic phospholipase A2 (cPLA(2)) inhibitor AACOCF3, and by the lyso-PAF acetyltransferase inhibitor sanguinarin, indicating that capsaicin-induced PAF production may be mediated by activation of cPLA(2), p38, and lyso-PAF acetyltransferase.	sanguinarine	184-195	mitogen-activated protein kinase 14	Homo sapiens	48-51
19788401-1	2009	Catalytic and immunochemical activities of cytochrome P450 (CYP) isoforms were investigated in argemone alkaloid, sanguinarine (SAN) intoxicated rats, pre-treated with different CYP inducers.	sanguinarine	114-126	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	43-58
20208361-0	2010	Sanguinarine as a potent and specific inhibitor of protein phosphatase 2C in vitro and induces apoptosis via phosphorylation of p38 in HL60 cells.	sanguinarine	0-12	mitogen-activated protein kinase 14	Homo sapiens	128-131
20208361-3	2010	In vivo, sanguinarine showed cytotoxicity toward human promyelocytic leukemia cell line HL60, with an IC(50) value of 0.37 microM, and induced apoptosis through a caspase-3/7-dependent mechanism involving the phosphorylation of p38, a PP2Calpha substrate.	sanguinarine	9-21	caspase 3	Homo sapiens	163-172
20208361-3	2010	In vivo, sanguinarine showed cytotoxicity toward human promyelocytic leukemia cell line HL60, with an IC(50) value of 0.37 microM, and induced apoptosis through a caspase-3/7-dependent mechanism involving the phosphorylation of p38, a PP2Calpha substrate.	sanguinarine	9-21	mitogen-activated protein kinase 14	Homo sapiens	228-231
20208361-3	2010	In vivo, sanguinarine showed cytotoxicity toward human promyelocytic leukemia cell line HL60, with an IC(50) value of 0.37 microM, and induced apoptosis through a caspase-3/7-dependent mechanism involving the phosphorylation of p38, a PP2Calpha substrate.	sanguinarine	9-21	protein phosphatase, Mg2+/Mn2+ dependent 1A	Homo sapiens	235-244
20208361-4	2010	The apoptosis activity induced by sanguinarine was partially inhibited by a p38 inhibitor, SB203580, and was involved in the phospho-p38 protein in HL60 cells.	sanguinarine	34-46	mitogen-activated protein kinase 14	Homo sapiens	76-79
20208361-4	2010	The apoptosis activity induced by sanguinarine was partially inhibited by a p38 inhibitor, SB203580, and was involved in the phospho-p38 protein in HL60 cells.	sanguinarine	34-46	mitogen-activated protein kinase 14	Homo sapiens	133-136
20032392-0	2009	Sanguinarine sensitizes human gastric adenocarcinoma AGS cells to TRAIL-mediated apoptosis via down-regulation of AKT and activation of caspase-3.	sanguinarine	0-12	TNF superfamily member 10	Homo sapiens	66-71
20032392-0	2009	Sanguinarine sensitizes human gastric adenocarcinoma AGS cells to TRAIL-mediated apoptosis via down-regulation of AKT and activation of caspase-3.	sanguinarine	0-12	AKT serine/threonine kinase 1	Homo sapiens	114-117
20032392-0	2009	Sanguinarine sensitizes human gastric adenocarcinoma AGS cells to TRAIL-mediated apoptosis via down-regulation of AKT and activation of caspase-3.	sanguinarine	0-12	caspase 3	Homo sapiens	136-145
20032392-4	2009	In the present study, we showed that treatment with TRAIL in combination with subtoxic concentrations of sanguinarine sensitized TRAIL-mediated apoptosis in AGS cells.	sanguinarine	105-117	TNF superfamily member 10	Homo sapiens	129-134
20032392-5	2009	Combined treatment with sanguinarine and TRAIL effectively induced Bid cleavage and loss of mitochondrial membrane potential, leading to the activation of caspases, and cleavage of poly(ADP-ribose) polymerase and beta-catenin.	sanguinarine	24-36	BH3 interacting domain death agonist	Homo sapiens	67-70
20032392-5	2009	Combined treatment with sanguinarine and TRAIL effectively induced Bid cleavage and loss of mitochondrial membrane potential, leading to the activation of caspases, and cleavage of poly(ADP-ribose) polymerase and beta-catenin.	sanguinarine	24-36	poly(ADP-ribose) polymerase 1	Homo sapiens	181-208
20032392-5	2009	Combined treatment with sanguinarine and TRAIL effectively induced Bid cleavage and loss of mitochondrial membrane potential, leading to the activation of caspases, and cleavage of poly(ADP-ribose) polymerase and beta-catenin.	sanguinarine	24-36	catenin beta 1	Homo sapiens	213-225
20032392-7	2009	In addition, the levels of Akt protein were markedly reduced in cells co-treated with sanguinarine and TRAIL.	sanguinarine	86-98	AKT serine/threonine kinase 1	Homo sapiens	27-30
19788401-1	2009	Catalytic and immunochemical activities of cytochrome P450 (CYP) isoforms were investigated in argemone alkaloid, sanguinarine (SAN) intoxicated rats, pre-treated with different CYP inducers.	sanguinarine	114-126	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	60-63
19788401-1	2009	Catalytic and immunochemical activities of cytochrome P450 (CYP) isoforms were investigated in argemone alkaloid, sanguinarine (SAN) intoxicated rats, pre-treated with different CYP inducers.	sanguinarine	128-131	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	43-58
19788401-1	2009	Catalytic and immunochemical activities of cytochrome P450 (CYP) isoforms were investigated in argemone alkaloid, sanguinarine (SAN) intoxicated rats, pre-treated with different CYP inducers.	sanguinarine	128-131	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	60-63
19788401-3	2009	SAN exposure to CON, and DEX, MC or ET pre-treated animals caused a decrease (22-37%) in glutathione-S-transferase (GST) activity, however, quinone reductase (QR) activity decreased (26-45%) in the MC pre-exposed group.	sanguinarine	0-3	hematopoietic prostaglandin D synthase	Rattus norvegicus	89-114
19788401-3	2009	SAN exposure to CON, and DEX, MC or ET pre-treated animals caused a decrease (22-37%) in glutathione-S-transferase (GST) activity, however, quinone reductase (QR) activity decreased (26-45%) in the MC pre-exposed group.	sanguinarine	0-3	hematopoietic prostaglandin D synthase	Rattus norvegicus	116-119
19346183-7	2009	This aside, sanguinarine also increased the activity of caspase-8.	sanguinarine	12-24	caspase 8	Homo sapiens	56-65
19346183-8	2009	As shown by flow cytometry using annexin V/propidium iodide staining, 0.5 microM sanguinarine induced apoptosis while 1-4 microM sanguinarine caused necrotic cell death.	sanguinarine	81-93	annexin A5	Homo sapiens	33-42
19063874-6	2009	Furthermore, the activities of MMP-2 and -9 in MDA-MB-231 cells were dose-dependently inhibited by treatment with sanguinarine, and this was also correlated with a decrease in the expression of their mRNA and proteins.	sanguinarine	114-126	matrix metallopeptidase 2	Homo sapiens	31-43
19135517-4	2009	Treatment with sanguinarine led to activation of caspases and MAPKs as well as increased MKP-1 expression.	sanguinarine	15-27	dual specificity phosphatase 1	Homo sapiens	89-94
19135517-6	2009	Moreover, pretreatment with NAC, a sulfhydryl group-containing reducing agent strongly suppressed the apoptotic response and caspase activation to sanguinarine.	sanguinarine	147-159	X-linked Kx blood group	Homo sapiens	28-31
18823950-1	2008	Structurally diverse chemotherapeutic and chemopreventive drugs, including camptothecin, doxorubicin, sanguinarine, and others, were found to cause covalent crosslinking of proliferating cell nuclear antigen (PCNA) trimers in mammalian cells exposed to fluorescent light.	sanguinarine	102-114	proliferating cell nuclear antigen	Homo sapiens	173-207
18823950-1	2008	Structurally diverse chemotherapeutic and chemopreventive drugs, including camptothecin, doxorubicin, sanguinarine, and others, were found to cause covalent crosslinking of proliferating cell nuclear antigen (PCNA) trimers in mammalian cells exposed to fluorescent light.	sanguinarine	102-114	proliferating cell nuclear antigen	Homo sapiens	209-213
18237541-0	2008	Sanguinarine-induced G1-phase arrest of the cell cycle results from increased p27KIP1 expression mediated via activation of the Ras/ERK signaling pathway in vascular smooth muscle cells.	sanguinarine	0-12	cyclin dependent kinase inhibitor 1B	Homo sapiens	78-85
18925736-1	2008	Despite their structural similarities, the natural products chelerythrine ( 5) and sanguinarine ( 6) target different binding sites on the pro-survival Bcl-X L protein.	sanguinarine	83-95	BCL2 like 1	Homo sapiens	152-159
18189268-0	2008	Sanguinarine-induced apoptosis: generation of ROS, down-regulation of Bcl-2, c-FLIP, and synergy with TRAIL.	sanguinarine	0-12	BCL2 apoptosis regulator	Homo sapiens	70-75
18189268-0	2008	Sanguinarine-induced apoptosis: generation of ROS, down-regulation of Bcl-2, c-FLIP, and synergy with TRAIL.	sanguinarine	0-12	CASP8 and FADD like apoptosis regulator	Homo sapiens	77-83
18189268-0	2008	Sanguinarine-induced apoptosis: generation of ROS, down-regulation of Bcl-2, c-FLIP, and synergy with TRAIL.	sanguinarine	0-12	TNF superfamily member 10	Homo sapiens	102-107
18189268-5	2008	Pretreatment with NAC or GSH attenuated sanguinarine-induced apoptosis, suggesting the involvement of ROS in this cell death.	sanguinarine	40-52	X-linked Kx blood group	Homo sapiens	18-21
18189268-6	2008	During sanguinarin-induced apoptosis, protein levels of pro-caspase-3, Bcl-2, cIAP2, XIAP, and c-FLIPs were reduced.	sanguinarine	7-18	caspase 3	Homo sapiens	56-69
18189268-6	2008	During sanguinarin-induced apoptosis, protein levels of pro-caspase-3, Bcl-2, cIAP2, XIAP, and c-FLIPs were reduced.	sanguinarine	7-18	BCL2 apoptosis regulator	Homo sapiens	71-76
18189268-6	2008	During sanguinarin-induced apoptosis, protein levels of pro-caspase-3, Bcl-2, cIAP2, XIAP, and c-FLIPs were reduced.	sanguinarine	7-18	baculoviral IAP repeat containing 3	Homo sapiens	78-83
18189268-6	2008	During sanguinarin-induced apoptosis, protein levels of pro-caspase-3, Bcl-2, cIAP2, XIAP, and c-FLIPs were reduced.	sanguinarine	7-18	X-linked inhibitor of apoptosis	Homo sapiens	85-89
18189268-6	2008	During sanguinarin-induced apoptosis, protein levels of pro-caspase-3, Bcl-2, cIAP2, XIAP, and c-FLIPs were reduced.	sanguinarine	7-18	CASP8 and FADD like apoptosis regulator	Homo sapiens	95-102
18189268-7	2008	Sanguinarine-mediated apoptosis was substantially blocked by ectopic expression of Bcl-2 and cFLIPs.	sanguinarine	0-12	BCL2 apoptosis regulator	Homo sapiens	83-88
18189268-8	2008	Additionally, we found that sub-lethal doses of sanguinarine remarkably sensitized breast cancer cells to TRAIL-mediated apoptosis, but the cell death induced by sanguinarine and TRAIL in combination was not blocked by overexpression of Bcl-2 or Akt.	sanguinarine	48-60	TNF superfamily member 10	Homo sapiens	106-111
18189268-8	2008	Additionally, we found that sub-lethal doses of sanguinarine remarkably sensitized breast cancer cells to TRAIL-mediated apoptosis, but the cell death induced by sanguinarine and TRAIL in combination was not blocked by overexpression of Bcl-2 or Akt.	sanguinarine	48-60	AKT serine/threonine kinase 1	Homo sapiens	246-249
18189268-8	2008	Additionally, we found that sub-lethal doses of sanguinarine remarkably sensitized breast cancer cells to TRAIL-mediated apoptosis, but the cell death induced by sanguinarine and TRAIL in combination was not blocked by overexpression of Bcl-2 or Akt.	sanguinarine	162-174	AKT serine/threonine kinase 1	Homo sapiens	246-249
18189268-9	2008	Therefore, combinatory treatment of sanguinarine and TRAIL may overcome the resistance of breast cancer cells due to overexpression of Akt or Bcl-2.	sanguinarine	36-48	AKT serine/threonine kinase 1	Homo sapiens	135-138
18189268-9	2008	Therefore, combinatory treatment of sanguinarine and TRAIL may overcome the resistance of breast cancer cells due to overexpression of Akt or Bcl-2.	sanguinarine	36-48	BCL2 apoptosis regulator	Homo sapiens	142-147
18325696-8	2008	Thus, our results demonstrated that rapid cytochrome c release in CEM T-leukemia cells exposed to sanguinarine or chelerythrine was not accompanied by changes in Bax, Bcl-2 and Bcl-X((L/S)) proteins in the mitochondrial fraction, and preceded activation of the initiator caspase-8.	sanguinarine	98-110	cytochrome c, somatic	Homo sapiens	42-54
18325696-2	2008	In this study, we found that sanguinarine and chelerythrine induce apoptosis in human CEM T-leukemia cells, and that is accompanied by an early increase in cytosolic cytochrome c that precedes caspases-8, -9 and -3 processing.	sanguinarine	29-41	cytochrome c, somatic	Homo sapiens	166-178
18325696-2	2008	In this study, we found that sanguinarine and chelerythrine induce apoptosis in human CEM T-leukemia cells, and that is accompanied by an early increase in cytosolic cytochrome c that precedes caspases-8, -9 and -3 processing.	sanguinarine	29-41	caspase 8	Homo sapiens	193-214
18325696-3	2008	During apoptosis induction by sanguinarine and chelerythrine, reactive oxygen species (ROS) was rapidly generated and DeltaPsi(mt) dissipated, while Bax, Bcl-2 and Bcl-X((L/S)) proteins" content in the mitochondrial fraction did not change significantly.	sanguinarine	30-42	BCL2 associated X, apoptosis regulator	Homo sapiens	149-152
18325696-3	2008	During apoptosis induction by sanguinarine and chelerythrine, reactive oxygen species (ROS) was rapidly generated and DeltaPsi(mt) dissipated, while Bax, Bcl-2 and Bcl-X((L/S)) proteins" content in the mitochondrial fraction did not change significantly.	sanguinarine	30-42	BCL2 apoptosis regulator	Homo sapiens	154-159
18325696-3	2008	During apoptosis induction by sanguinarine and chelerythrine, reactive oxygen species (ROS) was rapidly generated and DeltaPsi(mt) dissipated, while Bax, Bcl-2 and Bcl-X((L/S)) proteins" content in the mitochondrial fraction did not change significantly.	sanguinarine	30-42	BCL2 like 1	Homo sapiens	164-169
18237541-2	2008	Sanguinarine treatment of VSMC resulted in significant growth inhibition as a result of G1-phase cell-cycle arrest mediated by induction of p27KIP1 expression, and resulted in a down-regulation of the expression of cyclins and CDKs in VSMC.	sanguinarine	0-12	cyclin dependent kinase inhibitor 1B	Homo sapiens	140-147
18237541-3	2008	Moreover, sanguinarine-induced inhibition of cell growth appeared to be linked to activation of Ras/ERK through p27KIP1-mediated G1-phase cell-cycle arrest.	sanguinarine	10-22	cyclin dependent kinase inhibitor 1B	Homo sapiens	112-119
17610032-8	2008	Furthermore, cell treatment with sanguinarine or chelerythrine resulted in phosphorylation of approximately 70 kDa protein by PDK1.	sanguinarine	33-45	pyruvate dehydrogenase kinase 1	Homo sapiens	126-130
18243168-0	2008	Sanguinarine causes DNA damage and p53-independent cell death in human colon cancer cell lines.	sanguinarine	0-12	tumor protein p53	Homo sapiens	35-38
18667818-9	2008	Moreover, the quenching of ROS generation by N-acetyl-L-cysteine administration, a scavenger of ROS, reversed the sanguinarine-induced apoptosis effects via inhibition of ROS production, MMP collapse, tBid expression and the subsequent activation of caspases.	sanguinarine	114-126	caspase 8	Homo sapiens	250-258
18667818-11	2008	CONCLUSION: Our data imply that sanguinarine-induced ROS are key mediators of MMP collapse, which leads to the release of cytochrome c followed by caspase activation, culminating in apoptosis.	sanguinarine	32-44	cytochrome c, somatic	Homo sapiens	122-134
18667818-11	2008	CONCLUSION: Our data imply that sanguinarine-induced ROS are key mediators of MMP collapse, which leads to the release of cytochrome c followed by caspase activation, culminating in apoptosis.	sanguinarine	32-44	caspase 8	Homo sapiens	147-154
18560221-0	2008	Sanguinarine-induced apoptosis in human leukemia U937 cells via Bcl-2 downregulation and caspase-3 activation.	sanguinarine	0-12	BCL2 apoptosis regulator	Homo sapiens	64-69
18560221-0	2008	Sanguinarine-induced apoptosis in human leukemia U937 cells via Bcl-2 downregulation and caspase-3 activation.	sanguinarine	0-12	caspase 3	Homo sapiens	89-98
18560221-8	2008	Apoptosis by sanguinarine treatment was associated with the activation of caspase-3 and degradation of poly-(ADP-ribose) polymerase (PARP) and phospholipase C-gamma 1 protein.	sanguinarine	13-25	caspase 3	Homo sapiens	74-83
18560221-8	2008	Apoptosis by sanguinarine treatment was associated with the activation of caspase-3 and degradation of poly-(ADP-ribose) polymerase (PARP) and phospholipase C-gamma 1 protein.	sanguinarine	13-25	poly(ADP-ribose) polymerase 1	Homo sapiens	133-137
18560221-8	2008	Apoptosis by sanguinarine treatment was associated with the activation of caspase-3 and degradation of poly-(ADP-ribose) polymerase (PARP) and phospholipase C-gamma 1 protein.	sanguinarine	13-25	phospholipase C gamma 1	Homo sapiens	143-166
18560221-9	2008	Induction of apoptosis by sanguinarine was also accompanied by upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-2 expression.	sanguinarine	26-38	BCL2 associated X, apoptosis regulator	Homo sapiens	93-96
18560221-9	2008	Induction of apoptosis by sanguinarine was also accompanied by upregulation of pro-apoptotic Bax and downregulation of anti-apoptotic Bcl-2 expression.	sanguinarine	26-38	BCL2 apoptosis regulator	Homo sapiens	134-139
18560221-10	2008	Sanguinarine-induced caspase-3 activation and apoptosis were significantly attenuated in Bcl-2-overexpressing U937/Bcl-2 cells.	sanguinarine	0-12	caspase 3	Homo sapiens	21-30
18560221-10	2008	Sanguinarine-induced caspase-3 activation and apoptosis were significantly attenuated in Bcl-2-overexpressing U937/Bcl-2 cells.	sanguinarine	0-12	BCL2 apoptosis regulator	Homo sapiens	89-94
18560221-10	2008	Sanguinarine-induced caspase-3 activation and apoptosis were significantly attenuated in Bcl-2-overexpressing U937/Bcl-2 cells.	sanguinarine	0-12	BCL2 apoptosis regulator	Homo sapiens	115-120
18560221-11	2008	Furthermore, a caspase-3-specific inhibitor blocked caspase-3 activation as well as PARP degradation, and increased the survival rate of sanguinarine-treated U937 cells.	sanguinarine	137-149	caspase 3	Homo sapiens	15-24
18560221-12	2008	CONCLUSIONS: These results demonstrated that the induction of apoptosis by sanguinarine in U937 cells was associated with altering the balance of Bcl-2 and Bax protein expression and activation of the caspase-3 pathway.	sanguinarine	75-87	BCL2 apoptosis regulator	Homo sapiens	146-151
18560221-12	2008	CONCLUSIONS: These results demonstrated that the induction of apoptosis by sanguinarine in U937 cells was associated with altering the balance of Bcl-2 and Bax protein expression and activation of the caspase-3 pathway.	sanguinarine	75-87	BCL2 associated X, apoptosis regulator	Homo sapiens	156-159
18560221-12	2008	CONCLUSIONS: These results demonstrated that the induction of apoptosis by sanguinarine in U937 cells was associated with altering the balance of Bcl-2 and Bax protein expression and activation of the caspase-3 pathway.	sanguinarine	75-87	caspase 3	Homo sapiens	201-210
18667818-7	2008	RESULTS: The results of this study demonstrate that sanguinarine mediates ROS production, and that this mediation is followed by a decrease in MMP, the release of cytochrome c, activation of caspase-9 and caspase-3, and downregulation of antiapoptosis factor XIAP and cIAP-1.	sanguinarine	52-64	cytochrome c, somatic	Homo sapiens	163-175
18667818-7	2008	RESULTS: The results of this study demonstrate that sanguinarine mediates ROS production, and that this mediation is followed by a decrease in MMP, the release of cytochrome c, activation of caspase-9 and caspase-3, and downregulation of antiapoptosis factor XIAP and cIAP-1.	sanguinarine	52-64	caspase 9	Homo sapiens	191-200
18667818-7	2008	RESULTS: The results of this study demonstrate that sanguinarine mediates ROS production, and that this mediation is followed by a decrease in MMP, the release of cytochrome c, activation of caspase-9 and caspase-3, and downregulation of antiapoptosis factor XIAP and cIAP-1.	sanguinarine	52-64	caspase 3	Homo sapiens	205-214
18667818-7	2008	RESULTS: The results of this study demonstrate that sanguinarine mediates ROS production, and that this mediation is followed by a decrease in MMP, the release of cytochrome c, activation of caspase-9 and caspase-3, and downregulation of antiapoptosis factor XIAP and cIAP-1.	sanguinarine	52-64	X-linked inhibitor of apoptosis	Homo sapiens	259-263
18667818-7	2008	RESULTS: The results of this study demonstrate that sanguinarine mediates ROS production, and that this mediation is followed by a decrease in MMP, the release of cytochrome c, activation of caspase-9 and caspase-3, and downregulation of antiapoptosis factor XIAP and cIAP-1.	sanguinarine	52-64	baculoviral IAP repeat containing 2	Homo sapiens	268-274
18667818-8	2008	Sanguinarine also promoted the activation of caspase-8 and truncation of Bid (tBid).	sanguinarine	0-12	caspase 8	Homo sapiens	45-54
18667818-8	2008	Sanguinarine also promoted the activation of caspase-8 and truncation of Bid (tBid).	sanguinarine	0-12	BH3 interacting domain death agonist	Homo sapiens	73-76